<html lang="en"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <link rel="shortcut icon" href="./favicon.png">
    <link rel="preload" href="./static/media/SourceSansPro-Regular.DZLUzqI4.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-SemiBold.sKQIyTMz.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-Bold.-6c9oR8J.woff2" as="font" type="font/woff2" crossorigin="">

    <title>app</title>

    <!-- initialize window.prerenderReady to false and then set to true in React app when app is ready for indexing -->
    <script>
      window.prerenderReady = false
    </script>
    <script type="module" crossorigin="" src="./static/js/index.BlylrL8P.js"></script>
    <link rel="stylesheet" crossorigin="" href="./static/css/index.DpJG_94W.css">
  <style media=""></style><style data-emotion="st-emotion-cache-global" data-s=""></style><style data-emotion="st-emotion-cache" data-s=""></style><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.BqlD3NTA.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.DW_MHI2K.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FormClearHelper.UtDFKbpT.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FileHelper.DV2KuUj6.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/ProgressBar.BtMHwdZZ.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/Hooks.YZgOFmbn.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/UploadFileInfo.C-jY39rj.js"></head>
  <body>
    <noscript>You need to enable JavaScript to run this app.</noscript>
    <div id="root"><div class=""><div class="withScreencast" data-testid="stScreencast"><div class="stApp stAppEmbeddingId-t7u54kpdvqhd st-emotion-cache-1r4qj8v ee4bbma0" data-testid="stApp" data-test-script-state="notRunning" data-test-connection-state="CONNECTED"><header tabindex="-1" class="stAppHeader st-emotion-cache-12fmjuu e4hpqof0" data-testid="stHeader"><div class="stDecoration st-emotion-cache-1dp5vir e4hpqof1" data-testid="stDecoration" id="stDecoration"></div><div class="stAppToolbar st-emotion-cache-15ecox0 e4hpqof2" data-testid="stToolbar"><div class="stToolbarActions st-emotion-cache-1p1m4ay e1i26tt72" data-testid="stToolbarActions"></div><span id="MainMenu" class="stMainMenu st-emotion-cache-czk5ss ev04twb8" data-testid="stMainMenu" aria-haspopup="true" aria-expanded="false"><button kind="headerNoPadding" data-testid="stBaseButton-headerNoPadding" aria-label="" class="st-emotion-cache-l1ktzw em9zgd018"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path></svg></button></span></div></header><div class="stAppViewContainer appview-container st-emotion-cache-1yiq2ps eht7o1d0" data-testid="stAppViewContainer" data-layout="narrow"><section tabindex="0" class="stMain st-emotion-cache-bm2z3a eht7o1d1" data-testid="stMain"><div class="stMainBlockContainer block-container st-emotion-cache-mtjnbi eht7o1d4" data-testid="stMainBlockContainer"><div data-testid="stVerticalBlockBorderWrapper" data-test-scroll-behavior="normal" class="st-emotion-cache-0 eu6p4el5"><div class="st-emotion-cache-b95f0i eu6p4el4"><div class="stVerticalBlock st-emotion-cache-1n76uvr eu6p4el3" data-testid="stVerticalBlock" width="704"><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stHeading" data-testid="stHeading"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 id="olmocr">OLMOCR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#olmocr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="st-emotion-cache-8atqhb e1mlolmg0"><div class="stFileUploader st-emotion-cache-0 e17y52ym15" data-testid="stFileUploader" width="704"><label data-testid="stWidgetLabel" aria-hidden="true" class="st-emotion-cache-1s2v671 e1dx5vew0"><div data-testid="stMarkdownContainer" class="st-emotion-cache-wq5ihp e1icttdg0"><p>Upload a PDF or Image</p></div></label><section role="presentation" data-testid="stFileUploaderDropzone" aria-label="Upload a PDF or Image" class="st-emotion-cache-1gulkj5 e17y52ym0" tabindex="0"><input data-testid="stFileUploaderDropzoneInput" accept="application/streamlit,.pdf,.png,.jpg,.jpeg" type="file" style="border: 0px; clip: rect(0px, 0px, 0px, 0px); clip-path: inset(50%); height: 1px; margin: 0px -1px -1px 0px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap;" tabindex="-1"><div data-testid="stFileUploaderDropzoneInstructions" class="st-emotion-cache-u8hs99 e17y52ym1"><span class="st-emotion-cache-nwtri e17y52ym2"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-6rlrad ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19.35 10.04A7.49 7.49 0 0012 4C9.11 4 6.6 5.64 5.35 8.04A5.994 5.994 0 000 14c0 3.31 2.69 6 6 6h13c2.76 0 5-2.24 5-5 0-2.64-2.05-4.78-4.65-4.96zM19 18H6c-2.21 0-4-1.79-4-4 0-2.05 1.53-3.76 3.56-3.97l1.07-.11.5-.95A5.469 5.469 0 0112 6c2.62 0 4.88 1.86 5.39 4.43l.3 1.5 1.53.11A2.98 2.98 0 0122 15c0 1.65-1.35 3-3 3zM8 13h2.55v3h2.9v-3H16l-4-4z"></path></svg></span><div class="st-emotion-cache-j7qwjs e17y52ym4"><span class="st-emotion-cache-9ycgxx e17y52ym3">Drag and drop file here</span><small class="st-emotion-cache-1rpn56r ejh2rmr0">Limit 200MB per file • PDF, PNG, JPG, JPEG</small></div></div><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02">Browse files</button></section><div class="st-emotion-cache-fis6aj e17y52ym5"><ul class="st-emotion-cache-14m29r0 e17y52ym6"><li class="st-emotion-cache-1l95nvm e17y52ym7"><div class="stFileUploaderFile st-emotion-cache-12xsiil e17y52ym10" data-testid="stFileUploaderFile"><div class="st-emotion-cache-10ix4kq e17y52ym12"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-4mjat2 ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zM6 20V4h7v5h5v11H6z"></path></svg></div><div class="stFileUploaderFileData st-emotion-cache-1l4firl e17y52ym8"><div class="stFileUploaderFileName st-emotion-cache-1uixxvy e17y52ym9" data-testid="stFileUploaderFileName" title="Chapters_16-20.pdf">Chapters_16-20.pdf</div><small class="st-emotion-cache-1rpn56r ejh2rmr0">16.1MB</small></div><div data-testid="stFileUploaderDeleteBtn"><button kind="minimal" data-testid="stBaseButton-minimal" aria-label="" class="st-emotion-cache-8ccstr em9zgd06"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"></path></svg></button></div></div></li></ul></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stButton st-emotion-cache-8atqhb e1mlolmg0" data-testid="stButton"><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1hyd1ho e1icttdg0"><p>Submit</p></div></button></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p><strong>Processing file:</strong> Chapters_16-20.pdf</p></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p>CHAPTER 16</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cutaneous-malignancies">CUTANEOUS MALIGNANCIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cutaneous-malignancies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Grace Chung</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>Distinguish between premalignant and malignant skin lesions by different growth patterns and clinical presentations.</li>
<li>Identify the predisposing factors of cutaneous malignancies.</li>
<li>Describe the relationship of ultraviolet radiation exposure and genetic mutations in development of cutaneous malignancies.</li>
<li>Discuss the various treatment options available for patients diagnosed with cutaneous malignant diseases based on clinical and histologic assessment.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Tumors and pigmented lesions of the skin may be benign, premalignant, or malignant.</li>
<li>Regularly performed visual skin examinations and photoprotective behaviors are the most indispensable and cost-effective preventive measures against development of skin cancers.</li>
<li>Persistent hyperkeratotic and indurated actinic keratosis lesions should be considered for skin biopsy to rule out skin cancers.</li>
<li>Squamous cell carcinoma is locally invasive and has potential to metastasize.</li>
<li>Pearly appearance with telangiectasias is the most common presentation of basal cell carcinoma. A pigmented basal cell carcinoma, however, may resemble other types of growth lesions (e.g., nodular melanoma, pigmented seborrheic keratosis, melanocytic nevus).</li>
<li>The four types of malignant melanoma include superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma. The prognosis of a malignant melanoma depends on tumor thickness, depth of invasion, and distant metastasis.</li>
<li>Cutaneous T-cell lymphoma is a rare type of cancer that originates in white blood cells</li>
</ul>
<p>and typically appears in severely itch skin lesions. Patients with chronic skin rash that delays improvement, progresses through different stages of lesions, and repeated cycles of regression and recurrence should be evaluated for cutaneous T-cell lymphoma.</p>
<ul>
<li>Sézary syndrome is an aggressive form of leukemic cutaneous T-cell lymphoma variant.</li>
<li>Kaposi sarcoma is a multicentric, lymphatic, and vascular epithelial hyperplasia and not a sarcoma of mesenchymal origin.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="actinic-keratosis">ACTINIC KERATOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#actinic-keratosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Actinic keratosis (AK), also called solar keratosis or senile keratosis (nonrecommended synonym), is a premalignant neoplasm of the epidermis. AK presents as a solitary or multiple lesions on sun-exposed areas, and greater than 80% occur on the head, neck, forearms, and dorsal hands. History of AK correlates with increased risk for developing invasive squamous cell carcinomas (SCCs).</p>
<p>A. Definition: AK is a premalignant, atypical proliferation of mutated keratinocytes arising from the basal layer and remaining in the epidermis.</p>
<p>B. Incidence:</p>
<ol>
<li>One of the most commonly seen problems in dermatology visits, affecting more than 58 million people in the United States.</li>
<li>The incidence varies by skin type, geographic location, and amount of ultraviolet (UV) radiation exposure.</li>
</ol>
<p>C. Etiology:</p>
<ol>
<li>Chronic occupational and recreational UV radiation exposure</li>
<li>Genetic predisposition: fair skin and family history of skin cancers</li>
<li>Genetic disorders: ineffective or interference of DNA repair against skin sun damage (i.e., xeroderma pigmentosum, Bloom syndrome, and Rothmund-Thomson syndrome)</li>
<li>Gender (male &gt; female), advancing age, and geographic location</li>
<li>History of serious sunburn</li>
<li>Immunosuppression in organ transplant recipients and immunomodulatory medication (biologic) users in autoimmune disorders</li>
</ol>
<p>D. Pathogenesis:</p>
<ol>
<li>Chronic UV radiation exposure, mostly UVB (290 to 320 nm), induces mutation of epidermal keratinocyte DNA.</li>
<li>Keratinocyte DNA mutation in the p53 tumor suppressor gene located on chromosome 17p132 involves in cell cycle regulation, apoptosis (programmed cell death process), and DNA repair.</li>
<li>Mutated p53 gene leads to prolonged cell life span and delayed cell apoptosis, resulting in proliferation and clonal expansion of atypical keratinocytes and formation of AKs.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-clinical-variants">II. CLINICAL VARIANTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-clinical-variants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Common AK: few millimeters to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">2\mathrm{cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm">cm</span></span></span></span></span></span>  in diameter, pink or erythematous, keratotic papule or plaque (Figure 16-1)
B. Hypertrophic AK (HAK): tan, white, or gray, thick or exophytic (outward-growing) scaly papule or plaque, with erythematous base (Figure 16-2)
C. Atrophic AK: smooth pink or erythematous macule or patch, with absent keratotic scale
D. Pigmented AK: keratotic scale lying over hyperpigmented macule or patch
E. Cutaneous horn: keratotic projection (exophytic), with the mound of compact keratin resembling the shape of a cone or spicule
F. Actinic cheilitis (solar cheilosis): rough keratotic papule or plaque occurring on the lip; may be cracking (fissuring) or ulcerating</p>
<p><img src="assets/images/image-20251225-f382ea52.jpeg" alt="img-0.jpeg">
FIGURE 16-1. Actinic keratosis: pink keratotic plaques on this 58-year-old man's forearm. (Courtesy of Grace Chung.)</p>
<p><img src="assets/images/image-20251225-714bdac7.jpeg" alt="img-1.jpeg">
FIGURE 16-2. Hyperkeratotic actinic keratosis. Multiple hyperkeratotic papules and plaques with diffuse actinic damage on this patient's balding scalp. Two scabbed excoriated papules are at the center. (Courtesy of Grace Chung.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-laboratory-and-diagnostic-tests">III. LABORATORY AND DIAGNOSTIC TESTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-laboratory-and-diagnostic-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Often clinically diagnosed by visual inspection and palpation.</p>
<p>B. Dermoscopy using handheld device to magnify and illuminate lesions for making clinical diagnosis.
C. Skin biopsy is indicated when diagnosis is uncertain, to get definitive diagnosis and rule out malignancy or differentiate from other nonmalignant growth lesions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-differential-diagnosis">IV. DIFFERENTIAL DIAGNOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-differential-diagnosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Use a fingertip as the diagnostic tool to distinguish AK lesions from common flaky scales on dry skin surface.</p>
<p>A. Inflamed seborrheic keratosis
B. Pityriasis rubra pilaris
C. Porokeratosis
D. Prurigo nodularis
E. Psoriasis
F. Seborrheic dermatitis
G. Squamous cell carcinoma
H. Superficial basal cell carcinoma (BCC)
I. Viral wart</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="v-treatment-modalities">V. TREATMENT MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-treatment-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Cryotherapy: most common, first-line treatment option with a cure rate of 98.8%
B. Electrodessication and curettage: ideal treatment for hyperkeratotic AKs and those resembling the presentation of invasive SCC
C. Topical 5-fluorouracil (5-FU): interferes with DNA and RNA synthesis of the mutated keratinocytes by blocking the methylation reaction of deoxyuridylic acid to thymidylic acid
D. Imiquimod (immune response modifier): induces synthesis and release of cytokines such as interferon-tumor necrosis factors (TNF) and interleukins
E. Prevention: sun avoidance, use of sunscreen, photoprotective clothing, and self-screening exam</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vi-prognosis">VI. PROGNOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vi-prognosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>AKs are premalignant, but they have potential to progress into malignant lesions. Approximately 65% of all SCC and 36% of all BCC are transformed from preexisting AKs.</p>
<p>PATIENT EDUCATION</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="actinic-keratosis">Actinic Keratosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#actinic-keratosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Rough and scaly actinic keratosis (AK) lesions are easier felt than seen.</li>
<li>AK is a precancerous lesion. Patient should not get confused with the number of AK lesions removed by various types of treatment methods in reporting the history of skin cancer.</li>
<li>Reasons to remove AK lesions on the skin include cosmetic concerns (unsightliness), frequent irritation, and potential risk of developing into an SCC (rarely BCC).</li>
<li>Photoprotection is the key in preventing sun damage and future occurrence of AK.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="basal-cell-carcinoma">BASAL CELL CARCINOMA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#basal-cell-carcinoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>BCC is the most common nonmelanoma skin cancer (NMSC) in the United States. UV radiation exposure is considered the biggest contributing risk factor for BCC as evidenced by the common sites of occurrence on sun-exposed areas such as the scalp, face, neck, chest, and distal parts of extremities. The malignant nature of BCC is demonstrated by expansive growth, destruction, and invasion of local structures including bone. BCC often remains local with low metastatic potential, and it's highly curable.</p>
<p>A. Definition: BCC is a malignant epithelial neoplasm arising from the basal cells (in the basal layer) of the epidermis and its appendages.</p>
<p>B. Incidence:</p>
<ol>
<li>Over 3.5 million cases of NMSC among more than 2 million people annually.</li>
<li>Highest incidence among Caucasians and individuals with fair skin, approximately 75% to 80% of NMSC.</li>
<li>Greater than 70% occurrences are on the face, 15% on the trunk, and rare occurrences on non-sun-exposed areas including genital or perianal areas.</li>
</ol>
<p>C. Etiology:</p>
<ol>
<li>
<p>UV radiation exposure
a. Intermittent episodes of intense UV exposure and recreational sun exposure at any age.
b. Depletion of earth's protective ozone layer allows dangerous UV rays to penetrate the atmosphere.</p>
</li>
<li>
<p>Ionizing radiation exposure through occupation or therapeutic radiation for disorders such as facial acne, tinea capitis, psoriasis, eczema, or skin cancer.</p>
</li>
<li>
<p>Arsenic and carcinogenic exposures from contaminated drinking water, seafood, agricultural insecticides, or pharmacological mixtures (Fowler solution).</p>
</li>
<li>
<p>Genetic disorders and DNA repair capability:
a. Nevoid basal cell carcinoma syndrome (NBCCS) (also known as Gorlin syndrome)</p>
</li>
</ol>
<p>—a rare autosomal dominant genetic disorder, caused by the germline mutations (Figure 16-3)</p>
<p>(1) Affected individuals have multiple developmental anomalies in body systems (e.g., skin, bone, endocrine, and nervous system), unusual facial appearance, and predisposition for tumors including multiple BCCs at an early age.</p>
<p>b. Xeroderma pigmentosum (XP)—an autosomal recessive genetic disorder with defective DNA repair mechanism. Inability to repair UV radiation-induced DNA damage and mutations results in development of BCC.</p>
<ol start="5">
<li>BCC may arise in nevus sebaceous, a congenital hamartoma of the skin.</li>
</ol>
<p>D. Pathogenesis:</p>
<ol>
<li>
<p>The mutations in PTCH1, PTCH2, SMO and SUFU genes are well known to associate with the development of BCC. Over 70% of BCC development is caused by alteration in PTCH1 gene on chromosome 9q. PTCH1 is a tumor suppressor gene, functioning as the controller of proliferation and differentiation.</p>
</li>
<li>
<p>PTCH1 gene mutation causes loss of normal function and disruption in signaling pathways, resulting in uncontrolled growth in BCC tumorigenesis.</p>
</li>
<li>
<p>The mutations in P53 gene (early during carcinogenesis) and the MC1R gene are uncommonly involved in the development of BCC.</p>
</li>
<li>
<p>UV irradiation-induced skin inflammation: UV exposure results in inflammation of the skin, which leads to increased synthesis of prostaglandin and induction of cyclooxygenase-2 (COX-2). The key role of COX-2 inhibitors induced by the inflammation is to decrease the incidence of carcinogenesis in NMSC.</p>
</li>
<li>
<p>Langerhans cells, found in the basal layer of the epidermis, are functionally impaired by UVB and PUVA treatment leading to morphologic changes within the cell.</p>
</li>
</ol>
<p>a. PUVA, PUVB, broadband UVB, and narrow band UVB phototherapy are types of UV radiation treatments for many severe skin diseases.</p>
<p>(1) PUVA is a UV radiation treatment using a photosensitizing agent called Psoralens (P), such as methoxsalen (8-methoxypsoralen), 5-methoxypsoralen, and trisoralen orally or topically. Once the medication is applied (or taken orally 2 hours prior to the treatment), expose the treatment areas of the skin to UVA (long UV wavelength, 320 to 400nm) or UVB (290 to 320nm) in a therapeutic light box, a cabinet containing multiple fluorescent light bulbs to administer controlled amount of UV radiation, 2 to 3 times a week until optimal therapeutic outcomes are achieved.</p>
<p>(2) Since 2008 however, lack of supplies in Psoralens caused infrequent use of PUVA or PUVB; currently the most common form of phototherapy is Narrowband UVB phototherapy (NB-UVB). NB-UVB (311 to 312nm) is known to have lower risk associated with phototherapy in comparison to formerly used broadband UVB (290 to 320nm).</p>
<p>(3) Patients must use protective eyewear and cover sensitive skin areas (i.e. face and genitalia) for whole body exposure to limit UV radiation associated irritations, burning, and other damages during the treatment. Currently there are localized treatment instruments available for scalp, extremities, hands and feet.</p>
<p><img src="assets/images/image-20251225-7ca413cb.jpeg" alt="img-2.jpeg">
FIGURE 16-3. Nevoid basal cell carcinoma syndrome. (From DeVita, V. T., et al. (2008).</p>
<p>DeVita, Hellman, and Rosenberg's cancer: Principles and practice of oncology. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-clinical-variants">II. CLINICAL VARIANTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-clinical-variants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Superficial BCC (Figure 16-4): pearly pink, reddish, or eczematous, with a slightly scaling patch or slightly raised plaque.
B. Papulonodular BCC (Figure 16-5): pearly, shiny, or semitranslucent pink papule or nodule with a crater-like central umbilication and visible surrounding telangiectasia.
C. Sclerotic or morpheaform BCC (Figure 16-6): pale, atrophic, occasionally eroded, or crusting, cicatricial-appearing plaque.
D. Pigmented BCC (Figure 16-7): shiny papule, nodule, or plaque with focally speckled or entirely dark brown, blue-black, or black pigmentation while having pearly, semitranslucent rolled border at the base.
E. Basosquamous cell carcinoma: rarely occurring tumor but aggressive in nature and often classified as an SCC. This type must be confirmed by skin biopsy and histologic study.</p>
<p><img src="assets/images/image-20251225-d8016cc3.jpeg" alt="img-3.jpeg">
FIGURE 16-4. Superficial basal cell carcinoma. (From Dr. Barankin Dermatology Collection.)</p>
<p><img src="assets/images/image-20251225-a7c4422a.jpeg" alt="img-4.jpeg">
FIGURE 16-5. Nodular basal cell carcinoma. (From Lugo-Somolinos, A., et al. (2011). VisualDx: Essential dermatology in pigmented skin. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-469929c6.jpeg" alt="img-5.jpeg">
FIGURE 16-6. Morpheaform basal cell carcinoma. (From Khan, F. M., &amp; Gerbi, B. J. (2011). Treatment planning in radiation oncology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-dc2a7efb.jpeg" alt="img-6.jpeg">
FIGURE 16-7. Pigmented basal cell carcinoma. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-laboratory-and-diagnostic-tests">III. LABORATORY AND DIAGNOSTIC TESTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-laboratory-and-diagnostic-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Clinical evaluation and skin biopsy for a confirmation of diagnosis.
B. Skin biopsy is highly recommended for patients with atypical features of a lesion for BCC, no prior history of BCC, or other risk factors contributing to possible recurrence of BCC.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-differential-diagnosis">IV. DIFFERENTIAL DIAGNOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-differential-diagnosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Amelanotic melanoma
B. Dermal nevi
C. Eczema</p>
<p>D. Keratoacanthoma
E. Nodular melanoma
F. Nummular eczema
G. Psoriasis
H. Scar/cicatricial plaque
I. Squamous cell carcinoma</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="v-treatment-modalities">V. TREATMENT MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-treatment-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Treatment modalities are decided by the location and size of the tumor.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cryosurgery">Cryosurgery<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cryosurgery" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>A noninvasive procedure using liquid nitrogen.</li>
<li>Useful in small superficial BCC treatment on trunk and extremities.</li>
<li>Liquid nitrogen is administered by cone spray apparatus or by use of cryoprobes that conduct cold evenly.</li>
<li>May result in postinflammatory hypo- or hyperpigmentation (PIH).</li>
<li>No specimen available for evaluation of margins.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="electrosurgery-electrodessication-and-curettage">Electrosurgery (electrodessication and curettage)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#electrosurgery-electrodessication-and-curettage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Local anesthesia, minimal equipment, and quick office procedure.</li>
<li>Useful in treatment of well-differentiated primary BCCs located on trunk and extremities and on patients who are not candidates for invasive surgical procedures.</li>
<li>Disadvantages include lack of specimen for margin evaluation and possible hypertrophic scar development.</li>
<li>Contraindicated in patients with pacemaker or defibrillator implant, BCCs 2 cm or larger, recurrent BCC, or a BCC located in high-risk location for recurrence.</li>
<li>Electrodessication and curettage offers cure rate of 97% to 98%.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="de0d4afd">Carbon dioxide laser (CO₂)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#de0d4afd" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>May be used in conjunction with a curette in place of electrocautery.</li>
<li>Advantages include minimal nonspecific thermal injury to adjacent cells with more rapid healing and less pain postoperatively.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="surgical-excision">Surgical excision<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#surgical-excision" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Office procedure using local anesthetic</li>
<li>Useful for well-differentiated primary BCC lesions</li>
<li>Provides specimen for random evaluation of surgical margins</li>
<li>Time-consuming procedure requiring surgical skill, assistants, and more equipment</li>
<li>Highly efficacious with cure rate of 96.8% to 99% depends on the types, sizes, depths, and locations of the lesions.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="radiation-therapy">Radiation therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#radiation-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Superficial x-ray or high-energy electron beam radiation.</li>
<li>Useful for BCCs on the head and neck, with chance of metastasis</li>
<li>May cause radionecrosis over bone</li>
</ol>
<p>Mohs micrographic surgery, named after Frederic Mohs, MD, is defined as excision of skin cancer with histological margin control of deep and peripheral margins.</p>
<ol>
<li>Office procedure using local anesthesia.</li>
<li>Indications:
a. Primary BCC on cosmetic sensitive areas (e.g., face and ears).
b. Morpheaform BCC or tumors with indistinct margins.
c. Incompletely excised and recurrent BCC.
d. Certain anatomic areas best treated by the precision of Mohs surgery include central "H" zone of the face comprising the upper lip, nose, medial canthus, and temple.</li>
<li>Tumor is debulked and a layer of tissue is removed to be processed for margin evaluation in an on-site laboratory.</li>
<li>Tissue specimen is marked with color-coding inks to maintain the orientation of the specimen and the defect (surgical site).</li>
<li>The specimen is then frozen, sliced, and fixed on glass slides and treated in series of chemicals for staining.</li>
<li>Surgeon or dermatopathologist reads slides observing the base and epidermal edges of the specimen for the total clearance of the tumor; if BCC persists at one or more color-coded margins, another layer from the corresponding site(s) is harvested from the defect. (Same steps are repeated until the margins are free of tumor.)</li>
<li>Precise margin control and conservative removal of the benign skin surrounding the tumor offer advantage in cosmetic sensitive areas and higher cure rate.</li>
<li>Disadvantages include possible lengthy procedures with waiting periods; requires special training of surgeon, assistants, and technicians and specialized equipment.</li>
</ol>
<p>Other treatment modalities Topical 5-fluorouracil and imiquimod are effective treatments for superficial BCC and multifocal BCC. May also be used as pretreatment method prior to Mohs or excision surgery for ill-defined BCC lesions on diffuse sun-damaged skin.</p>
<p>Photodynamic therapy (PDT) for superficial BCC, which selectively destroys tumor cells by the administration of a photosensitizing topical agent that is activated by light creating oxygen products capable of cell destruction.</p>
<p>a. Beneficial for patients with nevoid BCC syndrome</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vi-prognosis">VI. PROGNOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vi-prognosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>BCCs' viability is dependent on the integumentary system (e.g., pilosebaceous units and loose connective tissue stroma). Therefore, they have low chance of metastasis and highly curable. Occasionally occurring metastases are associated with long-standing history of neglecting and untreating a large, ulcerating, and aggressively growing, nonhealing lesions.</p>
<p>PATIENT EDUCATION</p>
<p>Basal Cell Carcinoma</p>
<ul>
<li>UV radiation exposure, especially a person's life style, habits, and susceptibility to solar radiation, is the biggest contributing factor in developing a BCC.</li>
<li>Any nonhealing, new-growth lesions on sun-exposed areas should be evaluated for possible nonmelanoma skin cancers such as BCC.</li>
<li>Cryotherapy and topical agents (e.g., imiquimod, 5-fluorouracil) are effective treatments for superficial BCC without the need to undergo invasive surgical procedures.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="squamous-cell-carcinoma">SQUAMOUS CELL CARCINOMA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#squamous-cell-carcinoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>SCC is the second most common form of skin cancer. SCCs frequently develop on sun-exposed areas due to UV irradiation-induced skin keratinocytes damage and malignant transformation. Unlike BCC, SCC may metastasize via lymphatic or hematogenous spread.</p>
<p>A. Definition: SCC is a malignant epithelial neoplasm arising from the mutated keratinocytes in the epidermal layer of the skin.</p>
<p>B. Incidence:</p>
<ol>
<li>Approximately 20% of NMSC occurrence and over 700,000 case annually</li>
<li>Higher incidence among men, advanced age, history of excessive sun exposure, and having multiple AKs</li>
<li>Risk factors:</li>
</ol>
<p>a. Chronic sun exposure
b. Immunosuppression
c. Genetic predispositions
d. Chemical carcinogen exposures
e. X-ray irradiation
f. Geographic factors
g. Chronic inflammation/nonhealing wounds</p>
<p>C. Etiology:</p>
<ol>
<li>Cumulated dose of UV radiation: excessive UV light absorbed by DNA of keratinocytes results in damage and malignant transformation. Chronic UVB radiation including</li>
</ol>
<p>excessive childhood sun exposure is the most contributory cause of sun damage in cumulative sun exposure.</p>
<ol start="2">
<li>Ionizing radiation.</li>
<li>Scar including thermal injury.</li>
<li>Chronic inflammation: nonhealing wounds (e.g., chronic ulcer, burns, and infection) and chronic inflammatory dermatoses such as lichen sclerosus et atrophicus. Cutaneous SCC arising from a chronic wound is also known as Marjolin ulcer.</li>
<li>Immunosuppression: solid organ transplant recipients, immunosuppressant medication users, HIV infection, and prolonged use of oral prednisone.</li>
<li>Genetic disorders: XP, albinism, epidermolysis bullosa (EB) syndrome, epidermodysplasia verruciformis, Fanconi anemia, Fergus-Smith syndrome, dyskeratosis congenital, Rothmund-Thomson syndrome, Bloom syndrome, and Werner syndrome.</li>
<li>Human papillomavirus (HPV) infection: HPV-16, HPV-18, HPV-31, HPV-5, and HPV-8. Large group of HPV are DNA tumor viruses that affect the mucosa and skin epithelial layer, resulting in hyperproliferative lesions and development of SCCs.</li>
<li>Organic hydrocarbons (coal, tar, pitch, crude, paraffin oil, lubricating oil, fuel oil, anthracene oil, and creosote) and inorganic arsenic. Presence of palmoplantar arsenical keratoses is the clue of arsenic exposure.</li>
<li>PUVA: risk increases with number of treatments, previous exposure of ionizing radiation, and history of prior skin cancers.</li>
<li>Use of photosensitizing medications: voriconazole, oral contraceptives, and BRAF inhibitors (vemurafenib, dabrafenib)</li>
<li>Precursor lesions include solar keratoses, arsenical keratoses, thermal keratoses, chronic radiation keratoses, tar keratoses, chronic cicatrix keratoses, Bowen disease, erythroplasia of Queyrat, and EV (Lewandowsky-Lutz syndrome).</li>
</ol>
<p>D. Pathogenesis:</p>
<ol>
<li>
<p>Chronic UV exposure induces several different cellular responses, including the induction of stress protein, DNA damage repair process, and cytokine production.</p>
</li>
<li>
<p>In dose-dependent DNA damage, affected cells first either undergo apoptosis (cell death as sunburn cells) or cease proliferating (cell cycle arrest) in order to undergo genetic repair process. Then, hyperproliferation and epidermal thickening follow the growth arrest.</p>
</li>
<li>
<p>In SCC development, accumulated dose of UV radiation exposure induces DNA damage and manifestation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>p</mi><mn>53</mn></mrow><annotation encoding="application/x-tex">p53</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord">53</span></span></span></span></span> genetic mutation.</p>
</li>
<li>
<p>Mutated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>p</mi><mn>53</mn></mrow><annotation encoding="application/x-tex">p53</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord">53</span></span></span></span></span> in basal layer becomes resistant to UV-induced apoptosis and continuously increases the number of mutated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>p</mi><mn>53</mn></mrow><annotation encoding="application/x-tex">p53</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord">53</span></span></span></span></span> in clonal expansion.</p>
</li>
<li>
<p>Continuous UV irradiation causes second <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>p</mi><mn>53</mn></mrow><annotation encoding="application/x-tex">p53</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord">53</span></span></span></span></span> mutation and gains the growth advantage in squamous cell dysplasia in the epidermal layer.</p>
</li>
<li>
<p>Additional genetic alteration leads to proliferation of neoplastic clone and results in SCC <em>in situ</em> at the epidermal surface.</p>
</li>
<li>
<p>Neoplastic tumor progresses to develop invasive property by additional genetic alteration and acquisition of invasive capability to become invasive SCC.</p>
</li>
<li>
<p>Highly differentiated tumors in invasive SCC form epidermal keratinization and invade to the dermis with a broad tumor margin.</p>
</li>
<li>
<p>Continuous progression in tumorigenesis with genetic alteration allows the acquisition of the metastatic capacity in the metastasis of SCC.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-clinical-variants">II. CLINICAL VARIANTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-clinical-variants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Invasive SCC (Figure 16-8): dysplastic or malignant keratinocytes involve the full thickness of the epidermis and infiltrate through the basal layer, dermis, or deeper tissues/organs.</p>
<ol>
<li>Well differentiated: pink, violaceous, or erythematous; firm, indurated papulonodule or plaque, with hyperkeratotic scale</li>
<li>Poorly differentiated: erythematous or pale pink, soft granulomatous papule or plaque may have ulceration, necrosis, or hemorrhaging without hyperkeratosis.</li>
</ol>
<p>B. Nodular SCC (Figure 16-9): often well-differentiated, pink or erythematous nodule with keratotic scale.</p>
<p>C. SCC in situ (Bowen disease) (Figure 16-10): erythematous, crusty, rough, and scaly patch or slightly raised plaque.</p>
<p>D. Oral SCC (Figure 16-11): pink or pale indurated plaque, ulcer, or nodule developed on the floor of the mouth or on the ventral/lateral side of the tongue. SCC may arise from erythroplakia (premalignant erythematous patches) or leukoplakia (persistent white plaques) of the oral mucosa.</p>
<p>E. Erythroplasia of Queyrat (SCC in situ of the glans penis) (Figure 16-12): erythematous, well-demarcated velvety patch or slightly raised plaque.</p>
<p>F. Keratoacanthoma (Figure 16-13): fast-growing (1.5 to 2 cm in 4 to 6 weeks), erythematous, pink, or flesh-colored papule or nodule with central keratotic plug.</p>
<p>G. Verrucous carcinoma (Figure 16-14): indolent form of a well-defined, exophytic, large wart-like papillomatous growth involving oral mucosa (oral florid papillomatosis), anogenital areas (condyloma acuminatum of Buschke-Lowenstein), and plantar foot (epithelioma cuniculatum).</p>
<p><img src="assets/images/image-20251225-7bfaf5e0.jpeg" alt="img-7.jpeg">
FIGURE 16-8. Invasive squamous cell carcinoma. (From Weisel, S. W. (2013). Operative techniques in orthopaedic surgery. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-afd95d01.jpeg" alt="img-8.jpeg">
FIGURE 16-9. Nodular squamous cell carcinoma. (From Craft, N., et al. (2010). VisualDx: Essential adult dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-fb1eb411.jpeg" alt="img-9.jpeg">
FIGURE 16-10. Squamous cell carcinoma in situ. (From Craft, N., et al. (2010). VisualDx: Essential adult dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-b7ebad2b.jpeg" alt="img-10.jpeg">
FIGURE 16-11. Oral squamous cell carcinoma. (From DeLong, L., &amp; Burkhart, N. (2007). General and oral pathology for the dental hygienist. Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-64d933d9.jpeg" alt="img-11.jpeg">
FIGURE 16-12. Penile squamous cell carcinoma in situ. (From Craft, N., et al. (2010). VisualDx: Essential adult dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-83d82a59.jpeg" alt="img-12.jpeg">
FIGURE 16-13. Keratoacanthoma. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-f20dcdc4.jpeg" alt="img-13.jpeg">
FIGURE 16-14. Verrucous carcinoma. (From Craft, N., et al. (2010). VisualDx: Essential adult dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-laboratory-and-diagnostic-tests">III. LABORATORY AND DIAGNOSTIC TESTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-laboratory-and-diagnostic-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Clinical evaluation and skin biopsy for confirmation of diagnosis
B. Computed tomography (CT) scanning evaluation for possible metastasis to nearby bones and soft tissues for aggressively developing invasive-type SCC lesions
C. Magnetic resonance imaging (MRI) evaluation for possible involvement of perineural, orbital, or intracranial nerves for neurologic symptoms (local paresthesia, numbness, pain, visual changes, etc.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-differential-diagnosis">IV. DIFFERENTIAL DIAGNOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-differential-diagnosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Amelanotic melanoma
B. Basal cell carcinoma</p>
<p>C. Hyperkeratotic actinic keratosis
D. Inflamed seborrheic keratosis
E. Merkel cell carcinoma
F. Nummular eczema
G. Paget disease
H. Prurigo nodularis
I. Psoriasis
J. Pyogenic granuloma
K. Traumatic ulcer/chronic inflammation
L. Viral warts (verruca)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="v-treatment-modalities">V. TREATMENT MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-treatment-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Mohs micrographic surgery: a treatment of choice for invasive SCC and high-risk SCC. Mohs procedure is particularly preferred for cosmetically sensitive areas on the head and neck.</p>
<ol>
<li>Histopathologic evaluations of entire margins and depth of the specimen are performed during the procedure (repeated process of harvesting specimen from the surgical defect until total clearance).</li>
<li>Cure rate for tumors smaller than 2 cm is 98%; decreased cure rate to 75% for tumors larger than 2 cm.</li>
</ol>
<p>B. Conventional excision surgery: a typical treatment method for tumors smaller than 2 cm, low-grade, or well-differentiated type on the trunk and extremities.</p>
<p>C. Electrodessication and curettage: treatment for low-grade, small, superficial, and low-risk tumors, preferred on the trunk and extremities.</p>
<ol>
<li>Less invasive treatment option compared to conventional excision surgery</li>
<li>Useful treatment option for patients in advanced age and poor surgical candidates</li>
</ol>
<p>D. Cryotherapy: may be effective in treating very small, low-risk, superficial tumors.</p>
<p>E. 5-Fluorouracil (5-FU) and imiquimod topical treatments (biologic modifiers): effective in treating superficial type and early-stage SCC lesions progressing from AK.</p>
<p>F. PDT using photosensitizing agents with blue light (wavelength 400 nm) is effective in destroying skin cancer cells.</p>
<p>G. Radiation therapy is used in combination with other treatment modalities for large tumors; aggressive, recurrent, or inoperative cases; and poor candidates for invasive surgeries.</p>
<p>H. Regional control</p>
<ol>
<li>Nonpalpable nodes</li>
</ol>
<p>a. Close monitoring for lymphadenopathy
b. Sentinel node biopsy for high-risk SCCs, followed by elective lymph node dissection if node is positive
c. Radiation to draining (primary echelon) nodes for high-risk lesions</p>
<ol start="2">
<li>Palpable nodes</li>
</ol>
<p>a. Radiation
b. Surgery</p>
<p>c. Chemotherapy
d. Combination of above</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vi-prognosis">VI. PROGNOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vi-prognosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The risk of metastasis and prognosis for SCC depend on the size of the tumor, location, depth, perineural involvement, and immunosuppression. SCC lesions developed from ulcerated wounds, chronic inflammation, and recurrent cutaneous lesions are considered high risk for metastasis.</p>
<p><img src="assets/images/image-20251225-020c4df4.jpeg" alt="img-14.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="squamous-cell-carcinoma">Squamous Cell Carcinoma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#squamous-cell-carcinoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>History of chronic UV radiation exposure, including life style, occupational and recreational sun exposure, is the main contributing factor of developing SCC.</li>
<li>Contact with carcinogenic and arsenic chemicals may contribute to development of SCC in situ (Bowen disease).</li>
<li>SCC occurs most commonly on the head, neck, and arms.</li>
<li>Chronically inflamed, ulcerated, and nonhealing wounds should be considered for a skin biopsy to exclude SCC (Marjolin ulcer).</li>
<li>Regular practice of photoprotection (e.g., wearing sun protective clothing, sunglasses, and sunscreen topicals) and seeking treatments for precancerous lesions (AKs) may lead to early detection of SCC and effectively prevent further skin sun damage.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="keratoacanthoma">KERATOACANTHOMA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#keratoacanthoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Keratoacanthoma (KA) is a low-grade, well-differentiated variant of SCC, while the exact classification of the disease is still uncertain and some consider it a benign tumor. KA develops commonly on sun-exposed areas (e.g., head, neck, and extremities). It grows rapidly in 2 to 6 weeks to reach the average size of 0.5 to 2.5 cm in diameter, but it is rarely metastasized. It is manifested as a volcano-like dome-shaped plaque or an exophytic sharply circumscribed, crateriform nodule with central keratotic plug or scale. KA regresses in weeks to months if it is left untreated; however, the regression may result in an irregularly shaped</p>
<p>atrophic scar. KA resembles SCC clinically as well as microscopically and is very difficult to distinguish from an invasive SCC.</p>
<p>A. Definition: KA is a rapidly proliferating, highly differentiated tumor of squamous epithelia, with a keratin scale or keratotic plug, arising from the neck of the hair follicle.</p>
<p>B. Etiology: the origin of the KA is still unclear. Below are the proposed etiologies of KA:</p>
<ol>
<li>Exposure to carcinogenic chemicals such as tar pits.</li>
<li>Smoking</li>
<li>Immunosuppression</li>
<li>HPV infection</li>
<li>Associating with Muir-Torre syndrome (defective DNA mismatch repair gene)</li>
</ol>
<p>C. Pathogenesis:</p>
<ol>
<li>Some case studies report KA arises from p53 mutation and overexpression of P53 protein in signaling pathway.</li>
<li>Microsatellite instability and mismatch repair deficient in genetic defect may have association with cancer-prone Muir-Torre syndrome.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-clinical-variants">II. CLINICAL VARIANTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-clinical-variants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Clinical presentation of KA resembles SCC, even at the microscopic level; therefore, the differentiation between SCC and KA can be challenging.</p>
<p>A. Clinical stages in KA manifestation:</p>
<ol>
<li>Proliferative stage: sudden development and growth of firm papule with fine telangiectases for 2 to 4 weeks</li>
<li>Mature stage: formation of a nodular plaque with central keratotic scale or plug</li>
<li>Resolving/involution stage: tumor reabsorption within 4 to 6 months, result in slightly atrophic, depressed, and pale scar</li>
</ol>
<p>B. Solitary KA (Figures 16-15 and 16-16)</p>
<ol>
<li>KA centrifugum: solitary lesion that sizes up to 20 cm with simultaneous healing at the center of the lesion. Common sites are on the face, trunk, or extremities.</li>
<li>The giant KA: solitary, rapid-growing large lesion (average 9 cm or more). It's invasive and may involve underlying structures including cartilage.</li>
<li>Subungual KA: rapidly growing, locally aggressive tumor, originating in the nail bed. It's a persistent, tender, swollen, erythematous, and umbilicated lesion, frequently involving the thumb or little finger with potential local bony destruction.</li>
</ol>
<p>C. Multiple KAs (Figure 16-17):</p>
<ol>
<li>Ferguson-Smith (spontaneously regressing multiple KAs): sudden eruption of multiple KAs on sun-exposed areas such as face and extremities. Lesions resolve slowly with potential of recurrence. This condition is hereditary in an autosomal dominant pattern, and the incidence is usually during adulthood (approximately in the third decade of life).</li>
<li>Grzybowski (nonregressing grouped KA): suddenly erupting generalized, disseminated 2- to 3-mm papules resembling milia or early eruptive xanthomas. They involve anywhere on the body including hands and feet, oral mucosa, and larynx. May resolve slowly over</li>
</ol>
<p>many months, and the lesions on the face may result in mask-like facies, ectropion, and atrophic scars.</p>
<ol start="3">
<li>Muir-Torre syndrome (may have sebaceous differentiation): multiple sebaceous tumors and KA tumors start as erythematous papules and rapidly develop into shiny or flesh-colored nodules with telangiectases and central keratotic plug.</li>
</ol>
<p><img src="assets/images/image-20251225-5440ec19.jpeg" alt="img-15.jpeg"></p>
<p>FIGURE 16-15. Keratoacanthoma. An inflamed violaceous nodular plaque with a central keratotic plug. (Courtesy of Grace Chung.)</p>
<p><img src="assets/images/image-20251225-38baee48.jpeg" alt="img-16.jpeg"></p>
<p><img src="assets/images/image-20251225-6b2badb4.jpeg" alt="img-17.jpeg">
FIGURE 16-16. Keratoacanthoma. A solitary, pink nodule with central keratin-filled crater. (Courtesy of Grace Chung.)
FIGURE 16-17. Multiple keratoacanthoma. (From Craft, N., et al. (2010). VisualDx: Essential adult dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-laboratory-and-diagnostic-tests">III. LABORATORY AND DIAGNOSTIC TESTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-laboratory-and-diagnostic-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Clinical skin lesion evaluation: rapid growth of exophytic crateriform nodular lesion
B. Confirmation with skin biopsy: complete excisional biopsy, skin full-thickness shave biopsy, or incisional biopsy in order to obtain the full-thickness specimen down to the subcutaneous fat</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-differential-diagnosis">IV. DIFFERENTIAL DIAGNOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-differential-diagnosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Amelanotic melanoma</p>
<p>B. Basal cell carcinoma
C. Merkel cell carcinoma
D. Squamous cell carcinoma
E. Viral wart</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="v-treatment-modalities">V. TREATMENT MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-treatment-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Treatment modalities are defined by the location and size of the tumor.</p>
<p>A. Complete excision; close resemblance in clinical and histological appearance of KA and SCC suggests treatment of KA as invasive SCC.
B. Mohs micrographic surgery.
C. Electrodessication and curettage (ED&amp;C).
D. Radiation therapy.
E. Intralesional pharmacologic therapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vi-prognosis">VI. PROGNOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vi-prognosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The risk of metastasis is low in KA, but complete excision of the lesion is recommended when there is no clear distinction between KA and SCC. Although some believe that a KA is a benign tumor, it is commonly treated rather than observed for spontaneous resolution. KA has potential for recurrence, but it is highly curable.</p>
<p><img src="assets/images/image-20251225-e8f81814.jpeg" alt="img-18.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="keratoacanthoma">Keratoacanthoma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#keratoacanthoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Keratoacanthoma (KA) is a rapidly growing (in just a few weeks to a few months), nodular skin lesion commonly appearing on sun-exposed areas.</li>
<li>KA lesions are often described as mild to moderately tender to the touch, little volcano-like nodules with central keratotic scale.</li>
<li>People with history of excessive sun exposure through geographic location, occupation, recreation, and lifestyle are at risk of developing KA.</li>
<li>Treatment of KA is preferred over active monitoring to exclude the risk of SCC and minimize the scarring that may result from spontaneous solving.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="malignant-melanoma">MALIGNANT MELANOMA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#malignant-melanoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cutaneous malignant melanoma (MM) is a potentially life-threatening, dangerous skin cancer. The development of melanoma and its progression can be determined by genetic predisposition and mutation, mutagenic environmental factors, and the host's immune response. Melanoma can be successfully cured when detected and adequately treated early. Melanoma may disseminate to any organ, most commonly in skin and subcutaneous tissue, lymph nodes, lungs, liver, brain, bone, and gastrointestinal tract.</p>
<p>A. Definition: melanoma is a malignant neoplasm of melanocytes (pigment-forming cells) and nevus cells, with a manifestation of irregular size, shape, or atypical pigmentation. It may arise from a preexisting nevus or de novo (from a new nevus).</p>
<p>B. Incidence:</p>
<ol>
<li>Melanoma is the most dangerous form of skin cancer.</li>
<li>Most common form of malignant disease in young adults between 25 and 29 years old and the second most common form of malignant disease in adolescents.</li>
<li>Estimated 9,710 melanoma deaths and 76,100 new cases projected in 2014.</li>
<li>Melanoma accounts for approximately 75% of skin cancer-related deaths.</li>
<li>The lifetime risk of developing melanoma is 1 in 50 for Whites, 1 in 200 for Hispanics, and 1 in 1,000 for African Americans.</li>
<li>Gender difference in melanoma incidence varies by age groups:
a. Men &lt; women (under 40 years old)
b. Men &gt; women (over 40; twofold by age 60)</li>
<li>The risk of developing melanoma increases with advanced age.</li>
<li>The 5-year survival rate is 98% for early detected melanoma before lymph node involvement; the rate decreases to 62% and 16% for regional and distant metastasis, respectively.</li>
<li>Risk factors:
a. History of excessive sun exposure and blistering sunburns
b. Dysplastic nevi and familial multiple dysplastic nevi syndrome
c. Multiple moles (&gt;50)
d. Freckling
e. Personal and family history of melanoma
f. Genetic factors: fair skin, red hair, freckles
g. Socioeconomic status
h. Immunosuppression
i. Advanced in age
j. Gender (male &gt; female)</li>
</ol>
<p>C. Etiology:</p>
<ol>
<li>
<p>Occupational or recreational UV exposure (e.g., outdoor occupations, use of tanning beds, sun bathing)
a. UVA rays cause skin aging, wrinkling, and DNA damage.
b. UVB rays cause sunburn and skin DNA damage.</p>
</li>
<li>
<p>Dysplastic nevi (atypical moles) or multiple dysplastic nevi syndrome
a. Lifetime risk for persons with dysplastic nevi syndrome is greater than 10%.
b. Persons with congenital melanocytic nevi (moles present at birth) have risk of developing melanoma estimated between 0% and 10% depends on the size and location of the moles.</p>
</li>
<li>
<p>Fair skin, light hair and freckling, and burns easily
a. Ten times higher risk of developing melanoma for Whites compared to African Americans
b. More than double the risk of developing melanoma in people who had five or more severe sunburns during childhood and adolescence</p>
</li>
<li>
<p>Personal history of melanoma:
a. 5% chance of recurrence in persons with history of melanoma</p>
</li>
<li>
<p>Family history of melanoma:
a. About 10% of people with melanoma have family history of melanoma among their first-degree relatives.
b. Approximately 10% to 40% of genetic mutation involved in families with high rate of melanoma.
c. Abnormalities on chromosome 9p21 and melanoma-susceptible genes such as p16.</p>
</li>
<li>
<p>Genetic disorders such as XP-defective DNA mechanism to repair chronic UV damage led to development of skin cancers including melanoma in sun-exposed areas</p>
</li>
</ol>
<p>D. Pathogenesis:</p>
<ol>
<li>Different sites of the body, different amount of UV radiation, and different genetic makeups and oncogene mutations in each individual result in different types of melanoma.</li>
<li>Most common genetic mutations in melanoma involve disorders of the cell cycle pathways and transcriptional control mechanisms.</li>
<li>The mutation of CDKN2A gene located on chromosome 9p21 (codes for p16 and p14ARF proteins) is highly associated with the predisposition to develop melanoma.</li>
<li>The genetic mutation involving CDKN2A interferes with p53 in cell cycle progression and keeps on producing mutagenic DNA via cell division cycles and allows uncontrolled proliferation of mutated melanocytes.</li>
<li>CDKN2A involved in germline mutation, which explains the genetic factors in familial melanoma disease.</li>
<li>BRAF gene mutation is also found in about 40% to 60% of melanomas in intermittently sun-exposed individuals who developed melanoma, more commonly seen in young people.</li>
<li>NRAS-mutated oncogene is found in 15% to 20% of melanomas, more often in people with later age-at-onset melanomas.</li>
<li>C-KIT-mutated oncogene is most common in site-specific melanomas such as in mucosal (40%), acral (35%), and sun-damaged skin (25% to 30%) areas.</li>
<li>Melanoma is an immunogenic malignant tumor; therefore, complete or partial regression may occur.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-clinical-variants">II. CLINICAL VARIANTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-clinical-variants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Superficial spreading melanoma (SSM) (Figure 16-18)</p>
<ol>
<li>Most common subtype appears on any anatomic surface, but most common on the back for men and the legs for women.</li>
<li>Accounts for 70% of all diagnosed melanoma and is a leading cause of melanoma death for young adults.</li>
<li>It may occur at any age for both men and women, but slightly higher incidence in women.</li>
<li>Commonly appear as well-demarcated, asymmetrical, dark-pigmented macule or a patch or even slightly raised.</li>
<li>May arise within preexisting melanocytic nevus or <em>de novo</em>, with variegated colors including brown, black, pink, blue, gray, or white areas (possible regression) and with irregular borders.</li>
<li>Regression in SSM is a less pigmented area of a dark-pigmented SSM lesion, as a result of host’s immune responses trying to destroy it.</li>
</ol>
<p>B. Nodular melanoma (NM) (Figure 16-19)</p>
<ol>
<li>The second most common type of melanoma and accounts for 10% to 15% of all melanoma diagnosis.</li>
<li>May develop anywhere on the body and more commonly seen among persons aged 60 years and older.</li>
<li>Sudden appearance of nodular growth, in black, dark brown, or blue colors with well-defined border.</li>
<li>Rapid vertical growth of the tumor warrants deeper invasion and high potential of metastasis with poor prognosis.</li>
<li>Commonly arises <em>de novo</em> in uninvolved skin and often delays detection and treatment.</li>
<li>NM is typically a dark-pigmented lesion, but it may appear as a nonpigmented, flesh-colored nodule (amelanotic melanoma; Figure 16-20) or mimicking a scar or a benign cyst (desmoplastic neurotropic melanoma).</li>
</ol>
<p>C. Acral lentiginous melanoma (ALM) (Figure 16-21)</p>
<ol>
<li>Typically occurs on the palms, soles, subungual areas, and mucous membranes (mouth, nose, genitalia, anus, and urinary tract) in persons with more pigmented skin, such as Blacks, Asians, and non-White Hispanics. Accounts for 5% of total melanoma occurrence.
a. 2% to 8% occurrence in Whites
b. 29% to 72% in dark-skinned persons</li>
<li>It presents as a flat, tan, brown to darkly pigmented macule or patch.</li>
<li>Subungual melanoma is a variant type and appears as dark-pigmented spot or fixed streaks from the proximal nail bed that does not move even with the nail growth.</li>
<li>Appearance of pigmented nail fold skin and destruction of the nail plate may indicate advanced ALM.</li>
<li>Based on the history of no recent trauma and bleeding under the nail plate (subungual hematoma), nail separating from the nail bed should be evaluated.</li>
<li>Mucous membrane involvement is often found in the mouth or inside of the nose, with</li>
</ol>
<p>symptoms including frequent nosebleed, nasal congestion, and pigmented growth or a mass inside the nose and mouth.</p>
<p>D. Lentigo maligna melanoma (LMM) (Figure 16-22)</p>
<ol>
<li>Occurs on exposed surface of the body, often on the face and scalp of elderly persons.</li>
<li>Often misdiagnosed as a benign age spot, sun spot, or a lentigo simplex.</li>
<li>Typically, gradual growth and evolvement over 10 to 15 years results in irregular pigmentation, shape, and border, but it's not uncommon to see faster-growing LMM in matter of weeks to months.</li>
<li>A pigmented LMM patch may evolve into a nodular tumor, but it may also regress and appear as a blue-gray or white lesion.</li>
<li>An LMM can give rise to a desmoplastic melanoma, a fibrous tumor that has tendency to grow down and affect nerves of the skin.</li>
</ol>
<p><img src="assets/images/image-20251225-63436a16.jpeg" alt="img-19.jpeg">
FIGURE 16-18. Superficial spreading melanoma. (From Werner, R. (2012). Massage therapist's guide to pathology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-46ea0ec3.jpeg" alt="img-20.jpeg"></p>
<p><img src="assets/images/image-20251225-4140a375.jpeg" alt="img-21.jpeg">
FIGURE 16-19. Nodular melanoma. This melanoma lesion was a  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.2</mn><mrow><mo>−</mo><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">1.2\mathrm{-cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.2</span><span class="mord"><span class="mord">−</span><span class="mord mathrm">cm</span></span></span></span></span></span>  diameter nodule on a man's midback. Its maximum tumor thickness was at least  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.14</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">3.14\mathrm{mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3.14</span><span class="mord"><span class="mord mathrm">mm</span></span></span></span></span></span> , with mitotic rate  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">/</mi><msup><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">15 / \mathrm{mm}^2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mord">15/</span><span class="mord"><span class="mord"><span class="mord mathrm">mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span> , anatomic level IV, and staged as T3aN0M0. (Courtesy of Grace Chung.)
FIGURE 16-20. Amelanotic melanoma. A  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mrow><mo>−</mo><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">2.5\mathrm{-cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mord"><span class="mord">−</span><span class="mord mathrm">cm</span></span></span></span></span></span>  diameter,  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6.5</mn><mrow><mo>−</mo><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">6.5\mathrm{-mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6.5</span><span class="mord"><span class="mord">−</span><span class="mord mathrm">mm</span></span></span></span></span></span>  maximum tumor thickness, hypopigmented nodular amelanotic melanoma on a man's back. This patient's lymph node biopsy showed metastatic melanoma in 2 of 26 nodes. (Courtesy of Grace Chung.)</p>
<p><img src="assets/images/image-20251225-a3625899.jpeg" alt="img-22.jpeg">
FIGURE 16-21. Acral lentiginous melanoma. (Courtesy of Art Huntley, MD, University of California at Davis.)</p>
<p><img src="assets/images/image-20251225-0a7c65c0.jpeg" alt="img-23.jpeg"></p>
<p>1</p>
<p>FIGURE 16-22. Lentigo maligna melanoma. (From Penne, R. B. (2011). Wills Eye Institute—Oculoplastics. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-clinical-assessment-for-melanoma">III. CLINICAL ASSESSMENT FOR MELANOMA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-clinical-assessment-for-melanoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Early detection and diagnosis are the most critical factors in overall survival rates.</p>
<p>A. Suspected lesions most commonly include asymmetry, border irregularity, color variation, diameter greater than 6 mm, and elevated lesion (ABCDE rule).</p>
<p>B. The most suspicious sign for melanoma is persistently changing (size, color, elevation, itching) pigmented lesion.</p>
<p>C. Other findings that are suspicious include new pigmented lesions after the age of 30 to 40 and multiple halo nevi in mid-to-late adult life.</p>
<p>D. Ulceration correlates with tumor thickness and is a significant feature.</p>
<p>E. Atypical melanoma lesions may appear as nonpigmented, flesh-colored nodules (amelanotic melanoma) or mimicking scars or benign cysts (desmoplastic neurotropic melanoma).</p>
<p>F. Physical examination of the patient with melanoma should include:</p>
<ol>
<li>History of the patient and family, including history of the lesion</li>
<li>Computerized digital imaging to allow retrieval and comparison of previously stored images of new and existing lesions (if available)</li>
<li>Meticulous skin examination of entire skin surface including the scalp and genitalia</li>
<li>Careful palpation of all lymph nodes with special attention to primary draining nodes</li>
<li>Body systems evaluation especially of the brain, lungs, bone, gastrointestinal, and constitutional symptoms</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-laboratory-and-diagnostic-tests">IV. LABORATORY AND DIAGNOSTIC TESTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-laboratory-and-diagnostic-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Thorough history taking from patients including onset, duration, changes in color, shape, size, spontaneous bleeding and ulcerating, and evolution of the lesion. Visual inspection and comparison to the criteria of ABCDE rule:</p>
<ol>
<li>Asymmetry (A): mismatching half</li>
<li>Border (B): poorly defined, atypical, or irregular border</li>
<li>Color (C): variegated shades (e.g., black, blue, reddish brown, tan, white)</li>
<li>Diameter (D): frequently greater than 6 mm (may be smaller)</li>
<li>Elevation/evolution (E): evolving in color, shape, and size</li>
</ol>
<p>B. Dermoscopy/epiluminescence microscopy: clinical inspection using handheld magnifying/illuminating device for surface analysis</p>
<ol>
<li>
<p>Skin biopsy is strongly recommended for definitive diagnosis and guidance for further follow-up.</p>
</li>
<li>
<p>Determination of the type of skin biopsy is based on the clinical presentation of the suspicious lesion: narrow excision biopsy with safety margin of 2-mm normal skin provides entire lesion or avoid transection of the lesion, adequate specimen for analysis, and staging of the lesion.</p>
</li>
<li>
<p>Incisional biopsy (partial sampling) is acceptable for a lesion with low clinical suspicion and large lesions. Repeat biopsy is suggested if the interpretation (e.g., diagnosis or microstaging) is inconclusive due to the inadequate size of specimen.</p>
</li>
<li>
<p>Chest x-ray and CBC/LDH screening for biopsy are proven invasive melanoma diagnosis.</p>
</li>
<li>
<p>Immunohistochemistry including S100 protein and HMB-45 can be used with panel of antibodies against other tumor markers to help diagnose otherwise nonobvious melanoma (performed by dermatopathologists).</p>
</li>
<li>
<p>Lymphatic mapping with sentinel lymph node biopsy (SLNB) for patients at risk for occult regional lymph node metastases. (Determined and performed by oncologists.)</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="v-differential-diagnoses">V. DIFFERENTIAL DIAGNOSES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-differential-diagnoses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Basal cell carcinoma/pigmented basal cell carcinoma
B. Benign melanocytic nevus
C. Blue nevus
D. Epidermal inclusion cyst
E. Hypertrophic scar
F. Kaposi sarcoma
G. Merkel cell carcinoma
H. Neurofibroma
I. Pigmented seborrheic keratosis
J. Pyogenic granuloma
K. Solar lentigo
L. Spitz nevus
M. Verruca vulgaris</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vi-staging-classification">VI. STAGING CLASSIFICATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vi-staging-classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Summary of 2010 American Joint Commission on Cancer (AJCC) Melanoma Staging System</p>
<ol>
<li>
<p>The tumor-node-metastasis (TNM) system by the AJCC is the primary guideline for cancer staging and widely used (Table 16-1 and Box 16-1).</p>
</li>
<li>
<p>2010 AJCC melanoma staging system update: primary tumor mitotic rate (T1 mitoses/mm²) replaced Clark level of invasion as the primary criterion for staging and prognosis and predictor for survival. The presence of tumor ulceration remains as the criterion for adverse predictor for survival.</p>
</li>
<li>
<p>Tumor ulceration, a condition that has missing parts of the epidermis of the primary tumor, indicates deeper tissue involvement and greater chance of metastasis compared to</p>
</li>
</ol>
<p>nonulcerated tumors. This is determined by pathologists through microscopic examination of the tissue.</p>
<ol start="4">
<li>T is for classifying the tumor based on its three features: thickness (Breslow depth in millimeters [mm]), mitoses, and ulceration.</li>
</ol>
<p>N is for indicating involvement of the echelon (nearby) lymph nodes.</p>
<p>M is for indicating the metastatic status and involvement of distant sites.</p>
<ol start="5">
<li>
<p>Mitotic rate indicating the cell division of the tumor and the tumor thickness (Breslow depth) are the primary predictors of the survival.</p>
</li>
<li>
<p>The metastatic lymph nodes are determined by sentinel lymph node dissection (SLND) or elective lymph node dissection (ELND) of the echelon lymph nodes to examine the presence of the melanoma.</p>
</li>
</ol>
<p>a. Macrometastases can be palpated by physical examination of the lymph nodes.</p>
<p>b. Micrometastases are detected only by microscopic evaluation after SLN biopsy.</p>
<ol start="7">
<li>Metastasis to distant sites of skin and other vital organs is also screened by the level of serum lactate dehydrogenase (LDH). LDH elevation may indicate the metastatic disease status. Staging 0 to IV on the basis of the new TNM staging system:</li>
</ol>
<p>a. Stage 0 (TisN0M0): melanoma in situ. Tumor is confined to the epidermis.</p>
<p>b. Stage I melanoma: determined by the presence or absence of mitoses and ulceration. There are no other indications of regional lymph node involvement or distant metastasis.</p>
<ol>
<li>
<p>Stage IA, T1aN0M0: tumor 1 mm or smaller without mitosis or ulceration</p>
</li>
<li>
<p>Stage IB, T1bN0M0: tumor 1 mm or smaller with mitosis or ulceration</p>
</li>
</ol>
<p>c. Stage II melanoma: determined by the status of tumor thickness and ulceration. There are no other indications of regional lymph node involvement or distant metastasis.</p>
<ol>
<li>
<p>Stage IIA: T2bN0M0 or T3aN0M0</p>
</li>
<li>
<p>Stage IIB: T3bN0M0 or T4aN0M0</p>
</li>
<li>
<p>Stage IIC: T4bN0M0</p>
</li>
</ol>
<p>d. Stage III melanoma: determined by the level of lymph node metastasis. There are no other indications of distant metastasis.</p>
<ol>
<li>
<p>Stage IIIA: T1-T4aN1aM0 or T1-T4aN2aM0</p>
</li>
<li>
<p>Stage IIIB: T1-T4bN1aM0, T1-T4bN2aM0, T1-T4aN1bM0, T1-T4aN2bM0, or T1-T4a/bN2cM0</p>
</li>
<li>
<p>Stage IIIC: T1-4bN1bM0, T1-4bN2bM0, or T1-4a/bN3M0</p>
</li>
</ol>
<p>e. Stage IV melanoma: staging is determined by the location of sites of the metastases (e.g., skin, soft tissue, distant lymph nodes, and vital organs including liver, lungs, bones, and brain) and level of serum LDH.</p>
<ol>
<li>
<p>M1a: tumor metastasis to distant skin, the subcutaneous layers, or lymph nodes; serum LDH is normal.</p>
</li>
<li>
<p>M1b: tumor metastasis to lungs; serum LDH is normal.</p>
</li>
<li>
<p>M1c: tumor has metastasis to vital organs other than lungs; serum LDH is normal or elevated.</p>
</li>
</ol>
<p>TABLE 16-1 American Joint Committee on Cancer Melanoma Staging</p>
<p>System,
2010^{a}</p>
<table><thead><tr><th>Clinical Stage</th><th>Primary Tumor (T)</th><th>Regional Lymph Nodes (N)</th><th>Distant Metastasis (M)</th></tr></thead><tbody><tr><td>0</td><td>Tis</td><td>N0</td><td>M0</td></tr><tr><td>IA</td><td>T1a</td><td>N0</td><td>M0</td></tr><tr><td>IB</td><td>T1b</td><td></td><td></td></tr><tr><td>T2a</td><td>N0</td><td>M0</td><td></td></tr><tr><td>IIA</td><td>T2b</td><td></td><td></td></tr><tr><td>T3a</td><td>N0</td><td>M0</td><td></td></tr><tr><td>IIB</td><td>T3b</td><td></td><td></td></tr><tr><td>T4a</td><td>N0</td><td></td><td></td></tr><tr><td>N0</td><td>M0</td><td></td><td></td></tr><tr><td>M0</td><td></td><td></td><td></td></tr><tr><td>IIC</td><td>T4b</td><td>N0</td><td>M0</td></tr><tr><td>III</td><td>Any T</td><td>N1, N2, or N3</td><td>M0</td></tr><tr><td>IV</td><td>Any T</td><td>Any N</td><td>M1</td></tr></tbody></table>
<p>aClinical staging includes microstaging of the primary melanoma and clinical/radiologic evaluation for metastases. By convention, it should be used after complete excision of the primary melanoma with clinical assessment for regional and distant metastases.
Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010), published by Springer Science+Business Media. Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer, on behalf of the AJCC.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a66b281a">BOX 16-1. American Joint Committee on Cancer Tumor–Node–Metastasis Definitions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a66b281a" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="primary-tumor-t">Primary Tumor (T)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#primary-tumor-t" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>TX Primary tumor cannot be assessed (e.g., curettaged or severely regressed melanoma)
T0 No evidence of primary tumor
Tis Melanoma in situ
T1 Melanomas 1.0 mm or less in thickness
T2 Melanomas 1.01 to 2.0 mm
T3 Melanomas 2.01 to 4.0 mm
T4 Melanomas more than 4.0 mm</p>
<p>Note: a and b subcategories of T are assigned based on ulceration and number of mitoses per mm², as shown below:</p>
<table><thead><tr><th>Classification</th><th>Thickness (mm)</th><th>Ulceration Status/Mitoses</th></tr></thead><tbody><tr><td>T1</td><td>≤1.0</td><td>a: w/o ulceration and mitosis &lt; 1/mm2b: with ulceration or mitoses ≥ 1/mm2</td></tr><tr><td>T2</td><td>1.01–2.0</td><td>a: w/o ulcerationb: with ulceration</td></tr><tr><td>T3</td><td>2.01–4.0</td><td>a: w/o ulcerationb: with ulceration</td></tr><tr><td>T4</td><td>&gt;4.0</td><td>a: w/o ulcerationb: with ulceration</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="regional-lymph-nodes-n">Regional Lymph Nodes (N)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#regional-lymph-nodes-n" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>NX Patients in whom the regional nodes cannot be assessed (e.g., previously removed for another reason)</p>
<p>N0 No regional metastases detected</p>
<p>N1-3 Regional metastases based upon the number of metastatic nodes and presence or absence of intralymphatic metastases (in-transit or satellite metastases)</p>
<p>Note: N1 to N3 and a to c subcategories assigned as shown below:</p>
<table><thead><tr><th>N Classification</th><th>No. of Metastatic Nodes</th><th>Nodal Metastatic Mass</th></tr></thead><tbody><tr><td>N1</td><td>1 node</td><td>a: micrometastasia b: macrometastasib</td></tr><tr><td>N2</td><td>2–3 nodes</td><td>a: micrometastasia b: macrometastasib c: in-transit met(s)/ satellite(s) without metastatic nodes</td></tr><tr><td>N3</td><td>4 or more metastatic nodes, or matted nodes, or in-transit met(s)/satellite(s) with metastatic node(s)</td><td></td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="distant-metastasis-m">Distant Metastasis (M)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#distant-metastasis-m" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>M0 No detectable evidence of distant metastases</p>
<p>M1a Metastases to the skin, subcutaneous, or distant lymph nodes</p>
<p>M1b Metastases to the lung</p>
<p>M1c Metastases to all other visceral sites or distant metastases to any site combined</p>
<p>with an elevated serum LDH</p>
<p>Note: Serum LDH is incorporated into the M category as shown below:</p>
<table><thead><tr><th>M Classification</th><th>Site</th><th>Serum LDH</th></tr></thead><tbody><tr><td>M1a</td><td>Distant skin, subcutaneous, or nodal metastasis</td><td>Normal</td></tr><tr><td>M1b</td><td>Lung metastases</td><td>Normal</td></tr><tr><td>M1c</td><td>All other visceral metastases</td><td></td></tr><tr><td>Any distant metastasis</td><td>Normal</td><td></td></tr><tr><td>Elevated</td><td></td><td></td></tr></tbody></table>
<p>a Micrometastases are diagnosed after sentinel lymph node biopsy and completion of lymphadenectomy (if performed).
b Macrometastases are defined as clinically detectable nodal metastases confirmed by therapeutic lymphadenectomy or when nodal metastasis exhibits gross extracapsular extension.
Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010), published by Springer Science+Business Media. Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer, on behalf of the AJCC.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vii-metastatic-and-recurrent-melanoma">VII. METASTATIC AND RECURRENT MELANOMA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vii-metastatic-and-recurrent-melanoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Local recurrence is related to tumor thickness and defined as a recurrence in close proximity to the surgical scar or site of primary cutaneous melanoma (3% rate).
B. In-transit metastases/satellites are small cutaneous tumors present in the dermis and subdermal between the primary melanoma site and the draining nodal basin.
C. Lesions occurring within 2 cm of primary tumor are termed satellites, whereas in-transit metastases are more than 2 cm from site.
D. Regional lymph node metastasis</p>
<ol>
<li>Highly predictive of visceral metastases</li>
<li>Risk varies based on tumor thickness of primary
E. Distant metastasis is most frequently to nonvisceral sites, skin, subcutaneous tissue, and distant lymph nodes.
F. Late recurrences occur 10 or more years after initial diagnosis and treatment.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="viii-therapeutic-modalities-by-stage">VIII. THERAPEUTIC MODALITIES BY STAGE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#viii-therapeutic-modalities-by-stage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Stage 0 (Melanoma in situ) Complete excision with safety margins: wide local excision surgery (WLE) with appropriate benign margins (depends on the size and thickness of the</p>
<p>tumor)</p>
<ol>
<li>Melanoma in situ: 0.5-cm normal skin safety margin</li>
<li>Melanoma tumor less than 1 mm: 1-cm horizontal and vertical margin</li>
<li>Melanoma tumor greater than 1 mm: 2- to 3-cm resection margin decided by the anatomical location and conditions</li>
</ol>
<p>B. Stage I Treatment</p>
<ol>
<li>SLNB is recommended by AJCC for ulcerated lesion thicker than 1 mm in order to determine the involvement of local lymph nodes and guidance of treatment options.</li>
<li>Free of lymph node involvement leads to WLE surgery with appropriate benign margins (depends on the size and thickness of the tumor).</li>
</ol>
<p>C. Stage II Treatment</p>
<ol>
<li>SLNB is recommended before undergoing surgery for determining the involvement of local lymph nodes and guides treatment options.
a. Sentinel lymph node dissection: use blue dye or radiolabeled colloid injection at the melanoma site and open the close-by lymph node basin to check the presence of melanoma. Free of tumor at the closest lymph node from the primary tumor site suggests negative for metastasis.</li>
<li>WLE surgery with appropriate margins (depends on the size and thickness of the tumor).</li>
<li>Adjuvant therapy is considered for stage IB and stage IIC melanoma (e.g., interferon alfa-2a and interferon alfa-2b), which helps immune system fight the disease and delay or prevent recurrence.</li>
<li>Some clinical trials used vaccine therapy for patients who could not tolerate interferons; no significant increase in survival rate was shown in randomized controlled trials.</li>
</ol>
<p>D. Stage III Treatment</p>
<ol>
<li>WLE removal of the primary lesion is recommended for recurrent tumors and in-transit tumors.</li>
<li>Therapeutic lymph node dissection (TLND) of the melanoma affected regional lymph nodes for the patient with palpable lymph nodes for possible macrometastases.</li>
<li>Selected patients will have lymphatic mapping and SLND for determining involvement of sentinel node.</li>
<li>Systemic adjuvant therapy in addition to the surgery with interferons (alfa-2a and alfa-2b), which helps immune system to fight the disease and delay or prevent recurrence.</li>
<li>Radiation adjuvant therapy: may consider use of radiation therapy when the tumor has involved tissues beyond lymph nodes to control further spread of melanoma.
a. Regional metastasis radiation therapy (in-transit metastasis).
b. Adjuvant therapy recommended for postsurgical melanoma patients who are free of disease but at high risk for relapse and to complement surgery in the management of melanoma metastatic to lymph nodes.
c. Stereotactic radiation therapy is considered for brain metastases up to two sites; otherwise, radiation of the entire brain for more than two metastatic tumors.
d. Palliative radiotherapy for bone metastases.</li>
</ol>
<p>E. Stage IV Treatment</p>
<ol>
<li>
<p>Surgical removal of metastatic tumors for symptoms treatment</p>
</li>
<li>
<p>Systemic adjuvant therapyChemotherapy</p>
</li>
<li>
<p>Dacarbazine (DTIC) IV infusion</p>
</li>
<li>
<p>Temozolomide oral medication for advanced metastatic melanoma</p>
</li>
<li>
<p>IL-2 or IFNα (biochemotherapy) alone or combination treatment with dacarbazine, cisplatin, temozolomide, carmustine, vinblastine, and tamoxifen.</p>
</li>
<li>
<p>Immunotherapies (e.g., IL-2, INF-α2a and ipilimumab): Treatment strategies with vaccines utilizing tumor cells, antibodies, peptides, and dendritic cells.</p>
</li>
<li>
<p>Specific target therapies: Vemurafenib treatment for BRAF mutation genetic signaling pathways in metastatic and unresectable (inoperable) melanoma.</p>
</li>
<li>
<p>Radiation therapy including x-rays and gamma rays targeting cancer cells, and relieve symptoms to control pain in metastatic disease involving the brain</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ix-prognosis">IX. PROGNOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ix-prognosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-follow-up-recommendations">A. Follow-Up Recommendations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-follow-up-recommendations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Follow-up one to four times per year, for 2 years, depending on the thickness of the primary lesion and other risk factors, then one to two times per year thereafter.</li>
<li>Post melanoma treatment follow up should be tailored to each patient's history of type and thickness of melanoma, presence of atypical nevi, family history of melanoma, patient anxiety, and patient ability to recognize signs and symptoms of disease.</li>
<li>Strong evidence suggests that the majority of metastases and recurrences are discovered by the patient or a family member. Therefore, the patient education program should include how to perform self-conducted skin examination.</li>
<li>5-year and 10-year survival rate: the 5-year survival rate with stages I and II is over 90%, whereas with stage IV, it is approximately 10% to 20%.</li>
</ol>
<p><img src="assets/images/image-20251225-ff3c6114.jpeg" alt="img-24.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="melanoma">Melanoma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#melanoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>
<p>Melanoma is a dangerous type of skin cancer that arises from uncontrolled growth of skin cells that make pigment melanin. It typically appears as a pigmented skin lesion and metastasizes to vital organs, such as liver, lungs and brain, rapidly through the lymphatic system.</p>
</li>
<li>
<p>People with multiple moles (more than 50) should be screened for the familial atypical mole and melanoma syndrome.</p>
</li>
<li>
<p>Self-screening for melanoma can be guided by the ABCDE rule:</p>
</li>
<li>
<p>Asymmetry: irregular shape.</p>
</li>
<li>
<p>Irregular, ill-defined border.</p>
</li>
<li>
<p>Variegated colors like black, red, brown, blue, and white.</p>
</li>
<li>
<p>Diameter noticeably increasing in size.</p>
</li>
<li>
<p>Evolution, elevation, enlarging, and changing.</p>
</li>
<li>
<p>Avoid excessive sun exposure and use sunscreen (SPF 30 or higher) and reapply every 2 hours while staying in the sun.</p>
</li>
<li>
<p>Skin self-examination and clinical skin examination with health care providers are the crucial methods to achieve early detection and treatment of melanoma.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cutaneous-t-cell-lymphoma">CUTANEOUS T-CELL LYMPHOMA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cutaneous-t-cell-lymphoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Cutaneous T-cell lymphoma (CTCL) is a form of non-Hodgkin lymphoma and a type of neoplasm in immune system caused by a mutation of helper (CD4+) T cells. There are various types of CTCLs, but mycosis fungoides (MF) and Sézary syndrome (SS) are the two most common types. CTCL arises primarily in the skin and characterized by remission and exacerbation of skin disease.</p>
<p>A. Definition: CTCL is a malignant disease of T lymphocytes with cutaneous lesions, which arises from proliferation of the cancerous T lymphocytes in the dermis and has tendency to migrate into the epidermis. It progresses gradually through various stages of lesions evolving from a severely pruritic patch to a plaque and to a noduloulcerative lesion and increases the amount of infiltration of malignant T lymphocytes in the skin.</p>
<p>B. Incidence:</p>
<ol>
<li>CTCL represents approximately 4% of all non-Hodgkin lymphoma, with MF comprising the majority of the cases reported.</li>
<li>Age-adjusted incidence of 6.4 to 9.6 cases per million people in the United States.</li>
<li>Majority of the MF cases are among Whites (approximately 70%), and Blacks, Hispanics, and Asians have about 14%, 9%, and 7%, respectively.</li>
<li>Seen in both genders (more frequently in men than in women with 2:1 ratio) with the median age 55 to 60 years old.</li>
</ol>
<p>C. Etiology: no clear etiopathogenesis has been established, but there are several suggested causative factors of CTCL:</p>
<ol>
<li>
<p>Chronic antigen stimulation and accumulation of T-helper memory cells in the skin: Since neoplastic T cells have capability to express antigen-presenting cell (APC) ligands in gene regulation, it may self-stimulate and lead to T-cell expansion in the skin.</p>
</li>
<li>
<p>Infections:
a. Human T-cell leukemia/lymphoma virus (HTLV1), an exogenous RNA retrovirus.
b. Staphylococcus aureus and other associated enterotoxins may associate with the etiology of MF.
c. Epstein-Barr virus and cytomegalovirus.</p>
</li>
<li>
<p>Immunosuppression and immunosuppressive therapy in organ transplant patients</p>
</li>
<li>
<p>Genetic factor
a. Clonal abnormalities in gene expression that separates the entities of MF and SS.
b. Certain histocompatibility antigens are found with increased frequency in CTCL (e.g., increased expression of cutaneous lymphocyte antigen [CLA] and its ligand E-selectin).</p>
</li>
<li>
<p>Development from other dermatoses as many patients have a preceding eruption of variable duration
a. Atopic dermatitis is at risk for developing CTCL from chronic stimulation of T cells and possible induction of clonal proliferation.</p>
</li>
<li>
<p>Environmental factors in susceptible host (retrospective studies)
a. Chemicals (air pollutants, pesticides, solvents and vapors, detergents, disinfectants)
b. Drugs (tobacco, analgesics, tranquilizers, thiazides)
c. Occupational exposure (manufacturing especially in petrochemical, textile, metal, and machinery industries)</p>
</li>
</ol>
<p>D. Pathogenesis:</p>
<ol>
<li>Recent studies suggest different origin of the memory T-cell subsets for the MF and SS.</li>
<li>MF arises from the background of chronic inflammation. Reactive T cells are found along with dendritic cells and other immune cells such as macrophages, mast cells, and plasma cells.</li>
<li>High number of CD8⁺ cytotoxic T cells (antitumor response) in early skin lesions and advanced tumor lesions in later stage shows significantly decreased cytotoxic T cells.</li>
<li>Malignant T cells in the skin involve chemokines, cytokines, and adhesion molecules that facilitate lymphocyte extravasation and migration to the epidermis.</li>
<li>As the disease progresses, there is a change in cytokine expression, which correlates with erythroderma, high level of immunoglobulin E, immunosuppression, and susceptibility to bacterial infections in advanced MF and SS.</li>
<li>Disease progression in MF and SS has been characterized by altered immune system, such as in T-cell proliferation, accumulation in cytogenetic abnormalities, and apoptosis (programmed cell death); defective/dysfunctional apoptosis expressed by neoplastic T cell has been closely associated with advanced and aggressive disease.</li>
<li>Early lesions are often infiltrated with CD8⁺ cytotoxic T lymphocytes, most likely indicating a mediating antitumor response.</li>
<li>Loss of normal immunity with advancing disease compromises antitumor response.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-clinical-presentation">II. CLINICAL PRESENTATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-clinical-presentation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Clinical Stages</p>
<ol>
<li>Patch phase (see Figure 4-16)
a. Lesions typically present in non-sun-exposed areas as dusky red, violaceous, single or multiple scaly macules and patches in various sizes.</li>
</ol>
<p>b. Classic distribution is the buttocks, groin, underneath breasts, and axilla, with persistent pruritus.</p>
<p>c. May be transitory, spontaneously disappearing without scarring.</p>
<p>d. Phase may last months or years; diagnosis at this stage is often difficult.</p>
<p>B. Plaque phase</p>
<ol>
<li>
<p>Plaques may occur from patch-stage lesions or arise from de novo.</p>
</li>
<li>
<p>Eruptions are well defined and dusky red and may appear shiny with wart-like infiltrates; a reddish-blue halo may be observed outside the areas of infiltration.</p>
</li>
<li>
<p>As cells proliferate, lesions become firm, and the plaque varies in surface contour.</p>
</li>
<li>
<p>Lesions may spontaneously regress or coalesce into a large plaque and ulcerate or spontaneously disappear.</p>
</li>
<li>
<p>Associating symptoms are scaly scalp with hair loss, thickened and discolored nails, hyperkeratosis, and scaling/fissuring of the palms and soles; risk of misdiagnosing for eczema or psoriasis at this stage.</p>
</li>
<li>
<p>Patient may present with dermatologic emergency as erythroderma, unstable body temperature, weight loss, insomnia, malaise, vasodilation, and exfoliations, which may cause loss of protein, iron, and electrolytes.</p>
</li>
</ol>
<p>C. Tumor phase (T cells lose their affinity for the skin)</p>
<ol>
<li>
<p>May occur in CTCL plaques or de novo.</p>
</li>
<li>
<p>Lesions appear on the face, back, and body skinfolds as dull reddish brown or purplish red with smooth surface; softly palpable nodular lesions that rapidly grow in size and number.</p>
</li>
<li>
<p>Presentation of the lesions may show secondary infection and excoriation due to severe pruritus. Ulceration and necrosis may occur in later stage.</p>
</li>
<li>
<p>In SS, "red man disease" may occur (Figure 16-23)</p>
</li>
</ol>
<p>a. Term relates to generalized exfoliating erythrodermic CTCL patients with leukocytes and peripheral blood appearance of "monster" cells.</p>
<p>b. Intensely pruritic with lymphadenopathy starting either de novo, following premalignant eruption, or after established plaque stage of the disease.</p>
<ol start="5">
<li>
<p>Different from SS, erythrodermic condition in MF is a progression from the existing lesions, and it has low or no circulating "monster" cell counts.</p>
</li>
<li>
<p>Tumors gradually appear in infiltrative lesions often at the border; may shrink and disappear leaving a pigmented atrophic scar.</p>
</li>
<li>
<p>Widespread CTCL invasion is evidenced by palpable lymph nodes, bone marrow involvement in advanced stages, pulmonary involvement, and osteolytic lesions in the bone with pathologic fractures.</p>
</li>
<li>
<p>Complications of CTCL and cause of death include viral, fungal, and bacterial infections; immunosuppression; and vital organ involvement.</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-c76eebfe.jpeg" alt="img-25.jpeg">
A</p>
<p><img src="assets/images/image-20251225-6d0fef11.jpeg" alt="img-26.jpeg">
B
FIGURE 16-23. Sézary syndrome. A: Mycosis fungoides patient with cutaneous plaques and a tumor. B: Sézary syndrome patient with diffuse erythroderma. (From DeVita, V. T., et al. (2008). DeVita, Hellman, and Rosenberg's cancer: Principles and practice of oncology. Philadelphia, PA: Wolters Kluwer.)</p>
<p>III. LABORATORY AND DIAGNOSTIC TESTS</p>
<p>A. Combination of clinical examination and biopsy is necessary for establishing accurate diagnosis.
B. Molecular immunotyping can be helpful in diagnosing CTCL (e.g., CD4⁺ helper T-cell complex lack in expressing T-cell antigens CD7 and Leu-8).
C. Most sensitive test is Southern Blot test for T-cell antigen receptor rearrangements in peripheral blood (T-cell receptor gene rearrangement test).
D. CBC with determination of absolute lymphocytes count, serum chemistries (including liver and renal function tests), uric acid, LDH and quantitative immunoglobulins, human immunodeficiency virus (HIV), and HTLV-1 testing.
E. Depending on extent of disease, Sezary count, chest radiography, CT scans, PET scans, lymph node or bone marrow biopsy, or as suggested by history or physical examination.</p>
<p>IV. DIFFERENTIAL DIAGNOSIS</p>
<p>A. Allergic contact dermatitis
B. Atopic dermatitis
C. Irritant contact dermatitis
D. Lichen planus
E. Palmoplantar psoriasis
F. Parapsoriasis
G. Pemphigus foliaceus
H. Plaque psoriasis
I. Tinea corporis</p>
<p>V. TREATMENT MODALITIES</p>
<p>A. Skin-directed therapy</p>
<ol>
<li>
<p>Topical steroids are the most common treatment, and adjunct treatment with other topicals and systemic therapies at all stages.</p>
</li>
<li>
<p>Phototherapy with UVB.</p>
</li>
<li>
<p>Topical chemotherapy with mechlorethamine (nitrogen mustard HN2).</p>
</li>
<li>
<p>Photochemotherapy.</p>
</li>
<li>
<p>Carbon dioxide laser surgery.</p>
</li>
<li>
<p>Total skin electron beam therapy (limited penetration of electrons spares mucous membranes, bone marrow, gastrointestinal tract, and other vital internal organs). Whole body electron beam irradiation results in 85% complete remission rates with medial survival time of 9 years.</p>
</li>
<li>
<p>Surgical removal of solitary nodule or plaque confined to the skin.</p>
</li>
<li>
<p>Topical or intralesional steroids to control symptoms.</p>
</li>
</ol>
<p>B. Chronic disease (with nodal involvement)</p>
<ol>
<li>Follow protocol for skin-directed therapy.</li>
<li>Total skin electron beam therapy followed by topical HN2, phototherapy, or photopheresis to maintain remission. Total skin electron beam therapy is an option for patients with widespread skin lesions or patients who have deficient response to conservative therapies.</li>
<li>If necessary, systemic drug such as interferon-α, retinoids, or chemotherapeutic agent such as methotrexate.</li>
</ol>
<p>C. Postremission maintenance includes topical corticosteroids, nitrogen mustard, interferon (alpha), and phototherapy.</p>
<p>D. Tumors</p>
<ol>
<li>No nodal involvement—as above</li>
<li>Histologic nodal involvement</li>
</ol>
<p>a. Individualized palliative treatment
b. Local radiations to local symptomatic disease
c. Photopheresis
d. Retinoids/experimental protocols</p>
<p>E. Visceral involvement/Sézary syndrome</p>
<ol>
<li>Individualized palliative treatment</li>
<li>Systemic chemotherapy (fludarabine, 2-CDA, chlorambucil, pentostatin)</li>
<li>Extracorporeal photopheresis (palliative treatment), whereby leukocytes are selectively removed from peripheral blood by extracorporeal centrifugation technique, exposed to UVA light, and reinfused into the patient.</li>
</ol>
<p>a. Causes selective destruction of cancerous cells in the blood
b. Has been the only single treatment that has been shown to improve survival in patients with Sézary syndrome</p>
<ol start="4">
<li>Immune boosters such as interferon, interleukin-2, and monoclonal antibodies</li>
<li>Bone marrow transplant, currently limited by graft versus host disease, offers greatest potential for disease cure.</li>
<li>Combinations of skin-directed therapies and biological response modifiers to improve response rates.</li>
<li>Recent developments in CTCL therapy include:</li>
</ol>
<p>a. Targretin (bexarotene)—a retinoid X receptor-selective retinoid for all stages of CTCL and topical gel formation for the treatment of localized lesions
b. Ontak (denileukin diftitox): fusion toxin proteins selective for specific T cells; targets malignant T-cell clones
c. Systemic chemotherapy development including pegylated liposomal doxorubicin, gemcitabine, and pentostatin appears to have greatest potential.</p>
<ol start="8">
<li>Allogenic stem cell transplantation has curative potential for MF and reserved for advanced disease.</li>
</ol>
<p>VI. PROGNOSIS</p>
<p>The prognosis of CTCL depends on the stage of disease at the time of diagnosis, age, gender, immunocompetence, and the choice and tolerance of the treatments. While there is no cure for MF and SS, the treatment should focus on controlling and limiting the skin lesions, delay the progression, and minimize the recurrence of the disease. The care for the patients should be directed at quality-of-life consideration by optimally treating pruritus and xerosis and prevention of skin infection.</p>
<p><img src="assets/images/image-20251225-b84f1c9e.jpeg" alt="img-27.jpeg"></p>
<p>PATIENT EDUCATION</p>
<p>Cutaneous T-Cell Lymphoma</p>
<ul>
<li>CTCL is a rare type of cancer that originates in white blood cells and typically appears in severely itch skin lesions.</li>
<li>Chronic skin rash with delayed improvement, progress through various stages of lesions, and repeated cycles of regression and recurrence should be evaluated.</li>
<li>Multiple skin biopsies over time may be required to establish the diagnosis.</li>
<li>Topical corticosteroids are the treatment of choice for early stage of CTCL, and they provide effective adjunct therapy with other topical and systemic treatments in all stages of the disease.</li>
<li>Avoid hot showers and any skin products that aggravate itching and irritation (e.g., fragranced lotion, alcohol-based skin cleanser).</li>
<li>Although phototherapy (PUVA, UVB) is known to alleviate some of the itching symptoms associated with CTCL, maintain caution with regard to harmful effects of excessive sun exposure and wear proper sun protective clothing and sunscreen.</li>
<li>Severely itching, disseminated rash can limit activities of daily living and affect the quality of life. Joining a support group to connect with other people living with CTCL and share experiences may be helpful.</li>
</ul>
<p>KAPOSI SARCOMA</p>
<p>I. OVERVIEW</p>
<p>Kaposi sarcoma (KS) is an angioproliferative disorder and an opportunistic disease in immunosuppressed hosts. KS is a misnomer as it is not an actual sarcoma (a malignancy of</p>
<p>mesenchymal origin). It was first described by Kaposi as idiopathic multiple pigment sarcoma. This multifocal neoplasm is seen primarily as multiple vascular nodules in the skin and other organs. KS is associated with other neoplasms or immune disorders that occur before or after the diagnosis. KS is seen frequently in patients with HIV.</p>
<p>A. Definition: KS is a disease of proliferation in endothelial layer of lymph or blood vessels. Excessive proliferation of spindle cells placed together with other cells such as endothelial cells, inflammatory cells, and fibroblasts in an epithelial layer of the vascular origin results in a formation of a new blood vessel (neoangiogenesis).</p>
<p>B. Incidence:</p>
<ol>
<li>Incidence of KS varies according to geography.</li>
</ol>
<p>a. KS incidence in the United States before the acquired immunodeficiency syndrome (AIDS) epidemic was only 1 for every million people, mostly classic and transplant related.</p>
<p>b. AIDS epidemic increased KS incidence by 20 times, about 47 cases per million in 1990s, with 1 in 2 chance of developing KS among people infected with HIV. With improving KS treatment options, average KS incidence rate decreased to 6 cases per million each year.</p>
<p>c. Another higher prevalence is among organ transplant recipients, with the incidence of 1 in 200 people in the United States.</p>
<p>d. Mostly affects people of either Jewish descent or Mediterranean descent.</p>
<p>e. In classic KS, two thirds of patients develop lesions only after the age of 50.</p>
<p>f. Disease is strikingly frequent in a region in Africa that includes Kenya, Tanzania, and Zaire with a frequency of 1.3% to 10% depending on region.</p>
<p>g. Among people with AIDS, KS predominates in the third and fourth decade with a mean age of 40 years.</p>
<p>C. Etiology (cause may be multifactorial)</p>
<ol>
<li>Viral</li>
</ol>
<p>a. New human herpesvirus (HHV-8/KS) and subsequent identification of humoral immune response to this agent in patients with KS may be causally related to KS.</p>
<p>b. Causative agents of KS associated with disease among young homosexual men with signs of profound immunosuppression include HIV and other specific serologic association between cytomegalovirus (CMV) and classic endemic KS.</p>
<p>c. Other causative agents of KS may include various microorganisms such as hepatitis B virus, human papillomavirus (HPV), and Mycoplasma penetrans as possible sources of KS.</p>
<p>d. With the replication of retroviral particles in KS lesions, some hypothesize a non-HIV retrovirus etiological linkage to KS.</p>
<ol start="2">
<li>
<p>Genetic predisposition</p>
</li>
<li>
<p>Geographic factors</p>
</li>
<li>
<p>Possible hormonal influences</p>
</li>
</ol>
<p>D. Pathogenesis:</p>
<ol>
<li>Classic KS develops slowly and runs a benign course, although, infrequently, rapid courses with involvement of the lung, spleen, heart, and gastrointestinal tract have been</li>
</ol>
<p>reported.</p>
<ol start="2">
<li>In addition to cutaneous lesions, it may develop on mucous membranes of the oral cavity and gastrointestinal tract.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-clinical-variants">II. CLINICAL VARIANTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-clinical-variants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Classic (Mediterranean) KS (Figure 16-24)</p>
<ol>
<li>Chronic skin disease affecting predominantly elderly men of Mediterranean, East European, or Jewish heritage with a peak incidence in men after the age of 60. Lesions often appear on the legs.</li>
<li>Affected individuals survive an average of 10 to 15 years from diagnosis and most often die from an unrelated cause.</li>
<li>Lesions occur most commonly as red or purple nodule or blotch on lower limbs and then upper limbs and may occur on the trunk, head, neck, genitalia, or any skin surface. May appear as blue hues in dark-skinned individuals.</li>
<li>Telangiectases may be evident on or near the tumors, ulceration may occur, or the surface may appear verrucous.</li>
<li>Lesions may be painful; burning or itching may also be present.</li>
<li>Lesions may spontaneously regress as new ones appear; spontaneous remissions have been documented.</li>
<li>Occurrence may be in the hundreds in a single patient; nodules may cluster along veins.</li>
</ol>
<p>B. African or Endemic KS</p>
<ol>
<li>Found in eastern half of African continent near the equator.</li>
<li>Described in two distinct age groups</li>
</ol>
<p>a. Young adults with a mean age of 35 and a male/female ratio of 13:1
b. Young children with a mean age of 3 and a male/female ratio of 3:1</p>
<ol start="3">
<li>Most commonly nodular lesions that may regress spontaneously.</li>
<li>Florid variety is rapid growing and ulcerated and may bleed with tumors extending deep into the dermis and may involve underlying bone.</li>
<li>Infiltrative type is confined to the hand or foot appearing as deeply invasive, fibrotic, indurated tumors with nonpitting edema.</li>
<li>Rapidly growing enlarged lymph nodes, often confused clinically with lymphoma, typify lymphadenopathic type of KS occurring in children and young adults.</li>
</ol>
<p>C. Iatrogenic (Transplant-Related) KS</p>
<ol>
<li>Found in organ transplant patients, particularly renal transplants.</li>
<li>Seen in patients receiving chronic immunosuppressive drug therapy. Spontaneous remission after discontinuation of immunosuppressive therapy usually occurs.</li>
</ol>
<p>D. AIDS-Associated, Epidemic KS (Figure 16-25)</p>
<ol>
<li>
<p>KS is often the primary AIDS-defining illness.</p>
</li>
<li>
<p>Sexually transmitted cofactor may play a role in the development of AIDS-KS.</p>
</li>
<li>
<p>Incidence of AIDS-KS continues to rise as more HIV-infected patients progress to AIDS.</p>
</li>
<li>
<p>Lesions occur in the oral cavity, nose, postauricular, trunk, penis, legs, and feet appearing as small pink macules mimicking insect bites or small brown, tense papules.</p>
</li>
<li>
<p>Examination should include lymph node exam.</p>
</li>
<li>
<p>Macular lesions begin as salmon-colored with a pink halo.</p>
</li>
</ol>
<p>a. Small, slightly elevated, and round.
b. Macule becomes purple or brown within a week and halo disappears.
c. Multiple lesions widely distributed; may demonstrate a mirror-image distribution.</p>
<ol start="7">
<li>Papular and nodular lesions.</li>
</ol>
<p>a. May begin as macules.
b. Facial papules are round and less than  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">1\mathrm{cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm">cm</span></span></span></span></span></span>  in size; lesions of the trunk, neck, and extremities are 1 to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">2\mathrm{cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm">cm</span></span></span></span></span></span>  and oblong.</p>
<ol start="8">
<li>Plaques and lymphatic disease.</li>
</ol>
<p>a. Large purple plaques containing nodules with hyperkeratosis; resemble psoriasis.
b. Lymphatic involvement may produce numerous firm, red, round papules with local edema in affected nodal sites.</p>
<ol start="9">
<li>Mucocutaneous and ocular lesions.</li>
</ol>
<p>a. Oral involvement most commonly seen as lesions on the palate.
b. Macular lesions of the conjunctiva are relatively benign.</p>
<ol start="10">
<li>Visceral lesions may affect gastrointestinal tract and lungs as well as the pharynx, heart, bone marrow, urogenital tract, brain, kidney, and adrenal glands.</li>
</ol>
<p><img src="assets/images/image-20251225-61839e8a.jpeg" alt="img-28.jpeg">
FIGURE 16-24. Kaposi sarcoma. (From Werner, R. (2012). Massage therapist's guide to pathology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-c168b8a2.jpeg" alt="img-29.jpeg"></p>
<p>1</p>
<p>FIGURE 16-25. Kaposi sarcoma. Multiple papules and nodules are present on this patient's leg. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-laboratory-and-diagnostic-tests">III. LABORATORY AND DIAGNOSTIC TESTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-laboratory-and-diagnostic-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Combination of clinical assessment and histological conformation by skin biopsy
B. CT scan, bronchoscopy, and endoscopy based on the symptoms and clinical suspicion on other organs' involvement</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-differential-diagnosis">IV. DIFFERENTIAL DIAGNOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-differential-diagnosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Bacillary angiomatosis
B. Blue rubber bleb nevus syndrome
C. Melanocytic nevi
D. Pyogenic granuloma (lobular capillary hemangioma)
E. Tufted angioma</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="v-therapeutic-modalities">V. THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. There is no curative treatment for KS.
B. Local therapy</p>
<ol>
<li>Excision of cutaneous lesions (often for cosmesis)</li>
<li>Radiation therapy</li>
<li>Chemotherapy either single or multiagent. Most promising results in use of liposomal encapsulated doxorubicin and daunorubicin for both AIDs-associated KS and classic KS</li>
<li>Systemic treatment of interferon alpha, alone or in combination with cytotoxic therapy or with zidovudine for AIDS-KS</li>
<li>Highly active antiretroviral therapy (HAART) for AIDS-related KS</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vi-prognosis">VI. PROGNOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vi-prognosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The prognosis is dependent on the size and location of the KS lesions, the function of the immune system, and the comorbidities of the patient. Compromised immune system and underlying comorbidities may cause challenges in making choices for treatment.</p>
<p>PATIENT EDUCATION</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="kaposi-sarcoma">Kaposi Sarcoma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#kaposi-sarcoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Kaposi sarcoma (KS) typically presents as red or purplish spots and bumps on skin and mucosal layer of the body. It is essential to that a skin biopsy be performed to exclude cutaneous lymphoma.</li>
<li>KS may also involve internal organs including the intestines, lungs, genitals, and lymphatic system. Associated swelling, bleeding, discomfort, pain, and difficulty breathing depend on the affected organs.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bibliography">BIBLIOGRAPHY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bibliography" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>American Academy of Dermatology (AAD). (2014). Melanoma trends. Retrieved from <a href="http://www.aad.org" target="_blank" rel="noopener noreferrer">www.aad.org</a>
American Cancer Society. (2014). Skin cancer prevention and early detection. Retrieved from <a href="http://www.cancer.org/cancer/cancercauses/sunanduvexposure/skincancerpreventionandearlydetection/index" target="_blank" rel="noopener noreferrer">http://www.cancer.org/cancer/cancercauses/sunanduvexposure/skincancerpreventionandearlydetection/index</a>
American Joint Committee on Cancer. (2010). Melanoma of the skin staging (7th ed.). Chicago, IL: American Cancer Society.
Apisarnthanarax, J., Talpur, R., &amp; Duvic, M. (2002). Treatment of cutaneous T cell lymphoma: Current status and future directions (Review). American Journal of Clinical Dermatology, 3(3), 193-215.
Balch, C. M., Ross, M., Buzaid, A. C., Soong, S. J., Atkins, M. B., Cascinelli, N., ..., Thompson, J. F. (2001). Final version of the American joint committee on cancer staging system for cutaneous melanoma. Journal of Clinical Oncology, 19(16), 3635-3648.
Berg, D., &amp; Otley, C. C. (2002). Skin cancer in organ transplant recipients: Epidemiology, pathogenesis and management. Journal of the American Academy of Dermatology, 47(1), 1-17.
Bichakjian, C. K., Halpern, A. C., Johnson, T. M., Hood, A. F., Grichnik, J. M., &amp; Bhushan, R. (2011). Guidelines of care for the management of primary cutaneous melanoma. Journal of the American Academy of Dermatology, 65, 1032-1047.
Bouwhuis, S., &amp; Davis, M. D. (2001, June). Sezary syndrome: A summary. Dermatology Nursing, 13(3), 205-209.
Chartier, T. K., Aasi, S. Z., Stern, R. S., Robinson, J. K., &amp; Ofori, A. O. (2014). Treatment and prognosis of basal cell carcinoma. UpToDate. Retrieved from <a href="http://www.uptodate.com" target="_blank" rel="noopener noreferrer">www.uptodate.com</a>
Chung, G. (2014). A community-based educational intervention to improve melanoma screening among adult Hispanic Americans. Loma Linda University, CA.
Carbe, C., &amp; Bauer, J. (2012). Chapter 113. Melanoma. In J. L. Bolognia, J. L. Jorizzo, &amp; J. V. Schaffer (Eds.), Dermatology (Bolognia, Dermatology) (3rd ed.). New York, NY: Elsevier. Ebook ISBN: 9780702051821
Ghadially, R., &amp; Ghadially, F. N. (2002). Keratoacanthoma. In T. B. Fitzpatrick, A. Z. Eisen, K. Wolff, I. M. Freedberg, K. F. Austen, L. A. Goldsmith, &amp; S. L. Katz (Eds.), Dermatology in general medicine (5th ed., pp. 865-871). New York, NY: McGraw-Hill.
Grekin, R. C., Samlaska, C. P., &amp; Van-Christian, K. (2000). Epidermal nevi, neoplasms and cysts. In R. B. Odom, W. D. James, &amp; T. G. Berger (Eds.), Andrew's diseases of the skin clinical dermatology (9th ed., pp. 820-825, 1082-1087). Philadelphia, PA: WB Saunders Co.
Guill, C. K., &amp; Orengo, I. (2001, June). Cutaneous malignant melanoma. Dermatology Nursing, 13(3), 210-213.
Heald, P. W. (2002). Identifying and treating T-cell lymphoma. Skin Cancer Foundation Journal, XIX, 39-40.
Heald, P. W., &amp; Edelson, R. L. (1999). Cutaneous T cell lymphomas. In T. B. Fitzpatrick, A. Z. Eisen, K. Wolff, I. M. Freedberg, K. F. Austen, L. A. Goldsmith, &amp; S. L. Katz (Eds.), Dermatology in general medicine (5th ed., pp. 1227-1250). New York, NY: McGraw-Hill.</p>
<p>Hoppe, R. T., Kim, Y. H., Kuzel, T. M., Zic, J. A., &amp; Connor, R. F. (2014). Staging and prognosis of mycosis fungoides and Sezary syndrome. <em>UpToDate</em>. Retrieved from <a href="http://www.uptodate.com" target="_blank" rel="noopener noreferrer">www.uptodate.com</a></p>
<p>Jawed, S. I., Myskowski, P. L., Horwitz, S. H., Moskowiz, A., &amp; Querfeld, C. (2014a). Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. <em>Journal of the American Academy of Dermatology</em>, 70(2), 205–220.</p>
<p>Jawed, S. I., Myskowski, P. L., Horwitz, S. H., Moskowiz, A., &amp; Querfeld, C. (2014b). Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Part II. Prognosis, management, and future directions. <em>Journal of the American Academy of Dermatology</em>, 70(2), 223–241.</p>
<p>Lange, J. R. (2000). The current status of sentinel node biopsy in the management of melanoma. <em>Dermatologic Surgery</em>, 26(8), 809–810.</p>
<p>Langley, R. C., et al. (1999). Neoplasms: Cutaneous melanoma. In T. B. Fitzpatrick, A. Z. Eisen, K. Wolff, I. M. Freedberg, K. F. Austen, L. A. Goldsmith, &amp; S. L. Katz (Eds.), <em>Dermatology in general medicine</em> (5th ed., pp. 1080–1116). New York, NY: McGraw-Hill.</p>
<p>Lim, J. L., Asgari, M., Stern, R. S., Robinson, J. K., &amp; Corona, R. (2014). Epidemiology and risk factors for cutaneous squamous cell carcinoma. <em>UpToDate</em>. Retrieved from <a href="http://www.uptodate.com" target="_blank" rel="noopener noreferrer">www.uptodate.com</a></p>
<p>Liskay, A., &amp; Nicol, N. H. (1998). Anatomy and physiology of the skin. In M. J. Hill (Ed.), <em>Dermatology nursing essentials: A core curriculum</em> (pp. 3–13). Pitman, NJ: Dermatology Nurses’ Association.</p>
<p>Malignant Melanoma-Information for Medical Professionals. (2014). Retrieved from <a href="http://skincancer.dermis.net/content/e04typesof/e154/e156/index_eng.html" target="_blank" rel="noopener noreferrer">http://skincancer.dermis.net/content/e04typesof/e154/e156/index_eng.html</a></p>
<p>Melanoma Center. (n.d.). Your Source for melanoma information. Retrieved from <a href="http://www.melanomacenter.org/staging/stage4.html" target="_blank" rel="noopener noreferrer">http://www.melanomacenter.org/staging/stage4.html</a></p>
<p>Musse, L. (2002, February). Cutaneous T-cell lymphoma. <em>Dermatology Nursing</em>, 14(1), 55.</p>
<p>Padilla, R. S., Robinson, J. K., &amp; Corona, R. (2014). Epidemiology, natural history, and diagnosis of actinic keratosis. <em>UpToDate</em>. Retrieved from <a href="http://www.uptodate.com" target="_blank" rel="noopener noreferrer">www.uptodate.com</a></p>
<p>Petter, G., &amp; Haustein, U. F. (2000). Histologic subtyping and malignancy assessment of cutaneous squamous cell carcinoma. <em>Dermatologic Surgery</em>, 26(6), 521–529.</p>
<p>Piepkorn, M. (2001). <em>A new look at genetics breakthrough in melanoma</em>. Skin Cancer Foundation Journal, XIX, 46–47.</p>
<p>Rappersberger, K., Stingl, G., &amp; Wolff, K. (1999). Kaposi’s sarcoma. In T. B. Fitzpatrick, A. Z. Eisen, K. Wolff, I. M. Freedberg, K. F. Austen, L. A. Goldsmith, &amp; S. L. Katz (Eds.), <em>Dermatology in general medicine</em> (5th ed., pp. 1195–1203). New York, NY: McGraw-Hill.</p>
<p>Rigel, D. S. (2001). Melanoma update—2001. <em>Skin Cancer Foundation Journal</em>, XIX, 13–14.</p>
<p>Rivas, M. P., &amp; Nouri, K. (2005). Benign and malignant neoplasms. In B. E. Strober (Ed.), <em>Dermatology 2005 study guide and online practice exam</em>. Stiefel Laboratories.</p>
<p>Schmid-Wnedtner, M. H., Volkenandt, M., Plewig, G., Berking, C., Baumert, J., Schmidt, M., &amp; Sander, C. A. (2002). Cutaneous melanoma in childhood and adolescence: An analysis of 36 patients. <em>Journal of the American Academy of Dermatology</em>, 46(6), 874–879.</p>
<p>Schwartz, R. A., &amp; Stoll, H. L. (1999). Squamous cell carcinoma. In T. B. Fitzpatrick, A. Z. Eisen, K. Wolff, I. M. Freedberg, K. F. Austen, L. A. Goldsmith, &amp; S. L. Katz (Eds.), <em>Dermatology in general medicine</em> (5th ed., pp. 840–850). New York, NY: McGraw-Hill.</p>
<p>Sober, A. J., Chuang, T. Y., Duvic, M., Farmer, E. R., Grichnik, J. M., Halpern, A. C., ..., Lowery, B. J. (2001). Guidelines of care for primary cutaneous melanoma. <em>Journal of the American Academy of Dermatology</em>, 45(4), 579–586.</p>
<p>Sosman, J. A., Atkins, M. B., &amp; Ross, M. E. (2014). Overview of the management of advanced cutaneous melanoma. <em>UptoDate</em>. Retrieved from <a href="http://www.uptodate.com" target="_blank" rel="noopener noreferrer">www.uptodate.com</a></p>
<p>Soyer, H. P., Rigel, D. S., &amp; Wurm, E. M. T. (2012). Chapter 108. Actinic keratosis, basal cell carcinoma and squamous cell carcinoma. In J. L. Bolognia, J. L. Jorizzo, &amp; J. V. Schaffer (Eds.), <em>Dermatology (Bolognia, Dermatology)</em> (3rd ed.). New York, NY: Elsevier. Ebook ISBN: 9780702051821</p>
<p>Surveillance Epidemiology and End Results (SEER) Program. (2014). Retrieved from <a href="http://seer.cancer.gov/statfacts.html/melan.html" target="_blank" rel="noopener noreferrer">http://seer.cancer.gov/statfacts.html/melan.html</a></p>
<p>Swanson, N. A., &amp; Johnson, T. M. (1998). Management of basal and squamous cell carcinoma. In C. W. Cummings, J. M. Fredrickson, C. J. Krause, L. A. Harker, &amp; D. E. Schuller (Eds.), <em>Otolaryngology head and neck surgery</em> (3rd ed.). St. Louis, MO: Mosby.</p>
<p>Vargo, N. L. (2003). Basal cell and squamous cell carcinoma. <em>Seminars in Oncology Nursing</em>, 19(1), 12–21.</p>
<p>Vargo, N. L. (2003). Cutaneous malignancies. In M. J. Hill (Ed.), <em>Dermatology nursing essentials: A core curriculum</em> (pp. 119–135). Pitman, NJ: Dermatology Nurses’ Association.</p>
<p>Wu, P. A., Stern, R. S., Robinson, J. K., &amp; Corona, R. (2014). Epidemiology and clinical features of basal cell carcinoma. <em>UpToDate</em>. Retrieved from <a href="http://www.uptodate.com" target="_blank" rel="noopener noreferrer">www.uptodate.com</a></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Which of the following conditions is the most common reason for dermatology visits in the United States?</li>
</ol>
<p>a. Malignant melanoma
b. Basal cell carcinoma
c. Actinic keratosis
d. Squamous cell carcinoma</p>
<ol start="2">
<li>Many studies have shown that excessive sun exposure is the most common cause of skin damage and development of skin cancers. Which of the following describes the pathogenesis of basal cell carcinoma?</li>
</ol>
<p>a. Accumulative dose of chronic UV radiation exposure induces DNA damage and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>p</mi><mn>53</mn></mrow><annotation encoding="application/x-tex">p53</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord">53</span></span></span></span></span> genetic mutation.
b. Episodes of excessive UV radiation exposure, including childhood history of severe sunburn, induce genetic alteration of PTCH1 gene on chromosome 9q.
c. Excessive UV radiation exposure and genetic makeup involving the mutation of CDKN2A gene located on chromosome 9p21.
d. Excessive UV radiation exposure and genetic mutation involving CDKN2A interferes with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>p</mi><mn>53</mn></mrow><annotation encoding="application/x-tex">p53</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord">53</span></span></span></span></span> in cell cycle.</p>
<ol start="3">
<li>Assessment of an infiltrative squamous cell carcinoma includes which of the following?</li>
</ol>
<p>a. Dome-shaped lesion with central ulceration
b. Pearly lesion with raised borders with telangiectasias on the surface
c. Scaly, irregular, raised red patches occurring in actinically damaged skin
d. Vague, yellowish, scar-like plaque with indistinct margins</p>
<ol start="4">
<li>Which of the following types of cutaneous malignancies grows rapidly from a small papule to a large volcano-like nodule, with a central keratotic plug, in just 2 to 6 weeks?</li>
</ol>
<p>a. Keratoacanthoma
b. Basal cell carcinoma
c. Mycosis fungoides
d. Actinic keratosis</p>
<ol start="5">
<li>Which two types of cutaneous malignancies highly resemble each other clinically, as well as histologically?</li>
</ol>
<p>a. Actinic keratosis and squamous cell carcinoma
b. Basal cell carcinoma and malignant melanoma</p>
<p>c. Mycosis fungoides and Sézary syndrome
d. Keratoacanthoma and squamous cell carcinoma</p>
<ol start="6">
<li>The American Academy of Dermatology and the American Cancer Society recommend the use of the A (asymmetry), B (border), C (color), D (diameter), and E (evolution) pneumonic to screen for which of the following types of cutaneous malignancy?</li>
</ol>
<p>a. Kaposi sarcoma
b. Malignant melanoma
c. Cutaneous T-cell lymphoma
d. Keratoacanthoma</p>
<ol start="7">
<li>Which of the following describes a change in the 2010 American Joint Commission on Cancer Melanoma Staging System, 7th edition?</li>
</ol>
<p>a. Tumor thickness is recategorized as 1, 2, and 4 mm.
b. Tumor characteristic of ulceration became an unremarkable factor.
c. In-transit metastasis is separated from satellite lesions in staging.
d. Mitotic rate (T1 mitoses/mm²) replaced Clark level of invasion as the primary criterion for staging and prognosis.</p>
<ol start="8">
<li>Mr. Jones is a 65-year-old farmer. He is at a dermatology clinic with his wife who is concerned about a changing mole on his back. He describes it as a mole that he has had all of his life, but he has been experiencing increased itchiness, frequent burning-like sensation, and occasional spontaneous bleeding at the mole for the past 6 months. His wife believes the mole has been changing from a smooth-bordered light brown mole to an ill-defined bordered, reddish brown, partially white and black mole. Which of the following is your presumptive diagnosis of this lesion?</li>
</ol>
<p>a. Malignant melanoma
b. Squamous cell carcinoma
c. Basal cell carcinoma
d. Kaposi sarcoma</p>
<ol start="9">
<li>Mr. Duke is a 49-year-old AIDS patient with multiple comorbidities, and his medications have been causing frequent adverse reactions. For the past 3 months, his new symptoms include firm, purplish, nontender bumps and reddish patches around his ears, jawline, and chest areas. He is at a dermatology clinic, discussing possible skin biopsy for a diagnosis. Which of the following is your presumptive diagnosis of these lesions?</li>
</ol>
<p>a. Malignant melanoma
b. Squamous cell carcinoma
c. Basal cell carcinoma
d. Kaposi sarcoma</p>
<ol start="10">
<li>Mrs. Smith is a 57-year-old renal transplant recipient on immunosuppressant medications. She is at a dermatology clinic reporting a new lesion on her left temple, which was first noted about 4 months ago. She describes it as a shiny, dark brown growth approximately 5 mm in diameter, and it has a semitranslucent border at the base. Which of the following is your presumptive diagnosis of this lesion?</li>
</ol>
<p>a. Nodular melanoma
b. Nodular squamous cell carcinoma
c. Pigmented basal cell carcinoma
d. Kaposi sarcoma</p>
<ol start="11">
<li>Which of the following genetic diseases is most susceptible to developing both basal cell carcinoma and squamous cell carcinoma?</li>
</ol>
<p>a. Nevoid basal cell carcinoma syndrome
b. Muir-Torre syndrome
c. Epidermolysis bullosa syndrome
d. Xeroderma pigmentosum</p>
<ol start="12">
<li>Which of the following is optimal patient education for preventing melanoma and nonmelanoma skin cancers?</li>
</ol>
<p>a. Daily use of multivitamins containing vitamin A and drinking adequate amount of water.
b. Daily physical activities during morning and evening hours only to avoid midday sun exposure.
c. Daily journal writing to count total number of moles, and seeking medical attention when a new mole lesion is noted.
d. Daily use of sunscreen, photoprotective clothing, and performing regular skin self-examination.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="answers-to-study-questions">ANSWERS TO STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>1.c
2.b
3.a
4.a
5.d
6.b
7.d
8.a
9.d
10.c</p>
<p>11.d
12.d</p>
<p>CHAPTER 17</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="disorders-of-pigmentation-and-dermatologic-considerations-in-ethnic-skin">Disorders of Pigmentation and Dermatologic Considerations in Ethnic Skin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#disorders-of-pigmentation-and-dermatologic-considerations-in-ethnic-skin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Heather Onoday</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>Identify disorders of hypo- and hyperpigmentation.</li>
<li>Describe current treatment modalities used to treat pigment disorders including vitiligo, albinism, tuberous sclerosis, and melasma.</li>
<li>Differentiate different types of nevi.</li>
<li>List normal variations in pigmentation in people of color.</li>
<li>Describe skin disorders and treatment modalities of those disorders that are commonly occurring in ethnic individuals.</li>
<li>Identify the psychosocial impact imposed by skin diseases unique to individuals with disorders of pigmentation as well as ethnic population with skin disorders.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Pigmentation disorders, either hypo- or hyperpigmentation, can have tremendous impact on patients from both a cosmetic and a health standpoint.</li>
<li>Dermatology nurses must be knowledgeable of disorders of pigmentation and nevi to effectively care for patients and improve their outcomes.</li>
<li>Patients with hypopigmentation, hyperpigmentation, and nevi may require emotional support and education to assist with coping processes.</li>
<li>The U.S. Census Bureau estimates that by the year 2050, people of ethnic skin will make up almost half of the American population. These changing demographics will change health care needs.</li>
<li>For the purpose of this chapter, Asian, Black, and Hispanic skin types will be considered as representative of the ethnic population.</li>
<li>Distinguishing between normal and pathological variations in the ethnic population by</li>
</ul>
<p>the health care team is essential to the successful management of this group of clients.</p>
<ul>
<li>Social customs and traditional beliefs may influence adherence to treatment regimes.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="the-melanocyte">The Melanocyte<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-melanocyte" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The melanocyte comprises approximately 5%-10% of the cellular component of the interfollicular epidermis and an equal component of the hair bulb. They are cells of neural crest origin. (Refer to the discussion of melanocyte in the Cells in the Epidermis section in Chapter 1.) Melanocytes reside in the basal layer of epidermis, where they form the epidermal melanin units as a result of the relationship between one melanocyte and 30-40 associated keratinocytes. The ratio of melanocytes to keratinocytes is 1:10 in the epidermal basal layer.</p>
<p>A. Characteristics of the melanocyte</p>
<ol>
<li>Limited in number.</li>
<li>Major synthetic product is melanin.</li>
</ol>
<p>a. Melanin is the primary determinant of skin color and hair color.
b. Melanin accounts for racial and ethnic skin pigmentation differences.
c. Melanin functions to:</p>
<p>(1) Absorb ultraviolet light
(2) Protect genome of dividing basal keratinocytes and melanocytes
(3) Scavenge free oxygen radicals</p>
<ol start="3">
<li>Melanocytes can up- or downregulate pigmentation in response to:</li>
</ol>
<p>a. Physiologic stimuli (e.g., production of melanocyte stimulating hormone, MSH)
b. Environmental stimuli (e.g., ultraviolet radiation).
c. Pathologic stimuli (e.g., trauma)</p>
<p>B. Hypothesized to contribute to epidermal homeostasis during inflammation</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-disorders-of-pigmentation">II. Disorders of Pigmentation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-disorders-of-pigmentation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Disorders of pigmentation may present as either hypo- or hyperpigmentation (too much or too little melanin).</p>
<ol>
<li>Can be localized or diffuse</li>
<li>Can be acquired or congenital</li>
</ol>
<p>B. Acquired hypopigmentation</p>
<ol>
<li>Vitiligo</li>
<li>Postinflammatory (e.g., after laser treatment)</li>
<li>Inflammatory disorders (e.g., psoriasis, atopic dermatitis)</li>
<li>Neoplasms (e.g., cutaneous T-cell lymphoma)</li>
<li>Postinfection</li>
</ol>
<p>a. Bacteria: Treponema pertenue, Treponema carateum, and Mycobacterium leprae</p>
<p>b. Yeast: Pityrosporum orbiculare
c. Protozoan: Leishmania donovani
d. Helminth: Onchocerca volvulus
e. Fungus: tinea versicolor</p>
<p>C. Congenital hypopigmentation</p>
<ol>
<li>Albinism</li>
<li>Piebaldism</li>
<li>Tuberous sclerosis</li>
<li>Hypomelanosis of Ito (pigmentary mosaicism)</li>
</ol>
<p>D. Acquired hyperpigmentation</p>
<ol>
<li>Melasma</li>
<li>Chemically induced</li>
<li>Melanocytic nevi</li>
<li>Ephelides (freckles): small orange-brown or light-brown macules promoted by sun exposure, fading in winter months; usually on face, arms, and back; benign</li>
<li>Fixed drug eruptions or phototoxic eruptions</li>
<li>Café au lait spots: uniformly pale-brown macules seen on any cutaneous surface; present at birth; six or more macules of greater than 1.5 cm would warrant a workup for neurofibromatosis (von Recklinghausen disease)</li>
<li>Postinflammatory (e.g., thermal burns)</li>
</ol>
<p>E. Diffuse brown hyperpigmentation: Addison disease</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="disorders-of-hypopigmentation">Disorders of Hypopigmentation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#disorders-of-hypopigmentation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vitiligo">Vitiligo<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vitiligo" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A distinctive disorder of pigmentation in which the affected epidermis is devoid of one of its three main cell types (melanocytes) leading to a lack of melanin-based pigmentation in those affected areas.</p>
<p>A. Definition: acquired loss of pigmentation characterized histologically by complete absence of melanocytes in association with a total loss of epidermal pigmentation
B. Etiology</p>
<ol>
<li>Exact pathogenesis is unclear.</li>
<li>Generalized symmetric form. Thought to be an autoimmune disease associated with antibodies (vitiligo antibodies) and cell-mediated cytotoxicity directed against melanocytes.</li>
<li>May be genetic (a predisposing factor); over 30% of affected individuals have reported vitiligo in a parent, sibling, or child; polygenic (i.e., not caused by a single gene defect)</li>
<li>Other theories include cytotoxic mechanisms, an intrinsic defect of melanocytes, oxidant-</li>
</ol>
<p>antioxidant mechanisms, and neural mechanisms.</p>
<ol start="5">
<li>No definitive precipitating factor has been established; anecdotal correlation with the following environmental factors:
a. Psychological stress
b. Physical trauma
c. Pregnancy
d. Oral contraceptives
e. Sunlight and artificial ultraviolet light
f. Illness</li>
</ol>
<p>Note: These associations are frequently observed in a high percentage of normal individuals and have not been epidemiologically shown to occur more frequently in patients with vitiligo.</p>
<p>C. Pathophysiology</p>
<ol>
<li>Caused by a loss of melanin from the epidermis.</li>
<li>A decrease in the number of melanocytes in affected areas.</li>
<li>Pigment loss may be localized, generalized, or universal.</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>Worldwide prevalence of vitiligo is between 0.5% and 2%.</li>
<li>Up to 2.16% of children and adolescents are affected with vitiligo.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History</p>
<ol>
<li>Ask about initial presentation.</li>
<li>Ask about any somatic complaints or vision problems that may be associated with vitiligo.
a. Migraines
b. Decrease in hearing or pain with hearing (melanin may play important role in the structure and function of the auditory system)</li>
<li>Assess other diseases associated with vitiligo
a. Thyroid disease (hypo- and hyperthyroidism, Grave disease)
b. Diabetes mellitus
c. Pernicious anemia
d. Addison disease
e. Multiglandular insufficiency syndrome
f. Alopecia areata
g. Melanoma
h. Lupus erythematosus
i. Rheumatoid arthritis</li>
<li>Diseases that have been reported in patients with vitiligo
a. Immune deficiency diseases
b. Multiple myeloma
c. Dysgammaglobulinemia</li>
</ol>
<p>d. Cutaneous T-cell lymphoma
e. Thymoma</p>
<p>B. Clinical manifestations</p>
<ol>
<li>Initial presentation and progression: variable; but genital, anal, axillary, and periorbital are often first areas affected.</li>
<li>Usually a depigmented macule or patch (1 to 3 cm)</li>
<li>Distinct margins</li>
<li>Variations in color and margins can occur (margin may be hyperpigmented, hypopigmented, or exhibit erythema, which is suggestive of an inflammatory process).</li>
<li>Face, joints, hands, and legs are the most commonly affected areas (Figure 17-1).</li>
<li>Mucous membranes may be affected.</li>
<li>Often symmetrical in presentation (Figure 17-2).</li>
<li>Classification of patterns of distribution</li>
</ol>
<p>a. Localized</p>
<p>(1) Focal: one or more macules in one area
(2) Segmental: dermatomal pattern
(3) Mucosal: localized on mucous membranes
(4) "Lip-tip" pattern: involves skin around the mouth as well as on the distal fingers and toes; lips, nipples, and genitalia (tip of penis)</p>
<p>b. Generalized often remarkably symmetrical</p>
<p>(1) Acrofacial: distal extremities and face
(2) Vulgaris: diffuse presentation
(3) Mixed: combination of acrofacial and vulgaris</p>
<p>c. Universal-depigmented areas cover almost the entire body</p>
<ol start="9">
<li>Associated cutaneous findings</li>
</ol>
<p>a. White and prematurely gray hair
b. Alopecia areata
c. Halo nevi</p>
<p>C. Differential diagnosis</p>
<ol>
<li>Piebaldism</li>
<li>Lupus erythematosus</li>
<li>Tinea versicolor (pityriasis versicolor)</li>
<li>Pityriasis alba</li>
<li>Lichen sclerosus et atrophicus</li>
<li>Cutaneous T-cell lymphoma</li>
<li>Sarcoidosis</li>
<li>Scleroderma</li>
<li>Postinflammatory pigmentary alteration (PIPA)</li>
<li>Tuberous sclerosis</li>
<li>Hypomelanosis of Ito</li>
<li>Incontinentia pigmenti</li>
</ol>
<p><img src="assets/images/image-20251225-b7b4326b.jpeg" alt="img-30.jpeg">
FIGURE 17-1. Vitiligo. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<p><img src="assets/images/image-20251225-cc856d7e.jpeg" alt="img-31.jpeg"></p>
<p>FIGURE 17-2. Vitiligo symmetry. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Goals of treatment</p>
<ol>
<li>Restore normal function to epidermis</li>
<li>Cosmesis</li>
</ol>
<p>B. Medical therapy: aimed at stimulating proliferation and migration of melanocytes</p>
<ol>
<li>Topical steroids</li>
</ol>
<p>a. Topical class 3 can be employed.
b. Applied daily for several months or longer.
c. If pigmentation not seen within 3 months, steroid should be stopped for approximately 6 months and then may be reinstituted or another treatment modality used.</p>
<ol start="2">
<li>Topical immunomodulators</li>
</ol>
<p>a. Seem to be equally effective as topical steroids, especially when used in the face and neck region
b. Off-label indication for vitiligo
c. Black box warning for possible risk of cancer</p>
<ol start="3">
<li>Phototherapy (see Chapter 6, Phototherapy, for comprehensive discussion)</li>
</ol>
<p>a. Psoralen plus Ultra Violet A light (PUVA) either topical or systemic.
b. Topical or systemic PUVA is used two to three times weekly for several months; if no response, stop treatment for at least 6 months before trying again.
c. UVB narrowband (310- to 315-nm wavelength), two to three times weekly.
d. UVB narrowband therapy with excimer laser produces monochromatic rays at 308 nm to treat limited, stable patches of vitiligo, treated two to three times weekly, averaging 24 to 48 sessions.</p>
<ol start="4">
<li>Depigmentation</li>
</ol>
<p>a. Used when there is involvement of more than 50% of the skin surface.
b. Monobenzone (monobenzyl ether of hydroquinone [MBEH]) is applied to skin twice daily until satisfactory depigmentation is achieved.</p>
<p>(1) Frequently requires strength of 20% to 40% to induce necrotic death of melanocytes</p>
<p>c. Informed consent from the patient as depigmentation is permanent and increases photosensitivity and pruritus.</p>
<p>C. Surgical therapy</p>
<ol>
<li>Punch grafts: technique similar to hair transplantation</li>
</ol>
<p>a. Donor sites are pigmented areas of the skin.
b. Transplanted into depigmented areas of the skin.
c. Held in place with pressure dressings.
d. Repigmentation seen in 4 to 6 weeks after transplantation.
e. Residual pebbled skin may result, which can be cosmetically unacceptable.</p>
<ol start="2">
<li>
<p>Minigrafts: variant of the punch graft using smaller donor grafts to minimize pebbling</p>
</li>
<li>
<p>Suction blisters
a. Epidermal grafts are obtained by vacuum suction.
b. Blister roof is removed intact and grafted to depigmented site.
c. Good for large areas of depigmentation.
d. May be combined with phototherapy.
e. Repigmentation using this method may cause a mottled appearance.</p>
</li>
<li>
<p>Autologous cultures
a. Use autologous cultured melanocytes and keratinocytes from unaffected donor skin.
b. Applied to recipient sites that have had epidermis removed by suction, cryotherapy, or dermabrasion.
c. Color may be mottled or incompletely re-pigmented.</p>
</li>
<li>
<p>Autologous melanocyte grafts
a. Variant of autologous cultures.
b. Injected into the depigmented site or used on superficially dermabraded skin.
c. Culturing melanocytes requires expertise and several months.
d. Spread of pigmentation is minimal.</p>
</li>
<li>
<p>Problems with surgical therapies
a. Graft failure.
b. Donor sites may become depigmented (isomorphic response).
c. Risk of infection.
d. Risk of scarring in donor sites.
e. May be cost prohibitive.</p>
</li>
</ol>
<p>Note: Five general options for management are sunscreens, cover-up, repigmentation, minigrafting, and depigmentation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="albinism">Albinism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#albinism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A group of inherited disorders that are characterized by little or no production of melanin</p>
<p>A. Definition: genetically defined defect in the melanocyte system of the eye, skin, or both
B. Etiology</p>
<ol>
<li>One of four genetic mutations
C. Pathophysiology</li>
<li>Mutations in the gene disrupt the ability of cells to synthesize melanin.</li>
<li>Two classifications
a. Oculocutaneous albinism (OCA)
b. Ocular albinism (OA)
D. Incidence</li>
<li>OCA: 1:17,000</li>
<li>OA: not established</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History
B. Clinical manifestations</p>
<ol>
<li>OCA: diluted skin/hair pigmentation</li>
</ol>
<p>a. Skin</p>
<p>(1) In light-skinned individuals, skin is very light.
(2) In darkly pigmented individuals, large, pigmented freckles in light-exposed areas may be seen.</p>
<p>b. Hair</p>
<p>(1) In darkly pigmented individuals, hair is yellow to yellowish-brown.
(2) In lighter-skinned individuals, hair may range from white to cream, yellow to yellow-red, to vibrant red.</p>
<p>c. Eye</p>
<p>(1) Iris: blue/gray and translucent.
(2) Retina and choroid: paucity of pigment.
(3) In darkly pigmented individuals, the iris will be pale blue to cinnamon brown.
(4) Photophobia and nystagmus seen in all races.
(5) Visual acuity is decreased.
(2) OA</p>
<p>a. Decrease or absence of melanin in the iris and retinal pigment epithelium.
b. Nystagmus present.
c. Iris translucency may occur.
d. Decrease in visual acuity.
e. Hair and skin color are normal.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Treatment goals are surveillance and preventing complications.
B. Sunscreen use.
C. Regular skin inspection for early detection of skin cancers.
D. Appropriate eye protection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="piebaldism">Piebaldism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#piebaldism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Congenital absence of melanocytes in affected areas of the skin and hair (depigmentation) that may have spontaneous expansion and contraction</p>
<p>A. Definition: disorder of hypopigmentation, which involves skin and hair only
B. Etiology</p>
<ol>
<li>Autosomal dominant mutation of the c-kit or SNA12 gene, rare</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>
<p>Hypomelanosis</p>
</li>
<li>
<p>Histologically, absence or markedly decreased melanocytes in affected areas</p>
</li>
</ol>
<p>D. Incidence: 1:20,000 births</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History</p>
<ol>
<li>
<p>Screen for deafness.</p>
</li>
<li>
<p>Screen for congenital megacolon particularly in infants.</p>
</li>
</ol>
<p>B. Clinical manifestations</p>
<ol>
<li>Characteristic pattern</li>
</ol>
<p>a. White forelock</p>
<p>b. Occasionally white macules/patches on forehead, chin</p>
<p>c. Lack of pigmentation</p>
<p>(1) Trunk</p>
<p>(2) Anterior thorax</p>
<p>(3) Abdomen</p>
<p>(4) Midarm to wrist</p>
<p>(5) Midthigh to midcalf (anterior and posterior)</p>
<p>(6) Normal pigmentation of hands, upper part of arm, shoulders, upper thighs, and feet to midcalf</p>
<p>(2) Two features to distinguish piebaldism from vitiligo</p>
<p>a. Presence of islands of normal pigmentation (Figure 17-3) in areas of hypomelanosis</p>
<p>b. Characteristic distribution</p>
<p>c. Congenital</p>
<p>d. Frequently hereditary autosomal dominant pattern can be observed in family members.</p>
<p><img src="assets/images/image-20251225-08e2c2b7.jpeg" alt="img-32.jpeg"></p>
<p>FIGURE 17-3. Piebaldism. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Minigrafts: most successful
B. Culture grafts: not always cosmetically acceptable
C. PUVA: not always cosmetically acceptable</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="tuberous-sclerosis">Tuberous Sclerosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tuberous-sclerosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Also called tuberous sclerosis complex. Hypopigmentation is one of the earliest clinical signs of tuberous sclerosis.</p>
<p>A. Definition: rare, multisystem, genetic disease that causes benign tumors to grow in the brain and on other vital organs such as the kidneys, heart, eyes, lungs, and skin. Also affects the central nervous system, resulting in symptoms including seizure, developmental delay, and behavioral abnormalities.
B. Etiology</p>
<ol>
<li>Genetic
C. Pathophysiology</li>
<li>Melanocytes present</li>
<li>Melanosomes in melanocytes decreased and poorly melanized
D. Incidence</li>
<li>1:6,000 births</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>A. History
B. Clinical manifestations</p>
<ol>
<li>Common locations
a. Trunk
b. Lower extremities</li>
<li>Configurations
a. Ash leaf spot: lance-ovate (round at one end and pointed at the other); considered as a tertiary feature of tuberous sclerosis (Figure 17-4)
b. Oval
c. Polygonal
d. Shagreen patch area of thickened, elevated pebbly skin, usually found on lower back (Figure 17-5)</li>
<li>May see multiple 1- to 3-mm macules (“confetti-like”) with poliosis (loss of melanin) of</li>
</ol>
<p>scalp, hair, eyebrows, and eyelashes</p>
<ol start="4">
<li>Hypopigmented spots of the iris and fundus</li>
<li>Wood lamp enhances lesions in light-skinned patients.</li>
</ol>
<p><img src="assets/images/image-20251225-ae52d675.jpeg" alt="img-33.jpeg">
FIGURE 17-4. Ash leaf macule, seen in tuberous sclerosis. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<p><img src="assets/images/image-20251225-93699bb5.jpeg" alt="img-34.jpeg">
FIGURE 17-5. Shagreen patch, seen in tuberous sclerosis. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>None for skin lesions</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="disorders-of-hyperpigmentation">Disorders of Hyperpigmentation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#disorders-of-hyperpigmentation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="melasma">Melasma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#melasma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Disorders of hyperpigmentation can be caused by any of the following factors: hereditary/developmental, metabolic, endocrine, inflammatory, chemically induced, nutritional, or neoplastic. Melasma is one of the most commonly seen disorders of hyperpigmentation.</p>
<p>A. Definition: acquired, brown hypermelanosis of the face. Also called chloasma faciei
B. Etiology</p>
<ol>
<li>Secondary to an increase in the number and activity of melanocytes</li>
<li>No known cause. Melasma has been linked to:</li>
</ol>
<p>a. Oral contraceptives
b. Pregnancy
c. Cosmeceutical or medication (usually a phototoxic or allergic reaction)
d. Genetic predisposition
e. Endocrine (progesterone and estrogen both have an effect on melanogenesis)
f. Race
g. Nutrition
h. Metabolism
i. Sunlight</p>
<p>C. Pathophysiology</p>
<ol>
<li>Epidermal type: melanin is deposited in the basal and suprabasal layers of the epidermis.</li>
<li>Dermal type: melanophages in the superficial and deep dermis in addition to epidermal hyperpigmentation.</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>Unknown true incidence.</li>
<li>Almost 90% affected are women.</li>
<li>More common in persons of Latino origin living in tropical areas.</li>
<li>Commonly seen in women who are pregnant or using oral contraceptives or hormonal replacement.</li>
<li>Is seen in men, but usually without hormonal factors.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History: always take a complete history.
B. Clinical manifestations</p>
<ol>
<li>Symmetrical</li>
<li>Irregular light to dark-brown hyperpigmentation</li>
<li>Seen on the face
a. Centrofacial
(1) Most common presentation
(2) Involves cheeks, forehead, upper lip, nose, and chin
b. Malar
(1) Localized to cheeks and nose
(2) Second most common presentation
c. Mandibular
(1) Involves the ramus of the mandible
(2) Least common presentation</li>
<li>Four types (distinguished with the use of Wood light according to the depth of pigment deposition)
a. Epidermal: shows enhancement of pigmentation (most common type intense under Wood lamp).
b. Dermal: no enhancement of color (many melanophages) in the dermis.
c. Mixed: shows no or slight enhancement of color.</li>
</ol>
<p>d. Indeterminate or unapparent—lesions are not discernible under Wood light in skin types V to VI.</p>
<ol start="5">
<li>Differential diagnosis (partial list)
a. Drug-induced hyperpigmentation
b. Pigmented contact dermatitis
c. Postinflammatory hyperpigmentation
d. Exogenous ochronosis (blue-black or slate gray hyperpigmented changes secondary to prolonged topical application of hydroquinone, phenol, or resorcinol)</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Identify and eliminate causative factors.
B. Medications</p>
<ol>
<li>Hydroquinone alone (2% to 4% concentrations most commonly used)</li>
<li>Hydroquinone with retinoic acid (retinoic acid enhances epidermal penetration of hydroquinone and reduces the activity of the melanocytes)</li>
<li>Broad-spectrum sunscreen</li>
<li>Topical steroids (alone or in conjunction with hydroquinone, or hydroquinone plus retinoids)</li>
<li>5-Fluorouracil (effective particularly if patients have actinically damaged skin)</li>
<li>Azelaic acid (causes reversible inhibition of tyrosinase; may be used in conjunction with hydroquinone)</li>
</ol>
<p>C. Possible side effects of topical medications</p>
<ol>
<li>Hydroquinone therapy
a. Irritant contact dermatitis
b. Exogenous ochronosis
c. Brown discoloration of nails secondary to deposition of hydroquinone oxidated products
d. Vitiligo in predisposed individual</li>
<li>Topical steroids: hypopigmentation, atrophy</li>
</ol>
<p>D. Chemical peel (trichloroacetic acid or phenol solution). Phenol peels can cause cardiac, renal, and pulmonary toxicities.
E. Lasers (Q-switched, fractionated nonablative)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chemically-induced-hyperpigmentation">Chemically Induced Hyperpigmentation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemically-induced-hyperpigmentation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Hyperpigmentation has long been associated with exposure to a variety of chemicals.</p>
<p>A. Definition: unusual darkening of the skin as a direct result of exposure to chemicals
B. Etiology</p>
<ol>
<li>
<p>Direct deposition of the chemical into the skin.</p>
</li>
<li>
<p>Stimulation of melanin formation.</p>
</li>
<li>
<p>Binding of chemical to melanin.</p>
</li>
<li>
<p>Production of metabolites or nonmelanin pigment.</p>
</li>
<li>
<p>Hyperpigmentation may be enhanced by exposure to ultraviolet light.</p>
</li>
<li>
<p>Offending agents
a. Antimalarials
b. Antibiotics
c. Heavy metals, such as silver
d. Chemotherapeutic agents
e. Topical preparations (e.g., tar-containing compounds)
f. Antiarrhythmic, amiodarone</p>
</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Dependent on etiologic agent.</li>
<li>Antimalarials: hyperpigmentation appears in the dermis; may be a combination of melanin and hemosiderin.</li>
<li>Antibiotics: pigmentation depends on presentation; minocycline is used as an example here.
a. In areas of scarring, such as acne scars, hemosiderin and ferritin are present in macrophages and appear blue-black.
b. Blue-black, brown, or slate gray patches on extremities have pigmented macrophages that stain for both melanin and iron.
c. Generalized muddy-brown pigmentation sometimes exacerbated on sunlight-exposed regions.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History with emphasis on chemical exposure
B. Physical examination
C. Clinical manifestations</p>
<ol>
<li>May vary, as described.</li>
<li>Skin biopsy may be indicated to confirm diagnosis.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Often persistent.
B. Stop offending agent or exposure if known (particularly drug).
C. Prevent recurrent exposure.
D. Use sunscreens.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nevi">Nevi<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nevi" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="melanocytic-nevi">Melanocytic Nevi<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#melanocytic-nevi" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Nevi, or moles, are benign tumors composed of nevus cells that are derived from melanocytes and can occur anywhere on the cutaneous surface, and except for certain types (large congenital and dysplastic), most nevi have low-malignancy potential.</p>
<p>A. Definition</p>
<ol>
<li>
<p>Nevus cell: larger than melanocyte, may lack dendrites; has more abundant cytoplasm and coarse granules; aggregates in groups or proliferates in basal region at dermoepidermal junction</p>
</li>
<li>
<p>Types of nevi (Table 17-1)</p>
</li>
</ol>
<p>a. Common nevi: classified based on location within the skin</p>
<p>(1) Junction
(2) Compound
(3) Intradermal</p>
<p>b. Special forms</p>
<p>(1) Congenital (Figure 17-6)
(2) Halo nevus (Figure 17-7)
(3) Nevus spilus (speckled lentiginous nevus)
(4) Becker nevus
(5) Benign juvenile melanoma (Spitz nevus)
(6) Blue nevus (Figure 17-8)
(7) Labial melanotic nevus</p>
<p>B. Etiology</p>
<ol>
<li>Dependent on type</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Junctional: nevus cells at dermoepidermal junction</li>
<li>Compound: nevus cells at dermoepidermal junction and upper dermis</li>
<li>Dermal: nevus cells in dermis, rarely extends into superficial fat, usually along follicular structures</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>Very common</li>
<li>Present in 1% of newborns with incidence increasing throughout infancy and childhood, peaking at puberty</li>
</ol>
<p>TABLE 17-1 Types of Nevi</p>
<table><thead><tr><th>Type</th><th>Morphology</th><th>Comments</th></tr></thead><tbody><tr><td>Junctional</td><td>Initially 1–2 mm, expanding to 4–6 mm; flat, slightly elevated, smooth surface; sharply circumscribed; uniformly brown, tan, or black</td><td>Progression is slow, over decades; may change into compound nevus; rare at birth, develop after 2 years of age</td></tr><tr><td>Compound</td><td>Slightly elevated, dome-shaped, papule; skin-colored, brown, “halo nevus”; cells at dermoepidermal junction and upper dermis; hair may be present</td><td>Generally benign, may be a cosmetic concern</td></tr><tr><td>Dermal</td><td>Brown or black, but may lighten with age; vary in size, maybe a few millimeters up to a centimeter; dome-shaped nevi are most common; symmetric with smooth surface; white or translucent; surface telangiectasia may make lesion difficult to distinguish from a basal cell carcinoma; may be polypoin or verrucous in appearance; found on trunk, neck, axilla, groin</td><td>Elevated lesions often removed due to being prone to trauma; skin-colored border may be present making nevus look similar to a halo nevus; rarely degenerate into a melanoma but should be monitored, nonetheless</td></tr><tr><td>Congenital</td><td>Present at birth, vary in size from a few millimeters to several centimeters; may cover wide areas of the trunk (bathing suit distribution) extremity, or face; giant hair nevus is the largest form; may see coarse hair in the body of the nevus; uniformly brown or black but may be red or pink; surface flat at birth and becomes verrucous or nodular over time; high risk of degeneration into melanoma in very large lesions</td><td>Large, thick lesions—consider removal early due to tendency to become malignant; removal should be done with consideration of cosmesis; all congenital nevi should be checked regularly by a dermatology provider</td></tr><tr><td>Nevus spilus</td><td>Oval or irregular; hairless lesion that is brown with dots of darker pigmentation present; flat surface with the darker dots with some elevation; range in size from 1 to 20 cm; appear at any age</td><td>Degeneration into melanoma not documented; excision for cosmetic reason can be performed</td></tr><tr><td>Halo nevus</td><td>Can be a compound or dermal nevus that exhibits a skin-colored border(halo); sharply demarcated borders that are round or oval; generally located on the trunk, may occur on the palms or soles; develop spontaneously and frequently in adolescence; may be singular or multiple; incidence of vitiligo may be increased in individuals with halo nevi</td><td>Removal indicated if atypical features develop</td></tr><tr><td>Becker nevus</td><td>Lacks nevus cells; developmental anomaly; presents as a brown macules with a patch of hair or both; usually seen in adolescent males; seen on the shoulder, inframammary area, upper and lower back; vary in size; irregular border that is sharply demarcated</td><td>Malignant degeneration has not been reported; lesions are generally too large for excision; hair is sometimes removed for cosmetic reasons</td></tr><tr><td>Benign juvenile melanoma (Spitz nevus)</td><td>Common in children but can be seen in adults; hairless, red or reddish-brown; dome shaped; surface may be smooth or verrucous; range in size from 0.3 to 1.5 cm; vascular and may bleed with trauma; usually solitary but may be multiple; appear suddenly</td><td>Should be biopsied for histologic examination due to risk of malignant transformation</td></tr><tr><td>Blue nevus</td><td>Common on extremities and dorsum of hands; small, round lesions, slightly elevated; blue in color; appear in childhood</td><td>Large lesion may degenerate into a malignant lesion</td></tr><tr><td>Labial melanotic macule</td><td>Located on the lower lip, exhibit as brown macules; commonly seen in young adult women; do not darken with exposure to sunlight</td><td>Do not require removal. May be treated due to cosmetic considerations</td></tr></tbody></table>
<p><img src="assets/images/image-20251225-2b567de3.jpeg" alt="img-35.jpeg">
FIGURE 17-6. Congenital nevus. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<p>.</p>
<p><img src="assets/images/image-20251225-03812ac3.jpeg" alt="img-36.jpeg">
FIGURE 17-7. Halo nevi. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)
FIGURE 17-8. Blue nevus. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. History.
B. Clinical manifestations (Table 17-1)
C. Dermoscopy</p>
<ol>
<li>Noninvasive method that allows the in vivo evaluation of color and microstructures of the skin.</li>
<li>Introduction of this method of observing colors and structure within a nevus, not otherwise visible to the unaided eye, helps to predict the histopathology diagnosis.</li>
</ol>
<p>D. Longitudinal photography</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Common nevi</p>
<ol>
<li>Suspicious lesions</li>
</ol>
<p>a. Should be biopsied; then, any appropriate intervention taken after histology established
b. Removal for cosmetic purposes</p>
<ol start="2">
<li>Special forms</li>
</ol>
<p>a. Large congenital nevi—2.8% at risk for development of melanoma; surgical removal indicated
b. Nevus spilus: cosmetic surgical excision, longitudinal evaluation to identify early transformation.
c. Halo nevi: biopsy is unnecessary unless the nevus is otherwise suspicious or has an atypical presentation, atypical history of lesion, or in patients with history of or at high risk for melanoma.
d. Becker nevus (pigmented hairy epidermal nevus)—risk of malignant transformation appears to be very low.
e. Benign juvenile melanoma (Spitz nevus)—requires removal to determine risk.
f. Blue nevus—most commonly benign, biopsy not typically needed unless new or changing. Rare cases of malignant melanoma have been reported arising in association with cellular blue nevi.
g. Labial melanotic macule: removal not necessary unless it has suspicious features.</p>
<p>B. Dysplastic nevus syndrome (Table 17-2)</p>
<ol>
<li>Excisional biopsy</li>
<li>Photograph for comparison and follow-up (Figure 17-9)</li>
</ol>
<p>TABLE 17-2 Dysplastic Nevus Syndrome (Familial Dysplastic Nevus Syndrome) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">^a</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></p>
<table><thead><tr><th>Characteristics</th><th>Management</th></tr></thead><tbody><tr><td>Autosomal dominant</td><td></td></tr><tr><td>Develop melanoma at an early age</td><td></td></tr><tr><td>Predisposition to multiple primary melanomas</td><td></td></tr><tr><td>Tendency to develop superficial spreading melanomas</td><td></td></tr><tr><td>Distinctive large melanocytic nevi present (larger than common moles) (see Figure 17-9)</td><td></td></tr><tr><td>Mixture of colors including tan, brown, pink, and black</td><td></td></tr><tr><td>Irregular and indistinct border, may fade into surrounding skin</td><td></td></tr><tr><td>Surface may be both macular and papular</td><td></td></tr><tr><td>Characteristic presentation: pigmented papule surrounded by a macular collar of pigmentation (“fried egg lesion”)</td><td></td></tr><tr><td>Nevi not present at birth; present in midchildhood as common moles, which change appearance at puberty</td><td></td></tr><tr><td>Lesions may continue to appear after age of 40</td><td></td></tr><tr><td>Lesions occur in sun-exposed areas as well as scalp, buttocks, and breasts</td><td>History: document sun exposure, evolution of nevi, family history of melanoma or presence of large number of moles (particularly large moles)</td></tr><tr><td>Physical examination: entire integument should be examined, including scalp and eyes</td><td></td></tr><tr><td>Examinations should be done at minimum, every 1 yr, or as directed by provider</td><td></td></tr><tr><td>Excisional biopsy should be performed (≥1 DN); total excisional biopsy to avoid recurrence.</td><td></td></tr><tr><td>Consider excision of all new nevi, particularly those in the scalp</td><td></td></tr><tr><td>Photograph total body surface as a baseline for comparison on follow-up</td><td></td></tr><tr><td>Patient education is paramount to compliance with surveillance, treatment, and follow-up; self-examination should be emphasized</td><td></td></tr><tr><td>All family members should be examined on a regular basis for early detection</td><td></td></tr></tbody></table>
<p>aThe identification of the dysplastic nevus (DN) in melanoma-prone families led to the determination that DN are cutaneous. Markers, which identify individuals who are at increased risk for melanoma. DN may be the single most important precursor lesion of melanoma occurring in persons with melanoma-prone families and in persons who lack both a family history of melanoma and a personal history of melanoma.</p>
<p><img src="assets/images/image-20251225-a67dd39b.jpeg" alt="img-37.jpeg">
FIGURE 17-9. Dysplastic nevi. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="variants-of-ethnic-skin-types">Variants of Ethnic Skin Types<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#variants-of-ethnic-skin-types" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Most skin diseases occur in all types of skin. Fitzpatrick separated skin types by photoresponsiveness; skin types III, IV, V, and VI compose the ethnic population that is being addressed. It is important to recognize normal pigmentation variants in ethnic people in order to distinguish these variations from pathologic conditions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-differences-in-skin-type">A. Differences in skin type<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-differences-in-skin-type" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Clinical differences that may be appreciated in ethnic skin types include pigment, follicular response, fibroblast hyperresponsivity, curly hair, and ashiness.</li>
</ol>
<p>a. Skin pigment or skin color is determined by melanosome/melanin production. Melanosomes in keratinocytes in lighter-skinned individuals are smaller and distributed as membrane-bound complexes. In darker-skinned individuals, such as African Americans, melanosomes tend to be larger and distributed more individually. (Refer to melanin production discussion in Chapter 1.)</p>
<p>b. Follicular reactivity is common to many dermatologic diseases in darker skin types: follicular accentuation is clearly visible in darker-skinned individuals, as can be seen in pityriasis rosea, atopic dermatitis, nummular eczema, and sarcoidosis.</p>
<p>c. Fibroblast hyperresponsivity, which is thought to be induced by mast cell/fibroblast interaction and prolonged by a decrease in collagenase activity, leads to another characteristic of darker skin types (typically types IV to VI), in the case of keloid formation.</p>
<p>d. Curly hair: in people of African descent, hair tends to curl and spontaneously knot and break. Hair can be straightened with chemicals and heat and hot oils and tend to cause hair shaft fracture and scalp scarring, which can result in temporary or permanent alopecia.</p>
<p>e. Ashiness: those with dark skin may appear "ashy white" when the skin is dry and scaly; although this scaling occurs in lighter skin, it is not as clinically evident.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="normal-skin-changes-in-darker-skinned-patients">Normal Skin Changes in Darker-Skinned Patients<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#normal-skin-changes-in-darker-skinned-patients" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Definition: pigmentary demarcation lines (PDLs) also described as Voigt and Futcher lines consist of a demarcation between darkly pigmented and lightly pigmented portions of the upper arms in African Americans. For our purpose, we will deal with types A and B PDLs, which are those with sharp transitions.</p>
<p>B. Etiology</p>
<ol>
<li>Unknown.</li>
<li>One theory suggests that the purpose of PDLs is protective in nature. The dorsal skin is more heavily pigmented to provide protection from UV radiation.</li>
</ol>
<p>C. Incidence</p>
<ol>
<li>African descent: 20% to 60%.</li>
<li>Asian descent: less frequent.</li>
<li>Japanese: 4% (more often in women than in men).</li>
<li>Light-skinned individuals: rarely seen.</li>
<li>Evident at birth or is noted in childhood.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Physical examination</p>
<ol>
<li>PDL (Futcher, Voigt) lines are distinct lines of demarcation between darkly pigmented skin laterally and lighter skin anteromedially along the length of the arm.</li>
<li>Lines may follow the distribution of spinal nerves.</li>
<li>Lines are clearly seen on the skin.</li>
<li>PDL (Futcher, Voigt) lines can be present on the posteromedial aspect of the lower leg in</li>
</ol>
<p>women of African descent and may be more pronounced during pregnancy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-modalities">Treatment Modalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. PDLs have no clinical significance other than cosmetic considerations.
B. No treatment needed; no cosmetic treatment options available.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nail-pigmentation-longitudinal-melanonychia">Nail Pigmentation (Longitudinal Melanonychia)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nail-pigmentation-longitudinal-melanonychia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: longitudinal, linear, dark bands, brown to black, found in the nail plates
B. Etiology</p>
<ol>
<li>Pigmentation is due to increased melanin deposits in the nail plates.</li>
<li>May be associated with melanocytes within the nail matrix.</li>
</ol>
<p>C. Incidence</p>
<ol>
<li>African descent: 50%.</li>
<li>May exceed 90% in very dark-skinned individuals.</li>
<li>Ten to twenty percent in Asians.</li>
<li>One percent in light-skinned populations.</li>
<li>Increases with age.</li>
<li>Rate of subungual melanoma is 0.1/100,000 per year.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Physical examination</p>
<ol>
<li>Longitudinal, pigmented nail stripes in the nail plates, width varying from one to several millimeters; may be single or multiple in number.</li>
<li>Distribution of nail pigment may be diffuse rather than linear.</li>
<li>Most common in the thumb, index, or middle fingernails.</li>
<li>Use of dermoscopy is encouraged (assessing for asymmetry in structure or color).</li>
</ol>
<p>B. Diagnosis</p>
<ol>
<li>Related to distribution and clinical findings.</li>
<li>Melanoma should be considered.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-treatment-modalities">III. Treatment Modalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-treatment-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. No treatment is necessary for benign pigment changes.
B. Biopsy is warranted if suspicion of malignancy is present.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="palmar-and-plantar-pigmentation">Palmar and Plantar Pigmentation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#palmar-and-plantar-pigmentation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In dark skin, the palms and soles are usually lighter in color than the rest of the body. Palmar or plantar pigmentation frequently presents in varying degrees.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Physical examination</p>
<ol>
<li>Palmar pigmentation normally occurs in flexural and digital creases.</li>
<li>Small hyperkeratotic papules that evolve into discrete, conical depressions (pits) are also common; limited to palmar and digital creases.</li>
<li>Pigmented macules are commonly seen on the palms and soles of darker-skinned individuals; these lesions are usually multiple, nonerythematous, irregularly shaped with indistinct borders, varying in color from tan to dark brown.</li>
<li>Plantar pigmentation is normally present in those with dark skin; however, it may be present in light skin as well.</li>
</ol>
<p>B. Diagnosis</p>
<ol>
<li>Physical examination.</li>
<li>Plantar lesions also may occur in secondary syphilis.</li>
<li>Possibility of melanoma should be considered.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-treatment-modalities">III. Treatment Modalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-treatment-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. None indicated</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="common-diseases-in-the-darker-skinned-adult">Common Diseases in the Darker-Skinned Adult<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#common-diseases-in-the-darker-skinned-adult" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Dermatologic diagnosis is often more difficult to reach in the darker-skinned patient because subtle changes in skin color may be hidden. Pink and light red hues may be totally missed. Dark reds and browns may appear as purple, gray, or black. Patient history, distribution of lesions, and skin surface changes become the most important diagnostic tools.</p>
<p>A. Disorders that may appear differently in persons with darker skin types include atopic dermatitis, pityriasis rosea, psoriasis, and lupus erythematosus. Any inflammatory disease will appear different in more darkly pigmented skin than in lighter skin.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Follicular prominence in this disease may be more pronounced.
B. Fine scale in darker skin types seen in pityriasis rosea may be better appreciated.
C. Erythema may be less evident.
D. Papular and papulovesicular variants of pityriasis rosea may be more common in darker skin types.
E. Psoriasis plaques may appear more bluish black due to pigment incontinence.
F. All disorders are more likely to elicit postinflammatory hyperpigmentation or hypopigmentation in darker skin types (Figure 17-10).</p>
<p><img src="assets/images/image-20251225-6a5d7aaa.jpeg" alt="img-38.jpeg"></p>
<p>FIGURE 17-10. Psoriasis in darker-skinned individual. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="follicular-occlusion-triad">Follicular Occlusion Triad<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#follicular-occlusion-triad" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The follicular occlusion triad is made up of three diseases that often occur together: hidradenitis suppurativa, acne conglobata, and dissecting cellulitis of the scalp.</p>
<p>A. Definition: hidradenitis suppurativa is a disease involving the apocrine gland-bearing skin of the axilla, groin, inframammary area, and the anogenital region. Symptoms range from mild discomfort to debilitation with extensive scarring, painful draining inflammatory nodules, and the development of sinus tracts. The patient with acne conglobata is affected with multiple open comedones, inflammatory nodules with pus, extensive scarring, and sinus tracts of the back, buttocks, face, and chest. These large comedones tend to have multiple openings. The patient with dissecting cellulitis of the scalp (also known as perifolliculitis capitis abscedens et suffodiens) is plagued by inflammatory nodules, sinus tracts, chronic drainage, crusting alopecia, and scarring. All can be very difficult to treat.</p>
<p>B. Etiology</p>
<ol>
<li>Predisposing factors</li>
</ol>
<p>a. Obesity.
b. Predisposition to acne.
c. Obstruction of apocrine duct.
d. Bacterial infection.
e. Smoking tobacco may increase severity.</p>
<p>C. Pathophysiology</p>
<ol>
<li>Apocrine duct plugged with keratinous material</li>
<li>Dilatation of apocrine duct and hair follicle</li>
<li>Severe inflammation of apocrine gland</li>
<li>Bacterial growth in dilated ducts</li>
<li>Extension of inflammation/infection secondary to ruptured duct/gland</li>
<li>Extension of suppuration/tissue destruction</li>
<li>Ulceration and fibrosis/scar</li>
<li>Sinus tract formation</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>Onset puberty</li>
<li>May undergo a spontaneous remission with age (over 35)</li>
<li>Men tend to be affected in anogenital area and women in axillae.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History and physical examination</p>
<ol>
<li>Intermittent pain, mild to extreme pain.</li>
<li>Multiple inflamed erythematous nodular lesions. Abscesses are frequently recurrent and drain purulent/seropurulent material.</li>
<li>Sinus tracts form and drain pus; fibrosis, hypertrophic, and keloidal scars form; contractures.</li>
<li>Open comedones form. Double comedones may develop even when active nodules are absent.</li>
<li>Lesions may also be found in inguinal folds, gluteal cleft, perineum, or inframammary and may extend over the back and buttocks.</li>
<li>Obesity commonly seen.</li>
<li>Severe cystic acne.</li>
</ol>
<p>B. Diagnosis</p>
<ol>
<li>Clinical exam and history</li>
<li>Bacterial cultures from drainage to rule out infected of lesions
a. Staphylococcus aureus
b. Staphylococcus milleri
c. Anaerobic streptococcus
d. Bacteroides species
e. Pseudomonas aeruginosa</li>
</ol>
<p>III. Therapeutic Modalities</p>
<p>A. Medical</p>
<ol>
<li>Antibiotics
a. Early
(1) Erythromycin
(2) Tetracycline
(3) Minocycline
(4) Intralesional triamcinolone injections
b. Late
(1) Maintenance with antibiotics.
(2) Prednisone.
(3) Oral retinoids may have limited therapeutic benefit.
(4) Biologics (e.g., Anakinra) have been used to treat severe forms, however are not FDA approved for this use, though they have demonstrated some limited efficacy in randomized controlled trials.</li>
</ol>
<p>B. Surgical</p>
<ol>
<li>Axillary hidradenitis suppurativa may respond well to surgical excision of skin to include the removal or scarring of apocrine sweat glands.</li>
<li>Inguinal: surgical control is more difficult and less successful.</li>
<li>Oral retinoids may have more positive effective in early disease, when combined with surgical excision of individual lesions.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="keloids">Keloids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#keloids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Keloids represent exaggeration of the normal fibroblastic process involved in wound healing. Keloids are difficult to treat and commonly recur.</p>
<p>A. Definition: shiny, hyperpigmented, thick, elevated, firm, papules, plaques, and tumors characterized by deposition of excessive amounts of collagen (Figures 17-11 and 17-12)</p>
<p>B. Etiology</p>
<ol>
<li>Unknown.</li>
<li>Usually occur following injury to skin but may appear spontaneously without apparent skin trauma.</li>
<li>Keloids tend to form in dark-skinned individuals more frequently than in those with light skin.</li>
<li>Possible sources of keloid formation: any minor or major surgical procedure, many inflammatory or bullous skin disorders, burns, accidental traumatic events, vaccinations, acne, and secondary infections.</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Exuberant fibrous repair tissue following a cutaneous injury.</li>
<li>Benign growths.</li>
<li>Papules grow into large nodules or plaques, often with claw-like or contracted extensions.</li>
<li>Growth may be slow or become large in a short time.</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>Equal incidence in males and females.</li>
<li>More common in Fitzpatrick types IV to VI.</li>
<li>Occur more often on young adults.</li>
<li>Research indicates that keloids are also common in other groups.
a. Chinese population in Malaysia
b. Light-skinned people of Finland</li>
</ol>
<p><img src="assets/images/image-20251225-2b3b8bc2.jpeg" alt="img-39.jpeg">
FIGURE 17-11. Keloid. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<p><img src="assets/images/image-20251225-84002be0.jpeg" alt="img-40.jpeg"></p>
<p>FIGURE 17-12. Keloid. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History and physical examination</p>
<ol>
<li>Usually asymptomatic.</li>
<li>Commonly pruritic; maybe painful, especially with contractures.</li>
<li>Firm, smooth, hairless, shiny, and raised above the surrounding skin surface.</li>
<li>May be erythematous; progress to brownish-red hue; become hyperpigmented or hypopigmented over time.</li>
<li>Erythema may not be noticed in dark skin.</li>
<li>May be linear following traumatic or surgical injury. Sometimes confused with hypertrophic scars.</li>
</ol>
<p>a. Keloids differ from hypertrophic scars in that keloidal tissue growth, in a traumatized site, extends beyond the boundary of the injury.
b. Tissue growth from hypertrophic scar remains confined to the site of original injury.
c. Hypertrophic scars tend to regress, flatten, and soften spontaneous over time.
d. Keloids may continue to expand in size for years.
e. Hypertrophic scars are likely to form soon after injury, whereas keloids may not begin growing until months later.</p>
<ol start="7">
<li>Spontaneous regression is rare in keloids.</li>
<li>Common sites: ear lobes, shoulders, upper back, neck, chest, skin overlying the jaw, lateral chest (in women), and regions of higher tension on the skin.</li>
</ol>
<p>B. Diagnosis</p>
<ol>
<li>Clinical examination.</li>
<li>Biopsy not warranted; it may induce new or larger scar.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-therapeutic-modalities">III. Therapeutic Modalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Medical</p>
<ol>
<li>Intralesional corticosteroid injection: triamcinolone, typically once a month to reduce pruritus and sensitivity of lesion, reduce its volume, and flatten it.</li>
<li>Intralesional triamcinolone plus cryotherapy may be slightly more effective. The corticosteroid must be injected directly into the bulk of the keloid.</li>
<li>Corticosteroid injections may cause temporary hypopigmentation at or around the injection site. Usually resolves within a few months.</li>
<li>Atrophy may occur in the surrounding skin if corticosteroid inadvertently infiltrates the surrounding normal tissue.</li>
<li>Interferon injections 0.01 to 0.1 mg three times per week for 3 consecutive weeks.</li>
<li>Silicone gel sheeting for 12 to 24 hours daily for 8 to 12 weeks or longer may flatten keloid.</li>
</ol>
<p>B. Surgical</p>
<ol>
<li>Simple surgical excisions. Lesions may grow back larger than the original lesion.</li>
<li>Simple surgical excisions and steroid injections followed by pressure dressing. Pressure dressing is most effective if it is maintained for at least 4 to 6 months after surgery.</li>
<li>Other techniques employed: laser, interferon, tamoxifen, chemotherapeutic agents, imiquimod, calcineurin inhibitors, narrowband UVB, compression therapy, skin grafts, random pattern flaps, and radiation alone or with excision and electrosurgery.</li>
</ol>
<p>Hair Loss</p>
<p>Traction Alopecia/Central Centrifugal Cicatricial Alopecia</p>
<p>I. OVERVIEW</p>
<p>Hair and scalp disorders that may be related to grooming practices occur more frequently in those with darker skin and curly hair. Hot combing, chemical straightening, braids, and weaves are common methods of hairstyling. However, the repeated process that straightens and makes curly hair more manageable, may also damage the scalp and hair. Traction alopecia and central centrifugal cicatricial alopecia (CCCA), a scarring alopecia, are potential results of using these grooming techniques extensively. Evidence has not clearly demonstrated hot combing as the cause of CCCA, but discussing grooming practices should be part of the history in any instance of alopecia.</p>
<p>A. Definition: traction alopecia is a gradually developing patchy hair loss resulting from the cumulative effects of prolonged traction on the scalp and hair. Traumatic hair loss caused by straightening and styling the hair with a hot comb and the application of oils or pomades has been implicated in CCCA.</p>
<p>B. Etiology</p>
<ol>
<li>Traction alopecia</li>
</ol>
<p>a. Braiding: corn rowing the hair frequently and tightly; sometimes adding jewelry, beads, and synthetic hair.
b. Weaving: corn rowing the hair, then attaching natural human or synthetic hair to the hair or gluing it to the scalp. May glue human hair strand by strand to natural hair.</p>
<ol start="2">
<li>CCCA</li>
</ol>
<p>a. Heat from the hot comb causes the hair to break. Hot oil flows down the hair shaft damaging the fair follicles. This may contribute to alopecia.</p>
<p>C. Pathophysiology</p>
<ol>
<li>Damage may occur in the hair follicles with traction alopecia or CCCA.</li>
</ol>
<p>a. The individual's hair is braided with or without the addition of human or synthetic hair (Figure 17-13).</p>
<p>b. Extensive tension is placed on the hair follicle causing follicular erythema and follicular pustules.</p>
<p>c. Conditions may be exacerbated by oils and pomades.</p>
<p>d. Follicular atrophy may result in a noninflammatory permanent alopecia.</p>
<p>e. Commonly affects the frontal and temporal hairline in traction alopecia.</p>
<p>f. Pulling a heated metal comb from roots to end.</p>
<p>g. Curling the hair with electric or curling iron heated from 300°F to 500°F</p>
<p>h. Breakage and rearrangement of hydrogen bonds by the high temperature straightens the hair.</p>
<p>i. Reverse the process by adding moisture to the hair.</p>
<p>j. Burning of skin surface when hot oil flows down the hair shaft causing inflammation, which can lead to postinflammatory pigment changes.</p>
<p>k. Scarring causes a decrease in the number of hair follicles.</p>
<p>l. Vertex of scalp (central, frontal, and parietal areas) is most commonly seen in CCCA.</p>
<p>D. Incidence</p>
<ol>
<li>
<p>More common among African American. Can occur in all races.</p>
</li>
<li>
<p>Prepuberty to older adults.</p>
</li>
<li>
<p>CCCA pattern of hair loss may also occur in men who do not hot comb their hair but do use oil and pomades. May be clinical alopecia imitators of CCCA.</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-effc12cd.jpeg" alt="img-41.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. History and physical examination</p>
<ol>
<li>Traction alopecia/CCCA</li>
</ol>
<p>a. Hair loss in frontal and temporal hairline in traction alopecia and vertex in CCCA (Figure 17-14).
b. Lymphocytic perifollicular inflammation may be seen.
c. Hair breakage at anchoring sites in weaves.
d. Permanent hair loss/scarring.
e. Headache due to scalp tension.
f. Remaining hair may be broken, coarse, or thickened.</p>
<p>B. Diagnosis</p>
<ol>
<li>Clinical examination and history.</li>
<li>Should be distinguished from male pattern baldness (androgenetic alopecia) caused by genetic factors, age, and androgen production. Often misdiagnosed in women of color because hair loss is attributed to grooming causes.</li>
<li>Biopsy can help determine causes of alopecia</li>
</ol>
<p><img src="assets/images/image-20251225-9e7bdf48.jpeg" alt="img-42.jpeg">
FIGURE 17-13. Braids causing traction. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)
FIGURE 17-14. Central centrifugal cicatricial alopecia. (Copyright 2015 by the American</p>
<p>Academy of Dermatology. All rights reserved.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-therapeutic-modalities">III. Therapeutic Modalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Punch/follicular grafting and flap rotation techniques of hair transplantation to correct permanent hair loss/scarring</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="acne-venenata-pomade-acne">Acne Venenata (Pomade Acne)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acne-venenata-pomade-acne" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The practice of grooming the hair and scalp with oils and pomades is attributed partly to traditional and cultural beliefs for many African American individuals. Unfortunately, some of these products contribute to acneiform lesions or other sequelae.</p>
<p>A. Definition: follicular-based eruption of closed comedones with occasional papules and pustules</p>
<p>B. Etiology</p>
<ol>
<li>Prolonged application of oils or oil-based creams to the hair and scalp.</li>
<li>Inflammation occurs around the hair follicle.</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Pomades, which are liquid or solid preparation of mineral, petrolatum, and paraffin (hydrocarbons), straighten hair by plastering it into position.</li>
<li>The heavier solid pomades tend to occlude hair follicles.</li>
<li>Pustules form around the hair follicles producing an inflammatory reaction called folliculitis. The condition worsens as bacterial growth in the follicle increases.</li>
<li>Acne develops on the forehead and temples, clinically similar to acne vulgaris but more monomorphous.</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>Adults and children</li>
<li>Infantile acne secondary to pomade application to hair and scalp</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>A. History and physical examination</p>
<ol>
<li>Uniform open and closed comedones.</li>
<li>Papules, pustules, and cystic nodules may be present.</li>
<li>Hair may be oily.</li>
<li>On examination, may detect exogenous topical material.</li>
<li>Postinflammatory hyperpigmentation may follow acne lesions.</li>
<li>Common sites: scalp, forehead, and temples.</li>
</ol>
<p>B. Diagnosis</p>
<ol>
<li>Clinical examination; biopsy is not indicated.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-therapeutic-modalities">III. Therapeutic Modalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Discontinue use of oil-based products; typically resolves within a few months
B. Antibiotics to treat infection, as needed
C. Keratolytics (benzoyl peroxide) or topical retinoids</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="disorders-unique-to-african-americans">Disorders Unique to African Americans<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#disorders-unique-to-african-americans" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pseudofolliculitis-barbae">Pseudofolliculitis Barbae<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pseudofolliculitis-barbae" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Pseudofolliculitis barbae is one of the most troublesome conditions that can affect African American men. A standard treatment is to stop shaving the affected area.</p>
<p>A. Definition: an inflammatory disorder seen in many men of African descent who shave; also known as ingrown hairs
B. Etiology</p>
<ol>
<li>Hair follicles ingrow curved or tightly coiled.</li>
<li>When the hairs emerge on the skin surface, they have a sharp point caused by shaving, turning the hair back into the skin.</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Tightly coiled hair.</li>
<li>After shaving, the free end may re-enter the skin and incite an inflammatory foreign body reaction.</li>
<li>Also, the top of the coiled penetrating shaft may be shaved off, leaving small pieces of hair in the skin.</li>
<li>An inflammatory reaction occurs due to repeated hair penetrations and hair shaft remnants.</li>
<li>Common sites: chin, upper anterior neck, and mandible. May also develop on legs and axilla from shaving.</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>Occurs more frequently in African American men than in White men</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History and physical examination</p>
<ol>
<li>Irritated papular and pustular eruption on the neck, chin, and mandible (Figure 17-15).</li>
<li>Keloids can form.</li>
<li>Over time, postinflammatory hyperpigmentation occurs throughout the bearded area.</li>
<li>Severity: mildly bothersome to severe, scarring eruptions.</li>
</ol>
<p>B. Diagnosis</p>
<ol>
<li>Clinical examination</li>
<li>Bacterial culture yielding Staphylococcus albus. The disorder, however, is not primarily infectious.</li>
</ol>
<p><img src="assets/images/image-20251225-af280f2e.jpeg" alt="img-43.jpeg">
FIGURE 17-15. Pseudofolliculitis barbae. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-therapeutic-modalities">III. Therapeutic Modalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Discontinue shaving the affected area.
B. If unable to stop shaving, use a new razor each time; avoid electric razors.
C. Apply warm, wet towel to beard before shaving.
D. When possible, carefully free ingrown hairs.
E. Use razor that can leave longer extension of hair.
F. Brush beard gently before shaving to dislodge hairs that are attempting to re-enter the skin.
G. May use depilatory creams.
H. Limited success with topical corticosteroids, tretinoin creams, benzoyl peroxide cream or gel, and glycolic cream.
I. Topical or systemic antibiotics can be recommended.
J. Permanent hair reduction with electrolysis or hair laser, though risk of postinflammatory pigment alteration with any treatment that uses thermal energy.</p>
<p>Dermatosis Papulosa Nigra</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Dermatosis papulosa nigra is a common, benign condition experienced by many individual with darker skin types, in particular African American adults. It is characterized by growth on the face and neck of multiple pigmented papules. Adults who experience facial lesions also exhibit lesions on the body. Prepubescent children are rarely affected.</p>
<p>A. Definition: stuck-on appearing papules that may be hyperpigmented or the color of the surrounding skin. Lesions are typically 1 to 5 mm in size.</p>
<p>B. Etiology</p>
<ol>
<li>Unclear</li>
<li>Possible nevoid condition, hereditary disease, eruptive tumor, or simply a variant of seborrheic keratosis</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Histologically, epidermal tumors look similar to seborrheic keratoses with underlying acanthotic epidermis.</li>
<li>The keratinocytes are basaloid.</li>
<li>Horn cysts may be present.</li>
<li>Some lesions are deeply melanin pigmented.</li>
<li>They do not spontaneously regress.</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>Most unique to those of African descent; occurring in up to 35%.</li>
<li>Puberty onset.</li>
<li>Women are more often affected than men.</li>
<li>Prevalence increases with age.</li>
<li>Occurrence in other groups: Asian, Hispanic, and those with skin types IV to VI.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History and physical examination</p>
<ol>
<li>Multiple asymptomatic, brown, tan, or skin-colored papules.</li>
<li>Benign lesions can be smooth, rough, or verrucous.</li>
<li>Cosmetically unacceptable to the patient.</li>
<li>Common sites: face, scalp, neck, back, or chest.</li>
</ol>
<p>B. Diagnosis</p>
<ol>
<li>The clinical appearance of multiple lesions on the face suggests a diagnosis of dermatosis papulosa nigra. It is rarely biopsied (Figure 17-16).</li>
<li>Other tumors may be hidden among the many lesions.</li>
<li>Careful physical exam to ensure no other skin tumors go undetected.</li>
</ol>
<p><img src="assets/images/image-20251225-bca1aa57.jpeg" alt="img-44.jpeg">
FIGURE 17-16. Dermatosis papulosa nigra. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-therapeutic-modalities">III. Therapeutic Modalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. The right surgical approach is difficult to decide.
B. Low-energy electrodessication is effective; risk of hyperpigmentation/hypopigmentation.
C. Cryotherapy is not a treatment of choice because of the pigmentation alteration that may be produced.
D. Scissor excision or curettage to excise lesions; causes little bleeding and no postoperative complications.
E. Chemical peels with alpha hydroxy acids will soften and flatten these lesions and seem to prevent new lesions. Risk of pigment alteration.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="melanocytic-lesions-conditions-common-in-the-asian-patient">Melanocytic Lesions/Conditions Common in the Asian Patient<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#melanocytic-lesions-conditions-common-in-the-asian-patient" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nevus-of-ota">Nevus of Ota<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nevus-of-ota" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A macular lesion on the side of the face involving the conjunctiva and lids, as well as the adjacent facial skin, sclera, ocular muscles, and periosteum</p>
<p>A. Definition: the nevus of Ota is a facial, dermal melanocytic lesion common in the Asian patient. Nearly all lesions appear before age 30. The incidence in Japanese patients is from 0.1% to 0.2%. Females predominate.</p>
<p>B. Assessment</p>
<ol>
<li>History and physical examination.</li>
</ol>
<p>a. Unilateral blue-black or brown pigment.
b. Usually corresponds to the forehead, temple, eyelid, nose, ear, and/or scalp.
c. Pigmentation may also be found in the sclera and oral mucosa.
d. Cosmetically often unacceptable to the patient.
e. Bilateral occurrence is by age 30 if it happens.
f. Pigmentation is not necessarily symmetrical.</p>
<p>C. Diagnosis</p>
<ol>
<li>Histologically, melanocytes are found scattered in the upper and middermis.</li>
<li>Bilateral nevus of Ota can be confused with nevus of Ota-like macules.</li>
</ol>
<p>a. Pigmentation is more intense with bilateral nevus of Ota and more subtle with bilateral nevus of Ota-like macules.
b. The patient is almost always seen in Asian or darkly pigmented women.
c. Bilateral nevus of Ota-like macules never appear on the mucosa and are never congenital, whereas both congenital presentations and mucosal pigmentation often occur with bilateral nevus of Ota.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-therapeutic-modalities">II. Therapeutic Modalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Camouflage is the usual approach to treatment of the condition.
B. Laser surgery has been shown to decrease appearance of the pigment of nevus of Ota.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nevus-of-ito">Nevus of Ito<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nevus-of-ito" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Nevus of Ito is similar in appearance to nevus of Ota, but the characteristic location of nevus of Ota is periocular (Figure 17-17). Nevus of Ito has the distribution of the shoulder and neck.</p>
<p>A. Definition: nevus of Ito is a bluish discoloration of skin, which is innervated by the posterior supraclavicular and lateral brachial cutaneous nerves. Most common in Asians, rare in light-skinned populations.
B. Assessment</p>
<ol>
<li>History and physical examination</li>
</ol>
<p>a. Differentiation of epidermal nevus syndrome from hypomelanosis of Ito may be particularly difficult in children in whom there is wide variation in background pigmentation.</p>
<p>b. The classic lesion has its onset at birth or childhood and shows increased pigmentation in the skin.</p>
<p>c. Usual distribution on shoulders and neck.</p>
<p>d. Cosmetically unacceptable to most patients.</p>
<p>e. Pigmentation is not symmetrical.</p>
<p>f. Does not regress over time.</p>
<p>C. Diagnosis</p>
<ol>
<li>
<p>Histologically, melanocytes are found scattered in the upper and middermis.</p>
</li>
<li>
<p>Lesions typically present as blue macules/patches.</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-9cf04304.jpeg" alt="img-45.jpeg"></p>
<p>FIGURE 17-17. Nevus of Ota. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-therapeutic-modalities">II. Therapeutic Modalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Camouflage is the usual approach to treatment of the condition.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="congenital-dermal-melanocytosis">Congenital Dermal Melanocytosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#congenital-dermal-melanocytosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The congenital dermal melanocytosis (slate gray nevus, Mongolian spot) presents as a blue-to-gray patch on the sacrum or buttocks of a neonate.</p>
<p>A. Definition: congenital dermal melanocytosis (CDM) is a poorly defined blue-to-gray area of skin discoloration present at birth, usually in the area of the buttocks and lower spine. It may also involve other areas such as the upper back, shoulders, and arms or legs; palms and soles are spared. CDMs are flat birthmarks with wavy borders and irregular shapes, common among people of Asian, East Indian, African, and Latino descent.</p>
<p>B. Assessment</p>
<ol>
<li>History and physical examination.</li>
</ol>
<p>a. The pigmented area has large concentrations of skin cells called melanocytes, with normal skin texture. They commonly appear at birth or shortly after birth and may look like bruises (Figure 17-18).</p>
<p>b. CDM may cover a large area of the back.</p>
<p>c. Often appear on the base of the spine, on the buttocks, and sometimes on the ankles or wrists.</p>
<p>C. Diagnosis</p>
<ol>
<li>
<p>Histologic examination of a CDM shows elongated, dendritic, melanin-containing cells scattered lightly throughout the dermis.</p>
</li>
<li>
<p>The diagnosis of CDM is usually obvious, and a biopsy is not needed. The incidence varies according to the overall depth of this birthmark.</p>
</li>
</ol>
<p>a. African descent: 90%</p>
<p>b. Asian: 80%</p>
<p>c. Latina: 65%</p>
<p>d. European: 9.5%</p>
<ol start="3">
<li>The vague resemblance to a bruise has led to concerns of child abuse.</li>
</ol>
<p><img src="assets/images/image-20251225-c3f10a78.jpeg" alt="img-46.jpeg">
FIGURE 17-18. Congenital dermal melanocytosis. (Copyright 2015 by the American Academy of Dermatology. All rights reserved.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-therapeutic-modalities">II. Therapeutic Modalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. No specific treatment is required.
B. The color reaches a peak at 1 to 2 years of age and then begins to fade.
C. The majority of lesions are absent by adolescence.
D. Occasionally, lesions persist to adulthood and are usually localized to the buttocks.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bibliography">BIBLIOGRAPHY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bibliography" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Allemann, I. B., &amp; Goldberg, D. J. (Eds.) (2011). Basics in dermatological laser applications (p. 133). Basel, Switzerland: Karger Medical and Scientific Publishers.
Ardic, F. N., Aktan, S., Kara, C. O., &amp; Sanli, B. (1998). High frequency hearing and reflex latency in patients with pigment disorder. American Journal of Otolaryngology, 19(6), 365-369.
Arndt, K. A., Laboit, P. C., Robinson, J. K., &amp; Wintroub, B. U. (1996). Cutaneous medicine and surgery: An integrated program in dermatology. Philadelphia, PA: W.B. Saunders Company.
Bigby, M. E., David, A. K., &amp; Brown, A. E. (1994). Recognition and management of skin diseases in people of color. Boston, MA: Glaxo Wellcome, Inc.
Blattner, C., Polley, D. C., Ferritto, F., &amp; Elston, D. M. (2013). Central centrifugal cicatricial alopecia. Indian Dermatology Online Journal, 4(1), 50.
Boer, J. (2006). Oral retinoids for hidradenitis suppurativa. In G. B. E. Jemec, J. Revuz, &amp; J. J. Leyden (Eds.) Hidradenitis</p>
<p>suppurativa (pp. 128–135). Berlin/Heidelberg: Springer.</p>
<p>Boissy, R. E., &amp; Nordlund, J. J. (1996). Vitiligo. In K. A. Arndt, P. E. LeBoit, J. K. Robinson, &amp; B.U. Wintroub (Eds.), Cutaneous medicine and surgery: An integrated program in dermatology (pp. 1210–1218). Philadelphia, PA: W.B. Saunders Company.</p>
<p>Bolognia, J. L., &amp; Shapiro, P. E. (1996). Albinism and other disorders of pigmentation. In K. A. Arndt, P. E. LeBoit, J. K. Robinson, &amp; B. U. Wintroub (Eds.), Cutaneous medicine and surgery: An integrated program in dermatology (pp. 1219–1232). Philadelphia, PA: W.B. Saunders Company.</p>
<p>Bordere, A. C., Lambert, J., &amp; Van Geel, N. (2009). Current and emerging therapy for the management of vitiligo. Clinical, Cosmetic and Investigational Dermatology, 2, 15.</p>
<p>Chan, H. H., Alam, M., Kono, T., &amp; Dover, J. S. (2002). Clinical application of lasers in Asians. Dermatologic Surgery, 28(7), 556–563.</p>
<p>Cichorek, M., Wachulska, M., Stasiewicz, A., &amp; Tymińska, A. (2013). Skin melanocytes: biology and development. Advances in Dermatology and Allergology/Poste_py Dermatologii I Alergologii. 30(1):30–41. doi:10.5114/pdia.2013.33376.</p>
<p>Farber, M. J., Heilman, E. R., &amp; Friedman, R. J. (2012). Dysplastic nevi. Dermatologic Clinics, 30(3), 389–404.</p>
<p>Fitzpatrick, T. B., &amp; Mihm, M. C. (1971). Abnormalities of the melanin pigmentary system. In T. B. Fitzpatrick, K. A. Arndt, W. H. Clark, A. Z. Eisen, E. J. Van Scott, &amp; J. H. Vaughan (Eds.), Dermatology in general medicine (pp. 1591–1637). New York, NY: McGraw-Hill Book Company.</p>
<p>Fitzpatrick, T. B., Johnson, R. A., Polano, M. K., Suurmond, D., &amp; Wolff, K. (1994). Color atlas and synopsis of clinical dermatology common and serious diseases. New York, NY: McGraw-Hill, Inc.</p>
<p>Goldstein, A. M., &amp; Tucker, M. A. (2013). Dysplastic nevi and melanoma. Cancer Epidemiology, Biomarkers and Prevention, 22(4), 528–532.</p>
<p>Granter, S. R., McKee, P. H., Calonje, E., Mihm Jr, M. C., &amp; Busam, K. (2001). Melanoma associated with blue nevus and melanoma mimicking cellular blue nevus: A clinicopathologic study of 10 cases on the spectrum of so-called ‘malignant blue nevus’. American Journal of Surgical Pathology, 25(3), 316–323.</p>
<p>Grimes, P. E., &amp; Davis, L. T. (1991). Cosmetics in blacks. Dermatologic Clinics, 9(1), 53–68.</p>
<p>Grønskov, K., Ek, J., &amp; Brondum-Nielsen, K. (2007). Oculocutaneous albinism. Orphanet Journal of Rare Diseases, 2, 43.</p>
<p>Gul, U., Kilic, A., Tulunay, O., &amp; Kaygusuz, G. (2007). Vitiligo associated with malignant melanoma and lupus erythematosus. Journal of Dermatology, 34(2), 142–145.</p>
<p>Habif, T. P. (1990). Clinical dermatology: A color guide to diagnosis and therapy (2nd ed.). St. Louis, MO: The CV Mosby Company.</p>
<p>Habif, T. P. (2001). Skin disease: Diagnosis and treatment. St. Louis, MO: The CV Mosby Company.</p>
<p>Halder, R. M. (1991). Topical PUVA therapy for vitiligo. Dermatology Nursing, 3(3), 178–182.</p>
<p>Jefferson, J., &amp; Rich, P. (2012). Melanonychia. Dermatology Research and Practice, 2012, 952186.</p>
<p>Johnson Jr, B. L., Moy, R. L., &amp; White, G. M. (1998). Ethnic skin: Medical and surgical. St. Louis, MO: Mosby, Inc.</p>
<p>Kruger, C., &amp; Schallreuter, K. U. (2012). A review of worldwide prevalence of vitiligo in children/adolescent and adults. International Journal of Dermatology, 51(10), 1206–1212.</p>
<p>Lebwohl, M. G., Heymann, W. R., Berth-Jones, J., &amp; Coulson, I. (2013). Treatment of skin disease: Comprehensive therapeutic strategies (4th ed., p. 79, E-book). Netherlands: Elsevier Health Sciences.</p>
<p>McKee, P. H., Calonje, E., &amp; Granter, S. R. (2005a). Cutaneous adverse reactions to drugs and effects of physical agents. In P. H. McKee, E. Calonje, &amp; S. R. Granter (Eds.) Pathology of the skin with clinical correlations (3rd ed., pp. 638–642). London, UK: Elsevier.</p>
<p>McKee, P. H., Calonje, E., &amp; Granter, S. R. (2005b). Disorders of pigmentation. In P. H. McKee, E. Calonje, &amp; S. R. Granter (Eds.) Pathology of the skin with clinical correlations (3rd ed., pp. 993–997). London, UK: Elsevier.</p>
<p>Montagna, W., Prota, G., &amp; Kenney Jr, J. A. (1993). Black skin structure and function. San Diego, CA: Academic Press, Inc.</p>
<p>Njoo, M. D., Westerhof, W., Bos, J. D., &amp; Bossuyt, P. M. M. (1999). The development of guidelines for the treatment of vitiligo. Archives of Dermatology, 135(12), 1514–1521.</p>
<p>Onwudiwe, O., &amp; Callender, V. D. (2014). Pomade acne. In Acneiform eruptions in dermatology (pp. 155–159). New York, NY: Springer.</p>
<p>Ortonne, J. P., Bahadoran, P., Fitzpatrick, T. B., et al. (2003). Hypomelanosis and hypermelanosis. In I. M. Freedburg, A. Z. Eisen, K. Wolff, et al. (Eds.), Fitzpatrick’s dermatology in general medicine (6th ed., pp. 836–881). New York, NY: McGraw-Hill.</p>
<p>Rordam, O. M., Lenouvel, E. W., &amp; Maalo, M. (2012). Successful treatment of extensive vitiligo with monobenzone. Journal of Clinical and Aesthetic Dermatology, 5(12), 36–39</p>
<p>Rosen, T., &amp; Martin, S. (1981). Atlas of black dermatology. Boston, MA: Little, Brown and Company.</p>
<p>Sawada, M., Yokota, K., Matsumoto, T., Shibata, S., Yasue, S., Sakakibara, A., &amp; Akiyama, M. (2014). Proposed classification of longitudinal melanonychia based on clinical and dermoscopic criteria. International Journal of Dermatology, 53(5), 581–585.</p>
<p>Thompson, F. V. (1993). Management of a vitiligo patient: A case study. Dermatology Nursing, 5(2), 139–144.
Thong, H. Y., Jee, S. H., Sun, C. C., &amp; Boissy, R. E. (2003). The patterns of melanosome distribution in keratinocytes of human skin as one determining factor of skin colour. <em>British Journal of Dermatology</em>, 149(3), 498–505.
Torok, H. M., Jones, T., Rich, P., Smith, S., &amp; Tschen, E. (2005). Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: A safe and efficacious 12-month treatment for melasma. Cutis, 75(1), 57–62.
Torres, J. E., &amp; Sanchez, J. L. (1996). Melasma and other disorders of hyperpigmentation. In K. A. Arndt, P. E. LeBoit, J. K. Robinson, &amp; B. U. Wintroub (Eds.), Cutaneous medicine and surgery: An integrated program in dermatology (pp. 1233–1241). Philadelphia, PA: W.B. Saunders Company.
Tsatmali, M., Ancans, J., &amp; Thody, A. J. (2002). Melanocyte function and its control by melanocortin peptides. Journal of Histochemistry and Cytochemistry, 50(2), 125–133.
Watt, A. J., Kotsis, S. V., &amp; Chung, K. C. (2004). Risk of melanoma arising in large congenital melanocytic nevi: A systematic review. <em>Plastic and Reconstructive Surgery</em>, 113(7), 1968–1974.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>
<p>Piebaldism is an acquired disease of hypopigmentation.
a. True
b. False</p>
</li>
<li>
<p>Albinism is a disorder of hypopigmentation secondary to a defect in which of the following?
a. Melanocyte
b. Keratinocyte
c. Lymphocyte
d. Melanophage</p>
</li>
<li>
<p>Which of the following statements regarding melasma is false?
a. There is increased number and activity of melanocytes.
b. Hormones may influence the condition.
c. It is most commonly treated with narrowband UVB.
d. Common distribution is on the face.</p>
</li>
<li>
<p>Hyperpigmentation of the skin may be caused by which of the following?
a. Antimalarials
b. Heavy metals
c. Infection
d. Topical tar-containing preparations
e. A, B, and C
f. A and C
g. All of the above</p>
</li>
<li>
<p>First-line treatment for Becker nevus is surgical excision.</p>
</li>
</ol>
<p>a. True
b. False</p>
<ol start="6">
<li>
<p>Nevus spilus commonly evolves into melanoma.
a. True
b. False</p>
</li>
<li>
<p>Congenital dermal melanocytosis occurs rarely on the buttocks of Asian newborns.
a. True
b. False</p>
</li>
<li>
<p>Which of the following comprise the follicular occlusion triad?
a. Psoriasis, hidradenitis, and acne
b. Hidradenitis suppurativa
c. Acne conglobata
d. Dissecting cellulitis
e. B, C, and D</p>
</li>
<li>
<p>Dermatosis papulosa nigra is:
a. Most unique to people of African descent
b. A benign condition
c. Commonly seen as numerous 1- to 5-mm papules
d. Cosmetically unacceptable to most individuals
e. All of the above
f. A, B, and C</p>
</li>
<li>
<p>Keloids are common in:
a. Dark-skinned individuals
b. Individuals who easily sunburn
c. Light-skinned people of Finland
d. All of the above</p>
</li>
<li>
<p>The best treatment for pseudofolliculitis is which of the following?
a. Discontinuing shaving the affected area
b. Shaving against the direction of the hair growth
c. Applying shaving cream before shaving
d. Shaving as close as possible to the skin surface</p>
</li>
<li>
<p>Longitudinal melanonychia:</p>
</li>
</ol>
<p>a. Reveals melanin deposits in the nail plates
b. Are striped in appearance in the nail plates
c. Should include melanoma in the differential diagnosis
d. All of the above
e. A and C</p>
<ol start="13">
<li>Clinical features of psoriasis are the same in fair-skinned and dark-skinned individuals.
a. True
b. False</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="answers-to-study-questions">Answers to Study Questions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>1.b
2.a
3.c
4.g
5.b
6.b
7.b
8.e
9.e
10.a
11.a
12.d
13.b</p>
<p>CHAPTER 18</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hypersensitivities-drug-vascularities-and-inflammatory-disorders">Hypersensitivities, Drug Vascularities, and Inflammatory Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hypersensitivities-drug-vascularities-and-inflammatory-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cathleen K. Case • Kelli Turgeon-Daoust</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>List the four general types of hypersensitivity reactions.</li>
<li>Differentiate between immediate- and delayed-type hypersensitivities.</li>
<li>Understand diseases associated with hypersensitivity reactions.</li>
<li>Define the major characteristics of small-vessel vasculitis.</li>
<li>Understand management of adverse drug reactions.</li>
<li>Describe the spectrum of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and identify major features of erythema multiforme (EM).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>The immune system is designed to protect the host but may fail.</p>
</li>
<li>
<p>Assessment and history-taking skills are of paramount importance in the evaluation of a suspected hypersensitivity reaction.</p>
</li>
<li>
<p>Avoidance of allergens and irritants, when possible, is the best treatment of urticaria and other hypersensitivity reactions.</p>
</li>
<li>
<p>Differential diagnosis of many cutaneous eruptions includes drug reactions.</p>
</li>
<li>
<p>Urticarial lesions that last longer than 24 hours or present with purpura should be biopsied to rule out urticarial vasculitis.</p>
</li>
<li>
<p>Episode of urticaria lasting more than 6 weeks is considered chronic urticaria. First-line therapy for urticaria is nonsedating H1 antagonist antihistamines.</p>
</li>
<li>
<p>Erythema multiforme is a self-limited but potentially recurrent disease, commonly associated with herpes simplex virus infection.</p>
</li>
<li>
<p>Erythema nodosum is the most common type of panniculitis and may occur in association with systemic disease such as sarcoidosis or inflammatory bowel disease, drug therapy such as oral contraceptive pill, or other infection; half of cases are idiopathic.</p>
</li>
<li>
<p>Cutaneous small-vessel vasculitis, also called leukocytoclastic vasculitis and hypersensitivity vasculitis, is the most common form of small-vessel necrotizing vasculitis. Palpable purpura is characteristic for this disorder.</p>
</li>
<li>
<p>The characteristic lesion of pyoderma gangrenosum is a painful ulcer with a rolled or undermined border frequently on the legs; it is neither infectious nor gangrenous.</p>
</li>
<li>
<p>Toxic epidermal necrosis is a medical emergency with a high mortality rate.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>There are two opposite sides to immunity: host protection and injury. The immune response to an antigen is designed to protect the host. Disorders of the immune system include hypersensitivity, autoimmunity, and immunodeficiency. These response mechanisms produce a wide range of clinical conditions from local reactions to life-threatening diseases. The primary biological effects of the immune response are the humoral (antibody) and cellular recognition and elimination of infectious agents and other foreign antigens. If there is re-exposure to the same antigen in a previously sensitized individual, there may be an exaggerated or "hypersensitivity" reaction. This is a misdirected immune response that results in local tissue injury or systemic manifestations, which may include shock and death. Immune responses that result in tissue injury or other pathophysiologic changes are called allergic/immunopathologic (hypersensitivity) reactions. There are four types of hypersensitivity reactions.</p>
<p>A. Causes of tissue injury</p>
<ol>
<li>Release of vasoactive substances; primary and secondary mediators</li>
<li>Phagocytosis or lysis of cells</li>
<li>Activation of components of the complement system</li>
<li>Release of proteolytic enzymes, cytokines, and other mediators of tissue injury and inflammation from recruited inflammatory cells</li>
</ol>
<p>B. Hypersensitivity reactions, their mediators, and associated conditions (Table 18-1)</p>
<p>This chapter focuses on urticaria, angioedema, and anaphylaxis, certain drug reactions, cutaneous small-vessel vasculitis (CSVV), and other hypersensitivity syndromes, including:</p>
<ol>
<li>Erythema multiforme (EM)</li>
<li>Stevens-Johnson syndrome (SJS)</li>
<li>Toxic epidermal necrolysis (TEN)</li>
<li>Erythema nodosum (EN)</li>
<li>Pyoderma gangrenosum (PG)</li>
</ol>
<p>TABLE 18-1 Four Types of Hypersensitivity Reaction</p>
<table><thead><tr><th>Type</th><th>Mediators</th><th>Mechanism</th><th>Response Time</th><th>Appearance</th><th>Associated Conditions</th></tr></thead><tbody><tr><td>Type I (immediate, anaphylactic)</td><td>IgE, histamine, tryptase, and leukotrienes</td><td>IgE, produced in excessive amounts, interacts with mast cells to cause release of histamine and other vasoactive mediators of hypersensitivity</td><td>Usually 15–30 min; may have delayed onset of 10–12 h</td><td>Wheal and flare</td><td>Anaphylaxis, asthma, urticaria, and angioedema</td></tr><tr><td>Type II (cytotoxic)</td><td>IgM or IgG, complement</td><td>Antibody is bound to antigen on cell surface, triggering complement activation, cell lysis, and cytotoxicity</td><td>Minutes to hours</td><td>Lysis and necrosis</td><td>Transfusion reaction, some drug reactions, and drug-induced pemphigus</td></tr><tr><td>Type III (immune complex)</td><td>Immune complex IgG or IgM</td><td>Antigen–antibody immune complexes are deposited in tissue, activating mast cells, neutrophils, and phagocytes and triggering complement cascade</td><td>3–10 h</td><td>Erythema and edema, and necrosis</td><td>Serum sickness, Arthus reaction, vasculitis, and systemic lupus erythematosus</td></tr><tr><td>Type IV (delayed/ cell mediated)</td><td>Antigen-specific T cells, monocyte chemotactic factor, interleukin-2, interferon-gamma, TNF-alpha, and TNF-beta</td><td>Activated antigen-specific helper T cells stimulate release of cytokines and chemokines, which attract and activate macrophages, eosinophils, and neutrophils; cytotoxic T cells cause damage directly</td><td>1–3 d; up to 4 wk for some reactions</td><td>Erythema and induration</td><td>Allergic contact dermatitis, tuberculin reaction, granuloma formation secondary to infection and foreign antigens (tuberculosis, leprosy), and fixed drug eruption</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="urticaria-angioedema-and-anaphylaxis">Urticaria, Angioedema, and Anaphylaxis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#urticaria-angioedema-and-anaphylaxis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Approximately 1 in 5 people will experience urticaria. Urticaria may be more common in atopic individuals and is usually classified as acute or chronic; however, the majority of cases are acute lasting from hours to a few weeks. Chronic urticaria is defined as episodes of urticaria lasting for more than 6 weeks; however, all urticaria begins in an acute phase. Occasionally, acute urticaria is associated with deeper less well-demarcated edema referred to as angioedema.</p>
<p>Allergic angioedema can be associated with anaphylaxis including life-threatening bronchoconstriction and hypotension. The eyelids and lips are most typically affected by angioedema. The cause of acute urticaria may be identified and generally self-limiting; the cause of chronic urticaria may be determined in only  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span>  to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span>  of cases.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-definition">A. Definition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-definition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Urticaria, also called hives or wheals, is a common and distinctive cutaneous reaction pattern involving the superficial dermis. It is usually transient, demonstrating localized edema caused by dilatation and increased permeability of the capillaries and marked by the development of wheals. A wheal or hive is a well-demarcated, erythematous or white, nonpitting, edematous papule or plaque that is usually pruritic. The lesions are polymorphous and often form annular, arciform, or polycyclic plaques (Figures 18-1 and 18-2). The lesions change shape and size during the few hours or days they are present. Urticaria can be acute or chronic, and the physical urticarias depend on an external or exogenous factor. Chronic urticaria is defined as episodes of urticaria lasting for more than 6 weeks; however, all urticaria begins in an acute phase.</li>
<li>Angioedema (angioneurotic edema) is a hive-like swelling caused by increased vascular</li>
</ol>
<p>permeability in the subcutaneous tissue of the skin and mucosa and submucosal layers of the respiratory and gastrointestinal (GI) tracts. Hives and angioedema can occur simultaneously and may have the same etiology. Angioedema is usually located on the eyes, as seen in Figure 18-3, and mouth (Figure 18-4) but may also occur on the hands and feet or in the throat. Laryngeal edema does not usually occur with urticaria or simple angioedema. There are multiple syndromes of angioedema including idiopathic, allergic, and medication-induced angioedema; hereditary angioedema (HAE); and acquired angioedema (AAE). The presence or absence of hives is used to characterize the different syndromes of angioedema.</p>
<ol start="3">
<li>Anaphylaxis is a severe, potentially fatal, systemic allergic reaction that occurs suddenly after contact with an allergy-causing substance.</li>
</ol>
<p>B. Etiology</p>
<ol>
<li>Urticaria</li>
</ol>
<p>a. Most cases of acute urticaria are IgE-mediated type I hypersensitivity reactions. Circulating antigens such as foods, drugs, or inhalants react with cell membrane-bound IgE to release histamine. IgE antigen on the mast cell surface unites with the antigen of food, drug, stinging insect venom, or pollen and causes an immediate and large release of histamine and other vasoactive mediators from mast cells.</p>
<p>b. Complement-mediated acute urticaria may be caused by administration of whole blood, plasma, immunoglobulins, and drugs or by insect stings. Type III hypersensitivity reactions occur with deposition of insoluble immune complexes in vessel walls (Arthus reactions). The complexes are composed of IgG or IgM, the trapped complexes activate complement, and the process releases histamine from mast cells. A frequent reason for acute urticaria is viral infections of the upper respiratory tract, which increases mast cell reactivity.</p>
<p>c. Nonimmunologic release of histamine occurs when pharmacologic mediators, such as acetylcholine, opiates, polymyxin B, or strawberries, react directly with cell membrane-bound mediators to release histamine. Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) can cause nonimmunologic release of histamine; these patients may have a history of allergic rhinitis or asthma. The physical urticarias may be induced by both direct stimulation of cell membrane receptors and immunologic mechanisms.</p>
<p>d. Patients with history of hives lasting more than 6 weeks may be classified as having chronic urticaria. The lesional morphology is similar to acute hives, any skin surface can be affected, and the lesions last less than 24 hours. Angioedema occurs in 50% of cases of chronic urticaria. Chronic urticaria patients are likely to exhibit physical urticaria, is usually nonallergic, and is usually idiopathic. Angioedema associated with chronic urticaria is different from HAE in that it rarely affects the larynx. Table 18-2 displays the clinical classification of urticaria/angioedema.</p>
<p>e. A partial list of the etiologic classification of urticaria is found in Table 18-3.</p>
<ol start="2">
<li>Angioedema</li>
</ol>
<p>a. Most cases of angioedema are idiopathic. Angioedema will often occur with hives, and angioedema without wheals is seen with drug reactions and C1 inhibitor</p>
<p>deficiency.</p>
<p>b. Severe allergic type I immediate hypersensitivity IgE-mediated reactions can cause acute angioedema. Angioedema can occur with other symptoms of anaphylaxis including hypotension and respiratory distress.</p>
<p>c. Drugs such as contrast dyes, NSAIDs, aspirin, indomethacin, and ACE inhibitors can cause angioedema with nonimmunologic mechanism.</p>
<p>d. AAE results from an acquired C1 inhibitor deficiency considered to be an autoimmune disease. HAE is an inherited C1 inhibitor deficiency and results from lack of the functional C1 esterase inhibitor.</p>
<ol start="3">
<li>Anaphylaxis</li>
</ol>
<p>a. Immediate-type hypersensitivity reactions may occur locally or systemically causing mild symptoms or sudden death from anaphylactic shock. Food allergies, including allergy to tree nuts and peanuts, and crustaceans are common causes of serious anaphylactic reactions. Other common causes include antibiotics, especially penicillins; other drugs and chemicals, including radiographic contrast agents; and hymenoptera stings.</p>
<p>C. Incidence</p>
<ol>
<li>
<p>Estimates of the lifetime occurrence of urticaria range from less than 1% to as high as 30% of the population. Hives can occur at any age, is a worldwide disease, and may be more common in atopic patients.</p>
</li>
<li>
<p>Angioedema frequently occurs with acute urticaria, which is more common in children and young adults. Chronic urticaria is more common in women in the third to fifth decades of life; there is no consensus on the prevalence of chronic urticaria.</p>
</li>
<li>
<p>Most cases of angioedema are idiopathic. It can occur at any age but is most common in the 40- to 50-year-old age group, women being more affected than men. Angiotensin-converting enzyme inhibitors (ACEIs) are the number one drug cause of acute angioedema; the incidence may be higher in Black Americans. HAE affects between 1 in 10,000 and 1 in 50,000 persons and begins in late childhood or early adolescence.</p>
</li>
<li>
<p>True incidence of anaphylaxis is unknown; lifetime prevalence is 1% to 2% for the population as a whole.</p>
</li>
</ol>
<p>D. Pathologic processes</p>
<ol>
<li>
<p>There are several types of stimuli that cause urticaria, which include immunologic, nonimmunologic, physical, and chemical. Several are listed in Table 18-3.</p>
</li>
<li>
<p>The mast cell is the primary effector cell in urticaria. Release of mast cell mediators causes inflammation and mast cell degranulation that results in the release of histamine and inflammatory mediators, as well as an accumulation and activation of other cells including eosinophils, neutrophils, and, possibly, basophils. Histamine causes endothelial cell contraction that allows vascular fluid to leak between the cells through vessel walls, causing tissue edema and wheal formation.</p>
</li>
<li>
<p>When histamine is injected into the skin, there is vasodilation causing local erythema, a peripheral flare characterized by erythema beyond the border of local erythema (axon reflex), and a wheal produced by leakage of fluid from the postcapillary venules.</p>
</li>
<li>
<p>Angioedema is a hive-like swelling in the subcutaneous tissue of skin, mucosa, and</p>
</li>
</ol>
<p>submucosal layers of the respiratory and GI tracts. The reaction is similar to that of urticaria in the upper dermis. Hives and urticaria may have the same etiology and often occur simultaneously.</p>
<ol start="5">
<li>Anaphylaxis can be mediated by immunologic (IgE-mediated and non-IgE-mediated [e.g., IgG and immune complex complement-mediated]) and nonimmunologic factors, which include events resulting in sudden mast cell and basophil degranulation in the absence of immunoglobulins.</li>
</ol>
<p>E. Considerations across the life span</p>
<ol>
<li>Urticaria, angioedema, and anaphylaxis can occur at any age.</li>
</ol>
<p><img src="assets/images/image-20251225-c4b8e9ae.jpeg" alt="img-47.jpeg">
FIGURE 18-1. Large edematous plaques of urticaria. (From Elder, D. E. (2012). Atlas and synopsis of Lever's histopathology of the skin. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-1f612abe.jpeg" alt="img-48.jpeg">
FIGURE 18-2. Typical hives of different sizes. (From Anderson, M. K. (2012). Foundations of athletic training. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-b5af1541.jpeg" alt="img-49.jpeg">
FIGURE 18-3. Urticaria with angioedema around the eyes. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-d522b814.jpeg" alt="img-50.jpeg">
FIGURE 18-4. Angioedema of the lip, tense swelling of the dermis and subcutaneous tissue. (Neville, B., Damm, D., White, D., &amp; Waldron, W. (1991). Color atlas of clinical oral pathology. Philadelphia, PA: Lea &amp; Febiger. Used with permission.)</p>
<p>TABLE 18-2 Clinical Classification of Urticaria</p>
<table><thead><tr><th>Clinical Class</th><th>Duration</th></tr></thead><tbody><tr><td>Ordinary urticaria (acute and chronic)</td><td>3–36 h</td></tr><tr><td>Physical urticaria Adrenergic (stress) Aquagenic Cholinergic Cold Delayed pressure Dermatographism Exercise-induced urticaria (anaphylaxis) Solar Vibratory angioedema</td><td>30 min to 2 h except delayed pressure urticaria that may last longer than 2 h</td></tr><tr><td>Contact urticaria</td><td>1–2 h</td></tr></tbody></table>
<p>TABLE 18-3 Etiologic Classification of Urticaria</p>
<table><thead><tr><th>Etiology</th><th>Examples</th></tr></thead><tbody><tr><td>Food</td><td>Fish, shellfish, nuts, eggs, strawberries, cow’s milk, wheat, and yeast</td></tr><tr><td>Food additives</td><td>Salicylates, benzoates, penicillin, and sulfites</td></tr><tr><td>Drugs</td><td>Penicillin, aspirin, sulfonamides, and drugs that cause a nonimmunologic release of histamine (morphine, codeine, dextran, polymyxin, curare, quinine)</td></tr><tr><td>Infections</td><td>Chronic bacterial infections (sinus, dental, urinary tract), fungal infections, viral infections (hepatitis B prodrome, infectious mononucleosis, cox-sackie), intestinal worms, and malaria</td></tr><tr><td>Inhalants</td><td>Pollens, mold spores, animal dander, house dust, and aerosols</td></tr><tr><td>Internal disease</td><td>Systemic lupus erythematosus, hyperthyroidism, autoimmune thyroid disease, carcinomas, lymphomas, leukocytoclastic vasculitis, polycythemia vera, rheumatic fever, and transfusion reaction</td></tr><tr><td>Physical stimuli (physical urticarias)</td><td>Listed in Table 18-4</td></tr><tr><td>Nonimmunologic contact urticaria</td><td>Plants (nettles), animals (caterpillars, jellyfish), and medications (cinnamic aldehyde, dimethyl sulfoxide)</td></tr><tr><td>Uncertain mechanism</td><td>Ammonium persulfate used in hair bleach, chemicals, foods, textiles, wood, saliva, cosmetics, perfumes, and bacitracin</td></tr><tr><td>Skin diseases</td><td>Mastocytosis, dermatitis herpetiformis, pemphigoid, and amyloidosis</td></tr><tr><td>Hormones</td><td>Pregnancy and premenstrual flare (progesterone)</td></tr><tr><td>Genetic</td><td>Hereditary angioedema, familial cold urticaria, and vibratory urticaria</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The diagnosis of urticaria is often one of exclusion. It is essential to rule out the presence of serious illnesses of which recurring hives and/or edema can be a symptom. Examples of such illnesses may include hepatitis, hyperthyroidism, lymphomas, lupus, and cancers of the rectum, kidneys, and GI tract.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-history-and-physical-examination">A. History and physical examination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-history-and-physical-examination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>History and physical exams are the most important parts of the initial evaluation and should include an evaluation of the following factors.</li>
</ol>
<p>a. Association with any specific substance or activity: drug ingestion or exposure; respiratory infection; food and drink; exposure to pollens and chemicals; physical</p>
<p>location of work, travel, hobby, or home; and medications, supplements, or homeopathic compounds.</p>
<p>b. Appropriate description of the character of the primary lesion in urticaria is important, usually an edematous and erythematous papule or plaque.</p>
<p>c. Location of the lesions—itchy lesions that come and go, located anywhere on the skin.</p>
<p>d. Length of response—individual hives do not usually last for more than 24 hours. Note time of onset, appearance, day, year, and season. Duration of individual lesions: less than 1 hour, physical urticaria and typical hives; less than 24 hours, typical hives; longer than 25 hours, and that burn or resolve with purpura require a biopsy to exclude urticarial vasculitis.</p>
<p>e. Assessment of previous incidence of symptoms related to common causes of urticaria. Table 18-3 lists possible causes. Drugs are common causes in adults, and viral respiratory or streptococcal infections are common causes in children.</p>
<p>f. Evaluation of recent exposure to possible allergens.</p>
<p>g. Assessment of common subtypes of urticaria (Table 18-2).</p>
<p>h. Evaluate the role that occupation can play in establishing the diagnosis of urticaria.</p>
<p>i. Differentiation of angioedema from urticaria is of utmost importance related to the life-threatening possibilities associated with angioedema. Urticarial lesions are superficial and widespread, while lesions associated with angioedema are deep, and the eyelids and lips are the areas most typically affected. Urticaria and angioedema frequently occur at the same time. Any patient with recurrent angioedema or abdominal pain without wheals should be evaluated for HAE.</p>
<p>j. Evaluate for physical urticaria by stroking the arm with a tongue blade to test for dermatographism. This may indicate one of the physical urticarias.</p>
<p>k. Anaphylaxis almost always involves the skin and/or mucous membranes with a combination of erythema, urticaria, angioedema, or pruritus. Adults will present with cutaneous and respiratory symptoms and children may show more respiratory symptoms.</p>
<p>B. Skin findings</p>
<ol>
<li>A wheal or hive is a well-demarcated, erythematous or white, nonpitting, edematous papule or plaque that is usually pruritic. The lesions of urticaria change shape and size during the few hours or days they are present. The central area (wheal) can be pale compared to the surrounding erythematous area (flare). Wheals are sharply marginated and predominantly flat topped. Their color varies from light pink to dark red depending on the amount of fluid present between the skin surface and the underlying dilated vascular bed. Wheals frequently have a dimpled surface because of the anchoring effect of hair follicles as fluid fills the papillary dermis surrounding them. The physical urticarias have unique characteristics and are outlined in Table 18-4.</li>
</ol>
<p>a. The evolution of urticaria is dynamic and lesions are transient.</p>
<p>b. Hives result from local capillary vasodilation and dermal edema; the edema is in the superficial dermis.</p>
<p>c. Lesions vary in size from 2 to 4 mm seen in cholinergic urticaria up to a giant hive that may cover an entire extremity.</p>
<p>d. Lesions will be round, oval, polycyclic, or incomplete rings. Color may be solid red or white, or white in center with red border. Purpura within individual lesions may indicate urticarial vasculitis.</p>
<p>e. Thicker plaques with fluid in dermis and subcutaneous tissue are considered angioedema.</p>
<p>f. Hives are generally ITCHY; however, intensity may vary.</p>
<p>g. Purpura within a wheal may indicate urticarial vasculitis and will need biopsy.</p>
<ol start="2">
<li>The reaction of angioedema is deeper than wheals and produces more diffuse swelling. The swelling is painful and burning but not pruritic.</li>
</ol>
<p>a. Lips, palms, soles, trunk, limbs, and genitalia are commonly affected.</p>
<p>b. There may be involvement of respiratory or GI tracts producing dyspnea, dysphagia, abdominal pain, and diarrhea.</p>
<p>c. Angioedema may develop as a result of trauma.</p>
<ol start="3">
<li>The physiologic responses to the release of anaphylaxis mediators include smooth muscle spasm in the respiratory and GI tracts, vasodilation, increased vascular permeability, and stimulation of sensory nerve endings.</li>
</ol>
<p>a. These physiologic events lead to some or all of the classic symptoms of anaphylaxis: flushing; urticaria/angioedema; pruritus; bronchospasm; laryngeal edema; abdominal cramping with nausea, vomiting, and diarrhea; and feeling of impending doom.</p>
<p>C. Differential diagnosis</p>
<ol>
<li>Urticarial stage of bullous pemphigoid</li>
<li>Dermatitis herpetiformis</li>
<li>Drug eruptions</li>
<li>Erythema multiforme</li>
<li>Papular urticaria</li>
<li>Polymorphic eruption of pregnancy</li>
<li>Urticaria pigmentosa</li>
<li>Urticarial vasculitis</li>
</ol>
<p>D. Diagnostic tests</p>
<ol>
<li>Complete blood count (CBC) with differential.</li>
<li>Liver and thyroid function tests.</li>
<li>Urine analysis.</li>
<li>Erythrocyte sedimentation rate (ESR).</li>
<li>If the history provides evidence that warrants additional tests, consider test for hepatitis A, B, and C; infectious mononucleosis; thyroid antibodies; and antinuclear antibody (ANA).</li>
<li>Biopsy for urticarial lesions with purpuric center or for lesions that last for more than 36 hours to evaluate for urticarial vasculitis. Also, biopsy if there is fever, arthralgia, elevated ESR, or petechiae.</li>
<li>Sinus x-rays may be considered for evaluation of chronic urticaria if there is a corresponding history.</li>
<li>If HAE is suspected, C4 level can be a screening test.</li>
</ol>
<p>TABLE 18-4 The Physical Urticarias</p>
<table><thead><tr><th>Urticaria</th><th>Relative Frequency</th><th>Precipitant</th><th>Local Symptoms</th><th>Systemic Symptoms</th></tr></thead><tbody><tr><td>Symptomatic dermatographism</td><td>Most frequent</td><td>Stroking skin</td><td>Irregular, pruritic wheals</td><td>None</td></tr><tr><td>Delayed dermatographism</td><td>Rare</td><td>Stroking skin</td><td>Burning, deep swelling</td><td>None</td></tr><tr><td>Pressure urticaria</td><td>Frequent</td><td>Pressure</td><td>Diffuse, tender swelling</td><td>Flulike symptoms</td></tr><tr><td>Solar urticaria</td><td>Frequent</td><td>Various light wavelengths</td><td>Pruritic wheals</td><td>Wheezing, dizziness, and syncope</td></tr><tr><td>Familial cold urticaria</td><td>Rare</td><td>Change in skin tempera-ture from cold air</td><td>Burning wheals</td><td>Tremor, headache, arthralgia, and fever</td></tr><tr><td>Essential cold urticaria</td><td>Frequent</td><td>Cold contact</td><td>Pruritic wheals</td><td>Wheezing and syncope</td></tr><tr><td>Heat urticaria</td><td>Rare</td><td>Heat contact</td><td>Pruritic wheals</td><td>None</td></tr><tr><td>Cholinergic urticaria</td><td>Very frequent</td><td>General overheating of the body</td><td>Papular, pruritic wheals</td><td>Syncope, diarrhea, vomiting, salivation, and headaches</td></tr><tr><td>Aquagenic urticaria</td><td>Rare</td><td>Water contact</td><td>Papular, pruritic wheals</td><td>None reported</td></tr><tr><td>Vibratory angioedema</td><td>Very rare</td><td>Vibrating against skin</td><td>Angioedema</td><td>None reported</td></tr><tr><td>Exercise-induced anaphylaxis</td><td>Rare</td><td>Exercise; in some cases, ingestion of certain foods</td><td>Pruritic wheals</td><td>Respiratory distress and hypotension</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Systemic therapy for urticaria and associated angioedema</p>
<ol>
<li>First-line therapy is (nonsedating) second-generation H1 antagonists to inhibit mast cell mediators.</li>
</ol>
<p>a. Cetirizine  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  nightly or twice daily
b. Loratadine  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  daily or twice daily
c. Fexofenadine 120 to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>180</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">180\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">180</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  daily</p>
<ol start="2">
<li>First-line therapy may include first-generation H1 (sedating) antihistamines and/or H2 receptor antagonists if symptoms are not controlled after a week or two of treatment.</li>
</ol>
<p>a. Diphenhydramine 10 to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  four times daily.
b. Hydroxyzine HCl 10 to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  four times daily.
c. Doxepin 10 to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  nightly.
d. H2 receptor antagonists include cimetidine  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">400\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  twice daily, ranitidine  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">150\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  twice daily, or famotidine  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  twice daily.</p>
<ol start="3">
<li>Second-line therapy may include systemic corticosteroid.</li>
</ol>
<p>a. Prednisone 0.5 to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1\mathrm{mg / kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg/kg</span></span></span></span></span></span>  daily for short course may provide relief for severe cases.</p>
<ol start="4">
<li>Third-line therapy may include leukotriene receptor agonists and can be combined with antihistamines.</li>
</ol>
<p>a. Montelukast  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  daily
b. Zafirlukast  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  twice daily
c. Zileuton  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">600\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  four times a day</p>
<ol start="5">
<li>Treatment of choice for angioedema associated with anaphylaxis is epinephrine given intramuscularly (IM) (1:1,000 solution) when intravenous is not available. Diphenhydramine  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  can also be given IM. The IM route is better and more quickly absorbed than subcutaneous.</li>
</ol>
<p>B. Nonpharmacologic interventions</p>
<ol>
<li>Identify and eliminate underlying cause.</li>
</ol>
<p>a. Avoid common triggers such as aspirin, NSAIDs, food additives, heat, and alcohol.
b. Whether urticaria is acute or chronic, consider stopping vitamins, laxatives, antacids, toothpaste, cigarettes, cosmetics and all toiletries, chewing gum, household cleaning solutions, and aerosols.
c. Chronic hives are not caused by food allergies; however, some individuals find that hives are worsened after eating certain foods. Consider stopping fruits, tomatoes, nuts, eggs, shellfish, chocolate, milk, cheese, bread, diet drinks, and junk food.</p>
<ol start="2">
<li>Avoid eliciting stimuli.
a. Take cool showers or baths, apply cool compresses (except with cold urticaria), wear loose fitting clothes, and avoid strenuous activity.
b. Swimming in cold water is the most common cause of severe cold urticaria reaction. Patients should be advised never to jump into a cold body of water, and water activities should be done under supervision.
c. Strategies to reduce stress can be helpful.</li>
</ol>
<p>C. Medication therapy monitoring</p>
<ol>
<li>The role of pharmacotherapy is symptom management, and control of pruritus is critical in helping patients find relief.</li>
<li>Antihistamine therapy usually starts with nonsedating antihistamines; however, if symptoms are not managed well, sedating antihistamines will be needed.</li>
<li>All patients, especially the elderly, should be educated on possible side effects including sedation, dry mouth, urine retention, and dizziness.</li>
<li>Start with low dose to monitor tolerance.</li>
</ol>
<p>D. Other nursing interventions</p>
<ol>
<li>Discuss skin care with patients recommending emollients and bathing not too hot or cold.</li>
<li>Emollients with anti-itch properties such as menthol, phenol, and pramoxine can be helpful especially for spot treatment and comfort.</li>
<li>Quality-of-life issues for patients with chronic urticaria should be acknowledged and addressed especially around relief of pruritus. Disease management needs to be prompt, and an individual approach is necessary due to the complex nature of urticaria. In addition, the management must be a close working cooperation with the patient.</li>
<li>When the cause of acute urticaria is promptly avoided, symptoms resolve rapidly. Reassure patients with acute urticaria that most cases resolve within 6 weeks; patients are often frustrated and fearful especially with chronic urticaria. The evolution from acute to chronic urticaria is not well understood, and the prognosis for resolution after 6 months is unclear.</li>
</ol>
<p>E. Complementary alternative medicine</p>
<ol>
<li>Certain foods can act as natural antihistamine:
a. Foods high in vitamin C such as carrots, mangoes, spinach, and tomatoes.
b. Foods high in vitamin A such as oranges, lemons, tangerines, limes, and grapefruit.
c. Pineapples can also be considered as an alternative and natural antihistamine. Bromelain is an enzyme found in high concentration in pineapple. Adding pineapples to daily diet can act as an alternative way to prevent and treat hive outbreaks.</li>
</ol>
<p>PATIENT EDUCATION</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="urticaria-angioedema-and-anaphylaxis">Urticaria, Angioedema, and Anaphylaxis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#urticaria-angioedema-and-anaphylaxis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Evaluate extensive review of medications, environment exposures, supplements, diet preferences, and medical history. The patient should be an active participant in the search for inducing agents.</li>
<li>Discuss that physical urticarias are more common than expected and may require provocative tests; delayed urticaria from pressure may occur several hours after the stimulus.</li>
<li>Instruct patients and family to understand diagnosis.</li>
<li>Provide handouts and any other literature pertaining to diagnosis to have patient bring home. These are for future reference and to encourage patient to discuss with family for support.</li>
<li>Educate to prevent future flare-ups and promote treatment compliance. Treatment plan includes avoidance of contributing factors that can aggravate condition.</li>
<li>Reinforce that antihistamines or other medications may need to be taken for an extended time to prevent further hives or swelling. It is important to not abruptly stop treatment without provider advice.</li>
<li>Select patients who will need special education on use of EpiPen as prescribed for emergency situations if swelling of the lips, tongue, and face develops.</li>
<li>Reduce emotional and physical stress as may be helpful to minimize urticarial flares.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-home-care-and-follow-up">IV. Home Care and Follow-Up<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-home-care-and-follow-up" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Patients with chronic urticaria may need referral to allergist, immunologist, or urticaria specialist if the cause cannot be found and the urticaria is interfering with quality of life. Allergy testing may be helpful for urticaria evaluation, but it is imperative for individuals who have had an anaphylactic episode. In general, patients with urticaria can be cared for on an outpatient basis unless their urticaria is severe and does not respond to antihistamine therapy or if they progress to laryngeal angioedema and/or anaphylactic shock or have comorbidities that require inpatient therapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vasculitis">Vasculitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vasculitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Vasculitis is a nonspecific term that encompasses and a large and heterogeneous group of disorders characterized by inflammation of blood vessels. The process can involve the walls of any size or type of vessel causing damage that results in tissue necrosis. Cutaneous vasculitis may be limited to the skin, there may be secondary systemic involvement, or it may be a cutaneous manifestation of a systemic disease. There is no uniform classification system for vasculitis, although some classify according to the type of cell within the vessel walls (neutrophil, lymphocyte, or histiocyte), the type of circulating immune complexes, and the size and type of primary vessel involved (venule, arteriole, artery, or vein). The International Chapel Hill Consensus Conference of the Nomenclature of Systemic Vasculitides (CHCC2012) recently updated their system that specifies the name that should be used for a specifically defined disease process, used when a patient fulfills a definition. The spectrum of this group of diseases is too large for the context of this text, and therefore, the focus will be on some of the more common vasculitides affecting small vessels. This will include CSVV/leukocytoclastic vasculitis (LCV) and Henoch-Schönlein purpura (HSP).</p>
<p>A. Definition</p>
<ol>
<li>
<p>All vessel sizes of venous and arterial systems can be involved. Small vessels include arterioles, capillaries, and postcapillary venules that are found in the superficial and middermis of the skin. Medium-sized vessels include the main visceral arteries and veins, and small arteries and veins within the deep dermis and subcutaneous tissue. Large vessels include the aorta, major branches and corresponding veins, and other named arteries such as the temporal artery.</p>
</li>
<li>
<p>Table 18-5 lists the main vasculitides classified by vessel size.</p>
</li>
<li>
<p>CSVV has in the past been referred to as LCV and hypersensitivity vasculitis and is the most commonly seen form of small-vessel necrotizing vasculitis. The condition may be limited to the skin or may involve different organs.</p>
</li>
<li>
<p>HSP is acute LCV that occurs mainly in children between ages 2 and 10; however, adult cases are reported. HSP is characterized by deposits of IgA immune complexes in venules, capillaries, and arterioles. HSP is the most common systemic vasculitis in children.</p>
</li>
</ol>
<p>B. Etiology</p>
<ol>
<li>Generally, there is hypersensitivity to various antigens including drugs, chemicals, microorganisms, and endogenous antigens. This results in the formation of immune complexes that are deposited in the vessel walls. There are many diseases that may be associated with hypersensitivity vasculitis; however, in many cases, the cause is not determined. These include the following:</li>
</ol>
<p>a. Hepatitis B and C virus
b. Other infections
c. Drugs
d. Malignant neoplasm
e. Connective tissue disease
f. Rheumatologic disease
g. Inflammatory bowel disease</p>
<ol start="2">
<li>HSP may be preceded by a streptococcal or viral upper respiratory infection 1 to 3 weeks</li>
</ol>
<p>before the vasculitis presents and tends to occur in the spring. Other infectious agents and drugs have been implicated, but general etiology is unknown.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="c-pathologic-process">C. Pathologic process<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c-pathologic-process" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>The term LCV describes the histologic picture that is produced when leukocytes fragment during the inflammatory process, leaving nuclear debris or "dust." This is called leukocytoclasis. CSVV, also referred to as hypersensitivity vasculitis and LCV, is the most commonly seen form of small-vessel vasculitis. On histology, there is fibrinoid necrosis of small dermal blood vessels, leukocytoclasis, endothelial swelling, and extravasation of red blood cells.</p>
</li>
<li>
<p>IgA plays a major role in the pathogenesis of HSP. There are increased concentrations of serum IgA, IgA deposits in vessel walls, and renal mesangium. There can be widespread circulating IgA-containing immune complexes in vessel walls of the skin, kidneys, and GI tract, which will lead to systemic symptoms.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="d-incidence">D. Incidence<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d-incidence" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>CSVV is usually seen over age 16 and HSP usually under the age of 16 but is also reported in adults.</p>
</li>
<li>
<p>If a drug or viral illness has caused the CSVV, patients may only experience one episode. Multiple episodes may occur if associated with a systemic disease such as rheumatoid arthritis or systemic lupus erythematosus.</p>
</li>
<li>
<p>Adults with HSP usually have no precipitating event, lower frequency of abdominal pain and fever, higher frequency of joint symptoms, and more frequent and severe renal involvement.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="e-considerations-across-the-life-span">E. Considerations across the life span<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#e-considerations-across-the-life-span" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>CSVV is generally seen in adults, and HSP is generally seen in children.</li>
</ol>
<p>TABLE 18-5 Classification of Vasculitides Based on Vessel Size</p>
<table><thead><tr><th>Predominant Caliber of Affected Vessel</th><th>Classification</th><th>Subclassification</th></tr></thead><tbody><tr><td>Small</td><td>Cutaneous small-vessel vasculitis</td><td>Idiopathic Henoch-Schönlein purpura Acute hemorrhagic edema of infancy Erythema elevatum diutinum</td></tr><tr><td>Small and medium sized</td><td>Secondary Cryoglobulinemic ANCA associated</td><td>Infections and septic vasculitis Inflammatory disorders (SLE, rheumatoid arthritis, Sjogren syndrome) Drug exposure Neoplasms Microscopic polyangiitis Wegener granulomatosis Churg-Strauss syndrome</td></tr><tr><td>Medium sized</td><td>PAN</td><td>Systemic form Benign cutaneous form</td></tr><tr><td>Large</td><td>Temporal arteritis Takayasu arteritis</td><td></td></tr></tbody></table>
<p>ANCA, antinuclear cytoplasmic antibodies; PAN, polyarteritis nodosa; SLE, systemic lupus erythematosus.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. History and physical examination</p>
<ol>
<li>Complete review of systems to assess prodromal symptoms of fever, malaise, myalgia, skin pain or pruritus, and abdominal symptoms. Joint symptoms, kidney issues such as frank hematuria, and scrotal swelling in boys with HSP.</li>
</ol>
<p>B. Skin findings and systemic involvement</p>
<ol>
<li>Characteristic lesions of cutaneous small-vessel vasculitis are palpable purpura (Figure 18-5). May start asymptomatic and look like cutaneous hemorrhages that become palpable as blood leaks out of damaged vessels, and palpable purpura of vasculitis may be unifocal or bilateral. Ulceration, nodules, urticaria, and livedo reticularis may also be present.</li>
<li>Lesions coalesce and produce large areas of purpura. Hemorrhagic blisters and ulcers indicate more severe vessel inflammation and necrosis. Older lesions may have brownish red color.</li>
<li>Diascopy can be used to evaluate blanchable versus nonblanchable lesions. Press a glass slide over a purpuric papule, the red blood cells in the skin will blanch when not vasculitic. Vasculitic papules with fibrosis, necrosis, and thrombosis will not blanch.</li>
<li>There may be a few or numerous purpuric lesions, most commonly located on lower extremities but can be seen in any dependent area. Figure 18-6 shows a patient with HSP</li>
</ol>
<p>on the legs and buttocks.</p>
<ol start="5">
<li>
<p>Small lesions itch and are painful; nodules, ulcers, and bullae will be more painful.</p>
</li>
<li>
<p>CSVV systemic manifestations may include the following:</p>
</li>
</ol>
<p>a. Vasculitis of the kidneys causing microscopic hematuria and proteinuria; necrotizing glomerulonephritis may lead to chronic renal insufficiency.
b. Peripheral neuropathy with paresthesia or hypoesthesia.
c. Vasculitis of bowel will cause abdominal pain, nausea, vomiting, diarrhea, and melena.
d. Pulmonary vasculitis may be seen as nodule or infiltrate on chest film or with cough, shortness of breath, and hemoptysis.
e. Joint swelling, erythema, and pain.
f. Arrhythmias and congestive heart failure can be seen with myocardial angiitis.</p>
<ol start="7">
<li>Systemic manifestations of HSP include the following:</li>
</ol>
<p>a. GI symptoms of colicky abdominal pain, nausea, vomiting, GI bleeding, diarrhea, and blood in stool. GI symptoms may precede skin disease.
b. Arthralgia from periarticular edema involves the ankles, knees, and dorsum of hands and feet.
c. Nephritis occurs in 20% to 50% of children, and onset may be acute or delayed for weeks or months. Microscopic hematuria is a frequent feature, and gross hematuria occurs less frequently. Heavy proteinuria at onset of disease requires close and long-term follow-up; renal disease can reappear after recovery.
d. Acute scrotal swelling may be the only presenting feature of HSP vasculitis in a young boy and may mimic testicular torsion or incarcerated hernia.</p>
<p>C. Differential diagnosis</p>
<ol>
<li>Arthropod bites</li>
<li>Erythema multiforme</li>
<li>Morbilliform drug eruption with hemorrhage</li>
<li>Cellulitis</li>
<li>Thrombosis from hypercoagulable state</li>
<li>Over anticoagulation with warfarin or heparin</li>
<li>Livedoid vasculopathy</li>
<li>Urticaria</li>
<li>Pigmented purpura</li>
<li>Pyogenic granuloma</li>
<li>Panniculitis</li>
<li>Infection (Rocky Mountain spotted fever, subacute bacterial endocarditis, viral infections)</li>
<li>Sepsis</li>
<li>Cholesterol emboli</li>
</ol>
<p>D. Diagnostic tests</p>
<ol>
<li>Initial diagnostic test should be punch or excisional skin biopsy of new lesion preferable 24 to 48 hours old being sure to collect subcutaneous tissue to evaluate for larger involved vessels. Additional biopsy for direct immunofluorescence is needed to identify</li>
</ol>
<p>immunoglobulins and complement in the blood vessels; IgA may be found in HSP.</p>
<ol start="2">
<li>Workup will be determined by positive findings on review of systems and physical exam.</li>
<li>CBC with differential abnormalities may lead to investigation of infection, malignancy, or other underlying disease.</li>
<li>ESR and C-reactive protein are nonspecific inflammatory markers and are frequently elevated; may be more helpful for monitoring disease progress.</li>
<li>Electrolytes, blood urea nitrogen, and creatinine may reflect kidney involvement.</li>
<li>Urinalysis with microscopy to evaluate hematuria and proteinuria.</li>
<li>Abnormal liver function tests may indicate liver disease, infection, or malignancy.</li>
<li>Chest x-ray, cardiac workup, and stool guaiac considered based on exam.</li>
</ol>
<p><img src="assets/images/image-20251225-3167cb53.jpeg" alt="img-51.jpeg"></p>
<p><img src="assets/images/image-20251225-735013f8.jpeg" alt="img-52.jpeg">
FIGURE 18-5. Palpable purpura of CSVV. (From Dr. Barankin Dermatology Collection.)
FIGURE 18-6. Palpable purpura in a patient with HSP. Note the dark, necrotizing center of the lesions. (From Fleisher, G. R., Ludwig, S., &amp; Baskin, M. N. (2004). Atlas of pediatric emergency medicine. Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-systemic-therapy">A. Systemic therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-systemic-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Initial therapy for CSVV and HSP is aimed at identifying and removing the offending antigen (drug, chemical, or infection) and no other treatment may be necessary. Class I or II topical corticosteroids are usually very helpful for CSVV. NSAIDs are used for myalgia, arthralgia, fever, and persistent lesions. Prednisone may be necessary for ulcerated lesions and other systemic symptoms; slow taper is recommended to avoid rebound.</li>
<li>Second-line systemic therapy may include colchicine or dapsone.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="b-local-therapy-and-other-medical-interventions">B. Local therapy and other medical interventions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-local-therapy-and-other-medical-interventions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Supportive care includes rest with leg elevation and local wound care to any skin ulcerations.</li>
<li>Supportive medical care as indicated for systemic involvement. Monitor for secondarily infected lesions and treat with topical or systemic antibiotics as warranted.</li>
<li>Compression therapy with Unna boots; once edema has decreased, elastic compression stocking can be used in combination with leg elevation to prevent recurrence.</li>
</ol>
<p>PATIENT EDUCATION</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vasculitis">Vasculitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vasculitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Instruct patients and family to understand diagnosis.</li>
<li>Provide handouts and any other literature pertaining to diagnosis to have patient bring home. These are for future reference and to encourage patient to discuss with family for support.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-home-care-and-follow-up">IV. Home Care and Follow-Up<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-home-care-and-follow-up" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-continuity-of-care-concerns">A. Continuity of care concerns<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-continuity-of-care-concerns" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Children with HSP exhibiting abdominal pain and evidence of nephritis need appropriate and timely referrals to specialists. Those with renal involvement will need follow-up for at least 3 months monitoring blood pressure and urinalysis; females should be monitored for the same during any pregnancy.</li>
<li>If not healing:
a. Re-evaluate for infection.
b. Check patient compliance.
c. Consider change in current treatment plan.</li>
<li>If healing:
a. Continue to monitor care closely, approximately every 2 months.
b. Continue to educate patient on compliance and prevention.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cutaneous-drug-reactions">Cutaneous Drug Reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cutaneous-drug-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A cutaneous reaction may be caused by a chemical substance or combination of substances that are ingested, injected, inhaled, inserted, instilled, or topically applied to the skin or mucous membranes and is among the most frequently observed reactions. Adverse reactions may result from overdose, accumulation, pharmacologic side effect, drug–drug interactions, idiosyncrasy, microbiologic imbalance, exacerbation of existing latent or overt disease, hypersensitivity, autoimmune-like reaction, teratogenic effect, interaction of the drug and sunlight or other light sources, or other unknown mechanisms. Drug reactions are common; data on incidence differ. The most common causative agents are aspirin, penicillin, sulfa, and blood products.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-definition">A. Definition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-definition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>An adverse cutaneous reaction caused by a drug is any undesirable change in the structure or function of the skin, its appendages, or mucous membranes.</li>
</ol>
<p>B. Etiology</p>
<ol>
<li>
<p>Cutaneous drug eruptions/rashes are among the most common complications of drug therapy. They can occur in many forms and can mimic many other dermatoses.</p>
</li>
<li>
<p>Any cutaneous reaction that occurs within 2 weeks of starting a medication should be considered possibly drug induced.</p>
</li>
</ol>
<p>C. Pathologic process</p>
<ol>
<li>
<p>Immunologic mechanism: Common cutaneous drug eruptions are hypersensitivity reactions with an underlying immunologic basis. Hypersensitivity drug reactions may be grouped according to the classification outlined in Table 18-1. When drug-specific IgE antibodies bind to the corresponding mast cell or basophil surface receptor, vasoactive mediators are released causing immediate-type reaction. This is seen clinically as pruritus, erythema, urticaria, angioedema, or anaphylaxis.</p>
</li>
<li>
<p>Non-immunologic-mediated drug reactions account for the majority of all drug reactions. Some features include:</p>
</li>
</ol>
<p>a. Accumulation: blue-gray discoloration of nails and skin (argyria) can occur with the use of silver nitrate nasal sprays.</p>
<p>b. Adverse effects are normal but unwanted effects of a drug such as hair loss associated with several chemotherapeutic agents.</p>
<p>c. Direct release of mast cell mediators is dose dependent and does not involve antibodies. Aspirin, NSAIDs, radiographic contrast material, alcohol, opiates, cimetidine, hydralazine, atropine, and vancomycin are some drugs that can cause release of several mast cell mediators.</p>
<p>d. Idiosyncratic reactions may occur such as seen in certain patients with infectious mononucleosis who develop rash when given ampicillin.</p>
<p>e. Imbalance of endogenous flora may occur as seen in candidiasis occurring with antibiotic therapy.</p>
<p>f. Intolerance may occur in patients with altered metabolism. Individuals who have difficulty metabolizing the enzyme <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>N</mi></mrow><annotation encoding="application/x-tex">N</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">N</span></span></span></span></span>-acetyltransferase are at risk of developing drug-induced lupus from procainamide.</p>
<p>g. Overdose is considered an exaggerated response to an increased dose of a medication; increased doses of anticoagulants may cause purpura.</p>
<p>D. Incidence</p>
<ol>
<li>Drug eruptions occur in approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> of hospitalized patients and more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> of outpatients. Hospitalized patients are frequently on multiple medications.</li>
</ol>
<p>E. Considerations across the life span</p>
<ol>
<li>There is no correlation between development of adverse drug reaction and patient age, diagnosis, or survival. Adverse cutaneous reactions are more prevalent in women than in men and in elderly patients.</li>
</ol>
<p>II. ASSESSMENT</p>
<p>A. History and physical examination</p>
<ol>
<li>Determine the primary lesion and distribution. Morphology of the rash might give clue to causative agent.</li>
<li>When did it start? Is there pruritus? Interval of drug introduction and onset of eruption?</li>
<li>Note that some drugs cause itching, burning, and pain without rash.</li>
<li>Always suspect drug if hives are present.</li>
<li>Other constitutional symptoms: fever, chills, arthralgia, myalgia, tachycardia, palpitations, and hypotension.</li>
<li>Involvement of palms, soles, and mucous membranes.</li>
<li>Petechiae or nonpalpable purpura on lower extremities.</li>
<li>Palpable purpura that does not blanch on diascopy might suggest vasculitis.</li>
<li>Review complete medication list, including over-the-counter drugs and supplements.</li>
<li>Any history of previous adverse reactions to drugs.</li>
<li>Any concurrent infections, metabolic disorders, or is patient immunocompromised?</li>
</ol>
<p>B. Specific skin changes/clinical presentation</p>
<ol>
<li>Clinical patterns and the most frequently causal drugs are listed in Table 18-6. Some of the drug eruption presentations are discussed below; EM minor and major and SJS/TEN are discussed in separate section of this chapter.</li>
<li>Urticaria: hives can be induced by most drugs; aspirin, penicillin, and blood products are the most frequent causes. Drug-induced urticaria caused by anaphylactic and accelerated reactions (immunologic histamine release), nonimmunologic histamine release, and serum sickness.</li>
</ol>
<p>a. Anaphylactic immunoglobulin E—dependent reactions are immediate (in minutes) or accelerated (hours).
b. Serum sickness (circulating immune complex disease) has urticaria that may occur 4 to 21 days after drug ingestion and hives fade in less than 24 hours.
c. Nonimmunologic histamine reactions can occur in minutes. The drug or agent may exert a direct action on the mast cell (morphine, codeine, polymyxin B, lobster, strawberries).</p>
<ol start="3">
<li>Exanthem: maculopapular eruptions are the most frequent of all cutaneous reactions and are often indistinguishable from viral exanthem.</li>
</ol>
<p>a. Onset occurs 7 to 10 days after starting drug and may present after drug is stopped. Usually fades in 7 to 10 days, on occasion even if the drug continues.
b. Maculopapular eruption, red macules and papules, coalescing in generalized distribution often spares the face (Figure 18-7). Pruritus is common. Palms, soles, and mucous membranes may be involved.</p>
<ol start="4">
<li>
<p>Exfoliative erythroderma reactions are potentially life threatening. There is generalized redness and desquamation.</p>
</li>
<li>
<p>Fixed drug eruptions</p>
</li>
</ol>
<p>a. Single or multiple, round, sharply demarcated, dusky red papules or plaques appear soon after drug exposure and reappear in same site each time drug is taken. The area may blister then erode, brown pigmentation forms with healing, and itching or burning may precede or occur with the lesions (Figure 18-8).</p>
<p>b. Lesions can occur on any part of the skin or mucous membrane: lips, hands, genitalia (especially glans penis), and oral mucosa.</p>
<ol start="6">
<li>Drug-induced hyperpigmentation</li>
</ol>
<p>a. Drugs and chemicals may increase production of melanin causing pigment incontinence or hyperpigmentation caused by deposition (Table 18-6; Figures 18-9 and 18-10).</p>
<ol start="7">
<li>Lichenoid drug eruptions</li>
</ol>
<p>a. Clinically and histologically, this eruption resembles lichen planus with multiple, flat-topped, violaceous, pruritic papules, and oral lesions may be present (Figure 18-11). Lesions heal with brown pigmentation.</p>
<p>b. Latent period can be 3 weeks to 3 years from beginning of administration and the eruption.</p>
<ol start="8">
<li>Photosensitivity drug eruptions</li>
</ol>
<p>a. Systemic and topical medications can induce photosensitivity.</p>
<p>b. Phototoxic reactions are related to concentration of drug and can occur in anyone. Rash occurs within a few hours of drug exposure, resembles an exaggerated sunburn, confined to sun-exposed areas, can occur on first administration, and will subside when drug is stopped (amiodarone, ciprofloxacin, doxycycline, furosemide, lomefloxacin, 8-methoxypsoralen, naproxen, tetracycline, topical tar, and thiazides) (Figure 18-12).</p>
<p>c. Photoallergic reaction is less common, not related to concentration, and may spread to areas not exposed to sun (possible autosensitization); reaction can persist for years even without further drug exposure (griseofulvin, ketoprofen, piroxicam, quinidine, quinine, quinolones, sulfonamides).</p>
<p>d. Onycholysis may occur with photosensitivity to tetracyclines, psoralens, and fluoroquinolones.</p>
<ol start="9">
<li>Small-vessel vasculitis</li>
</ol>
<p>a. Any drug can evoke vasculitis in a predisposed patient.</p>
<p>b. Small-vessel vasculitis, palpable purpura, is most often seen on the lower legs; kidneys and joints may be involved.</p>
<ol start="10">
<li>Chemotherapy-induced acral erythema</li>
</ol>
<p>a. This palmoplantar reaction is characterized by symmetric, well-demarcated, painful erythema of the palms and soles. Tingling on the skin is followed in a few days by symmetric, painful, well-defined swelling and erythema and may progress to desquamation or blisters.</p>
<p>b. Treatment is supportive and may require modification of the chemotherapy dose schedule.</p>
<ol start="11">
<li>Acute generalized exanthematous pustulosis (AGEP)</li>
</ol>
<p>a. AGEP is characterized by small superficial pustules covering most of the body (Figure 18-13).</p>
<p>b. Antibacterial agents (penicillin) is the most common cause.</p>
<p>c. Occurs within 5 days of ingestion of the drug and usually resolves within 15 days.</p>
<p>d. Fever, leukocytosis, and ill-appearing patient is common; desquamation occurs.</p>
<p>C. Differential diagnosis</p>
<ol>
<li>Viral exanthem</li>
<li>Infection</li>
<li>Collagen vascular disease</li>
<li>Primary skin conditions</li>
<li>Neoplasia</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="d-diagnostic-tests">D. Diagnostic tests<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d-diagnostic-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Skin biopsy has nonspecific histology but may rule out other diseases.</li>
<li>Drug levels may be helpful for comatose patient or overdose.</li>
<li>Patch test if considering contact dermatitis.</li>
<li>Referral for allergy testing if indicated with urticarial reaction.</li>
<li>Blood tests will be determined by the differential diagnosis.</li>
</ol>
<p>TABLE 18-6 Drug Reactions and Some of the Drugs That Cause Them  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{}^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<table><thead><tr><th>Type of Reaction</th><th>Causative Agents</th></tr></thead><tbody><tr><td>Maculopapular (exanthema-tous) eruptions</td><td>Ampicillin, barbiturates, gentamicin, gold salts, isoniazid, phenothiazines, phenylbutazone, phenytoin, quinidine, sulfonamides, thiazides, thiouracil, and trimethoprim-sulfamethoxazole (in patients with AIDS)</td></tr><tr><td>Anaphylactic reactions</td><td>Aspirin, penicillin, radiographic dye, and animal-derived sera</td></tr><tr><td>Serum sickness</td><td>Aspirin, penicillin, streptomycin, sulfonamides, and thiouracils</td></tr><tr><td>Acneiform (pustular) eruptions</td><td>Bromides, hormones (androgens, corticosteroids, oral contraceptives), iodides, isoniazid, lithium, and phenytoin</td></tr><tr><td>Alopecia</td><td>Allopurinol, anticoagulants, antithyroid drugs, chemotherapy agents, colchicine, hypocholesteremic drugs, indomethacin, levodopa, oral contraceptives, propranolol, retinoids, thallium, and vitamin A</td></tr><tr><td>Erythema nodosum</td><td>Iodides, oral contraceptives, sulfonamides</td></tr><tr><td>Exfoliative erythroderma</td><td>Allopurinol, arsenicals, barbiturates, captopril, cefoxitin, chloroquine, cimetidine, gold salts, hydantoins, isoniazid, lithium, mercurial diuretics, para-aminosalicylic acid, sulfonamides, and sulfonylureas</td></tr><tr><td>Fixed drug eruptions</td><td>Aspirin, barbiturates, methaqualone, phenazones, phenolphthalein, phenylbutazone, sulfonamides, tetracyclines, trimethoprim-sulfamethoxazole, and many others reported</td></tr><tr><td>Erythema multiforme-like eruptions</td><td>Allopurinol, barbiturates, carbamazepine, hydantoins, minoxidil, nitrofurantoin, nonsteroidal anti-inflammatory agents, penicillin, phenolphthalein, phenothiazines, rifampin, sulfonamides, sulfonylureas, and sulindac</td></tr><tr><td>Lupus-like eruptions</td><td>Antitumor necrosis factor-α agents, carbamazepine, chlorpromazine, hydralazine, isoniazid, methyldopa, minocycline, procainamide, propylthiouracil, quinidine, and sulfasalazine</td></tr><tr><td>Photosensitivity</td><td>Amiodarone, carbamazepine, chlorpropamide, doxycycline (less with tetracycline and minocycline), furosemide, griseofulvin, lomefloxacin, methotrexate, nalidixic acid, naproxen, phenothiazines, piroxicam, psoralens, quinine, sulfonamides, thiazides, and tolbutamide</td></tr><tr><td>Skin pigmentation</td><td>ACTH (brown as in Addison disease), amiodarone (slate gray), anticancer drugs, antimalarials (blue-gray or yellow), arsenic (brown, diffuse, macular), bleomycin (brown, patchy, linear), cyclophosphamide (nails), doxorubicin (nails), chlorpromazine (slate gray in sun-exposed areas), clofazimine (red), heavy metals (silver, gold, bismuth, mercury), minocycline (patchy or diffuse blue-black), oral contraceptives (chloasma, brown), psoralens, and rifampin—high dose (red man syndrome)</td></tr><tr><td>Vesicles and blisters</td><td>Barbiturates (pressure areas), bromides, captopril (pemphigus-like), cephalosporins (pemphigus-like), clonidine (cicatricial pemphigoid-like), furosemide (phototoxic), iodides, naproxen (like porphyria cutanea tarda), penicillamine (pemphigus foliaceous-like), phenothiazines, piroxicam, and sulfonamides</td></tr><tr><td>Chemotherapy-induced acral erythema</td><td>Bleomycin, cyclophosphamide, cytosine, doxorubicin, fluorouracil, hydroxyurea, mercaptopurine, methotrexate, and mitotane</td></tr><tr><td>Stevens-Johnson syndrome/toxic epidermal necrolysis</td><td>Allopurinol, aminopenicillins, antiretroviral drugs, barbiturates, carbamazepine, lamotrigine, phenylbutazone, phenytoin, piroxicam, sulfadiazine, sulfasalazine, trimethoprim-sulfamethoxazole, and many others reported</td></tr><tr><td>Vasculitis</td><td>Anti-TNF agents, COX-2 inhibitors, GCSF, leukotriene inhibitors, NSAIDs, penicillins, propylthiouracil/other antithyroid agents, quinolones, serum, and streptokinase</td></tr></tbody></table>
<p>ACTH, adrenocorticotropic hormone; AIDS, acquired immunodeficiency syndrome; COX, cyclooxygenase; GCSF, granulocyte colony-stimulating factor; NSAIDs, nonsteroidal anti-inflammatory drugs; TNF, tumor necrosis factor.
aNot a complete list.</p>
<p><img src="assets/images/image-20251225-791dcaff.jpeg" alt="img-53.jpeg">
FIGURE 18-7. Exanthematous reaction to penicillin. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-a3f0a221.jpeg" alt="img-54.jpeg">
FIGURE 18-8. Fixed drug eruption. An oval lesion occurred at the identical site where it had occurred previously. In both episodes, the rash emerged after this patient ingested a sulfonamide antibiotic. Note the eroded blister in the center of the lesion. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-3d565bf1.jpeg" alt="img-55.jpeg">
FIGURE 18-9. Drug-induced hyperpigmentation of the lips secondary to minocycline. (From Dr. Barankin Dermatology Collection.)</p>
<p><img src="assets/images/image-20251225-6d7a1a15.jpeg" alt="img-56.jpeg">
FIGURE 18-10. Punctate hyperpigmentation secondary to minocycline. (From Craft, N., Taylor, E., Tumeh, P. C., Fox, L. P., Goldsmith, L. A., Papier, A., ..., Rosenblum, M. (2010). VisualDx: Essential adult dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-a427e6a7.jpeg" alt="img-57.jpeg">
FIGURE 18-11. Lichen planus drug eruption induced by quinine. (From Lugo-Somolinos, A., Lee, I., McKinley-Grant, L., Goldsmith, L. A., Papier, A., Adigun, C. G., ..., Fredeking, A. (2011). VisualDx: Essential dermatology in pigmented skin. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-77c31be6.jpeg" alt="img-58.jpeg">
FIGURE 18-12. Topical drug-induced (8-methoxypsoralen) phototoxic eruption. (From Goodheart, H. P. (2010). Goodheart's same-site differential diagnosis: A rapid method of diagnosing and treating common skin disorders. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-14c66c03.jpeg" alt="img-59.jpeg">
FIGURE 18-13. Multiple small opaque pustules are characteristic of AGEP. (From Lugo-Somolinos, A., Lee, I., McKinley-Grant, L., Goldsmith, L. A., Papier, A., Adigun, C. G., ..., Fredeking, A. (2011). VisualDx: Essential dermatology in pigmented skin. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-6758c0f5.jpeg" alt="img-60.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cutaneous-drug-reactions">Cutaneous Drug Reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cutaneous-drug-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Educate patients on allergies and/or adverse reactions to medications and the importance of communicating the information with provider.</li>
<li>Review warnings about any related cross-reacting drugs and risk of family members for patients who have had severe reactions.</li>
<li>Educate patient on signs and symptoms of adverse reactions, and stress the importance of stopping drugs under supervision of provider, which may possibly be causing</li>
</ul>
<p>cutaneous reactions (rash).</p>
<p>Promote proper hygiene and skin care to reduce chance of infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Interventions</p>
<ol>
<li>Stop offending drug.</li>
<li>Provide symptomatic relief with cool compresses.</li>
<li>Topical corticosteroid creams are helpful for rash and itching.</li>
<li>Oral prednisone may be indicated with extensive eruption for 7- to 10-day course.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="erythema-multiforme-and-stevens-johnson-syndrome-toxic-epidermal-necrolysis">Erythema Multiforme and Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#erythema-multiforme-and-stevens-johnson-syndrome-toxic-epidermal-necrolysis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>EM is a distinct disorder with different clinical signs, epidemiology, and precipitating factors than SJS and toxic epidermal necrolysis (TEN). SJS and TEN are considered variants of the same entity within a spectrum of adverse drug reactions.</p>
<p>A proposed classification system divides the spectrum of these reactive skin disorders into five categories but does not account for differences in etiology. EM minor is not included in this spectrum, with little or no mucosal involvement and no systemic involvement:</p>
<p>A. EM major: detachment of less than 10% of body surface area (BSA) plus localized target lesions
B. SJS: detachment of less than 10% of BSA plus widespread erythematous or purpuric macules or flat atypical lesions
C. Overlapping SJS/TEN: detachment between 10% and 30% of BSA plus widespread erythematous or purpuric macules or atypical target-like annular patches
D. TEN with spots: detachment of greater than 30% BSA plus widespread erythematous or purpuric macules or atypical target lesions
E. TEN without spots: detachment in large epidermal sheets greater than 10% BSA without purpuric macules or target lesions</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="erythema-multiforme">Erythema Multiforme<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#erythema-multiforme" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition</p>
<p>EM is an acute, self-limiting skin disease with an abrupt onset of papular "target" lesions. Papular lesions may be typical with three separate zones or atypical with only two different zones and poorly defined border. EM minor has mostly typical papular target</p>
<p>lesions with little or no mucosal involvement and no systemic symptoms. EM major will have typical and may have atypical papular target lesions with severe mucosal involvement and systemic symptoms. Generally, EM is self-limited but may be recurrent. The most common precipitating factor is herpes simplex virus (HSV) infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="b-etiology">B. Etiology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-etiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The most common precipitating factor is HSV infection; there may be other preceding infectious agents or rarely drug exposure. Mycoplasma pneumoniae infection is an important cause of EM, especially in children. Drugs that have been implicated in EM include NSAIDs, sulfonamides, antiepileptics, and antibiotics; drug etiology is less than 10% of cases; and infection represents approximately 90% of cases with HSV being the most common.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="c-pathology">C. Pathology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c-pathology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>EM is thought to be a mucocutaneous manifestation of a distinct skin-directed cytotoxic immune response to drug antigen, infection most commonly HSV, and in certain predisposed individuals. Immune complex formation and subsequent deposition in the cutaneous microvasculature play a role in the pathogenesis of EM.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="d-incidence">D. Incidence<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d-incidence" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The annual incidence of EM is unknown. It is predominantly seen in young adults and very common during childhood. There is a slight male preponderance.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-history-and-physical-examination">A. History and physical examination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-history-and-physical-examination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Clinical history to include acute onset, self-limiting or episodic course, signs and symptoms of associated infections such as HSV (Figure 18-14) or pneumonia, and history of new medications.</li>
<li>Clue to diagnosis includes targetoid lesions, raised atypical papules, or mucosal involvement.</li>
<li>Symptoms may include itching and burning skin, swelling of hands and feet, and pain with mucosal erosions.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="b-clinical-findings">B. Clinical findings<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-clinical-findings" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>EM with mucosal involvement may have prodromal symptoms of fever, malaise, or myalgias.</li>
<li>Target lesions and papules are dusky red maculopapules that appear in symmetric pattern on palms and soles, dorsum of hands and feet, and extensor arms and legs that spread in centripetal manner. Trunk, face, or neck may be involved in more severe cases.</li>
<li>Classic target or “iris” lesion results from centrifugal spread of red macule or papule that becomes cyanotic, purpuric, or vesicular in the center with outer zone of erythema; there may be a middle zone of pale edema. Target lesions evolve over 24 to 48 hours, appear in crops, and resolve in 1 to 2 weeks (Figures 18-15 and 18-16).</li>
<li>Atypical EM may be partially formed targets, round, edematous papules with only two zones, poorly defined border, annular, or polycyclic.</li>
<li>Bullae and erosions may form in the oral cavity; most common sites are lips and buccal</li>
</ol>
<p>mucosa. Genital and ocular involvement is less frequent.</p>
<ol start="6">
<li>Subsets of patients may experience recurrent EM over many years or persistent EM that is prolonged and uninterrupted occurrence of lesions.</li>
</ol>
<p>C. Differential diagnosis</p>
<ol>
<li>Urticaria</li>
<li>Stevens-Johnson syndrome</li>
<li>Fixed drug eruption</li>
<li>Pemphigoid or pemphigus</li>
<li>Sweet syndrome</li>
<li>Polymorphous light eruption</li>
<li>Urticarial vasculitis</li>
</ol>
<p>D. Diagnostic tests</p>
<ol>
<li>Laboratory findings are not specific with EM. Increased ESR, white blood cell count, and liver enzymes may be seen in severe cases.</li>
<li>Skin biopsy for hematoxylin and eosin stain with direct immunofluorescence to rule out autoimmune blistering disease when diagnosis in question.</li>
</ol>
<p><img src="assets/images/image-20251225-81d5a54a.jpeg" alt="img-61.jpeg">
FIGURE 18-14. Erythema multiforme. This patient has a recurrent herpes simplex virus infection. Note the drying crust of the herpetic "cold sore" on his lower lip and the target-like lesions on his palm. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-e741365a.jpeg" alt="img-62.jpeg">
FIGURE 18-15. (A) Bulla and (B) target (or iris) lesion (in erythema multiforme). (From Bickley, L. S., &amp; Szilagyi, P. (2003). Bates' guide to physical examination and history taking (8th ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-2d465522.jpeg" alt="img-63.jpeg">
FIGURE 18-16. Erythema multiforme (type II hypersensitivity). (Reproduced with permission from Roche Laboratories. Sauer, G. C., &amp; Hall, J. C. (1996). Manual of skin diseases (7th ed.). Philadelphia, PA: Lippincott-Raven.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-therapy">A. Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Most patients with EM do not require treatment.</li>
<li>Widespread EM may be treated with systemic corticosteroids, and prednisone should be given 40 to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">y</mi></mrow></mrow><annotation encoding="application/x-tex">80\mathrm{mg/day}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg/day</span></span></span></span></span></span>  until lesions resolve and dose tapered; this approach is controversial.</li>
<li>Recurrent HSV-associated EM can be prevented with suppressive therapy: oral acyclovir  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">200\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  two or three times a day or  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">400\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  twice daily; valacyclovir  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">500\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  daily, and famciclovir  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>125</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">125\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">125</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  twice daily.</li>
<li>Eroded skin or blisters can be treated with topical antibiotics or antibiotics for symptomatic improvement.</li>
<li>Oral lesions can be symptomatically treated with the following:</li>
</ol>
<p>a. Mixture of kaolin, viscous lidocaine, and diphenhydramine elixir may help discomfort of oral lesions.
b. Half-strength aqueous hydrogen peroxide (1.5%) mouthwash three to five times a day for cleansing.</p>
<p>c. Dyclone solution, viscous lidocaine, or a mixture of kaopectate in elixir of diphenhydramine can be applied directly to oral lesions for discomfort.
d. Chloraseptic mouthwash may be helpful for relief of discomfort and cleansing.</p>
<p><img src="assets/images/image-20251225-599ef4d7.jpeg" alt="img-64.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="erythema-multiforme">Erythema Multiforme<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#erythema-multiforme" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Educate the patient about erythema multiforme and specific symptoms and treatment to promote adherence to the treatment plan.</li>
<li>Stress the importance of avoiding any identified triggers or agents to decrease the risk of recurrence.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="stevens-johnson-syndrome">Stevens-Johnson Syndrome<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#stevens-johnson-syndrome" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-definition">A. Definition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-definition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>SJS and TEN have been considered the most severe forms of EM in the past. It has been proposed that EM major is distinct from SJS and TEN on the basis of clinical criteria. EM is characterized by typical target lesions, most often postinfectious disorder and most commonly HSV, and is often recurrent but with low morbidity. The SJS/TEN spectrum is characterized by widespread blisters and purpuric macules; usually a severe drug-induced reaction with high morbidity, SJS involves a relatively smaller percentage of BSA when compared to TEN; TEN has highest morbidity and a worse prognosis. The categorization of EM, SJS, and TEN remains a topic of controversy, and there are differing opinions of the classification of EM major and SJS as well as SJS and TEN. Currently, EM is considered to be a separate condition distinct from SJS and TEN. SJS and TEN have been unified within a spectrum of the same entity based on similar clinical and histologic features with variable severity in epidermal detachment.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-sjs-is-a-vesiculobullous-disease-of-the-skin-mouth-eyes-and-genitals">A. SJS is a vesiculobullous disease of the skin, mouth, eyes, and genitals.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-sjs-is-a-vesiculobullous-disease-of-the-skin-mouth-eyes-and-genitals" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Cutaneous findings are preceded by upper respiratory symptoms.</li>
<li>SJS requires involvement of two or more mucosal surfaces with less than 10% BSA of cutaneous erythematous or purpuric macules or flat atypical lesions (Figure 18-17).</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="b-ten-presents-with-symptoms-similar-to-sjs-mucous-membrane-disease-and-progresses-to-diffuse-generalized-detachment-of-the-epidermis-through-the-dermoepidermal-junction">B. TEN presents with symptoms similar to SJS mucous membrane disease and progresses to diffuse, generalized detachment of the epidermis through the dermoepidermal junction.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-ten-presents-with-symptoms-similar-to-sjs-mucous-membrane-disease-and-progresses-to-diffuse-generalized-detachment-of-the-epidermis-through-the-dermoepidermal-junction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>TEN requires greater than 30% BSA involvement with epidermal detachment.</li>
<li>TEN may or may not have purpuric macules or target lesions.</li>
<li>TEN is a systemic disease involving ophthalmic, pulmonary, genitourinary, and GI</li>
</ol>
<p>systems, in addition to the skin, and results in high death rate.</p>
<p>C. Overlapping SJS/TEN has between 10% and 30% of BSA with widespread erythematous or purpuric macules or atypical target-like annular patches.</p>
<p>B. Etiology</p>
<ol>
<li>Drugs are implicated in approximately 50% of cases of SJS and over 95% of cases of TEN.</li>
<li>Patients at greater risk include those who are immunocompromised with a thousandfold increase in those with human immunodeficiency virus (HIV).</li>
<li>The most frequently implicated drugs include allopurinol, antibiotics (chloramphenicol, macrolides, penicillin, quinolones, sulfonamides, sulfasalazine, cephalosporins), anticonvulsants (carbamazepine, lamotrigine, phenobarbital, phenytoin, valproate), and NSAIDs.</li>
<li>TEN reaction is independent of drug dosage; seen frequently with conditions requiring simultaneous drug treatment for infections and pain.</li>
<li>TEN may be linked to an inherited defect in the detoxification of drug metabolites.</li>
</ol>
<p>C. Pathologic Process</p>
<ol>
<li>Skin biopsy in SJS shows full-thickness epidermal necrosis with little dermal change; biopsy can distinguish TEN from staphylococcal scalded skin syndrome (SSSS); direct immunofluorescence will rule out autoimmune blistering disease.</li>
<li>The marked skin sloughing in TEN may be due to increased keratinocyte programmed cell death (apoptosis), subepidermal blister formation, and keratinocyte necrosis; cytotoxic T cells may contribute to the pathogenesis of blister formation by causing degeneration of drug-altered keratinocytes.</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>SJS and TEN have annual incidence of 1.2 to 6 and 0.4 to 1.2 million persons, respectively; death rate for SJS is 1% to 5% and 34% to 40% for TEN.</li>
<li>SJS can occur in all ages but is more common in children and young adults; TEN occurs in all age groups and is more frequent in women and the elderly.</li>
</ol>
<p>E. Considerations across the life span</p>
<ol>
<li>Treatment considerations for children are the same as for adults.</li>
</ol>
<p><img src="assets/images/image-20251225-9e5ef904.jpeg" alt="img-65.jpeg">
FIGURE 18-17. Patient diagnosed with SJS has bullous lesions on lips and buccal mucosa and targetoid lesions on the hand. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-assessment">I. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. History and physical examination</p>
<ol>
<li>Initial symptoms for SJS include fever, stinging eyes, and pain with swallowing that precedes skin manifestations by 1 to 3 days. Prodromal symptoms for TEN include fever and upper respiratory infection symptoms including headache and sore throat. Clinical history of symptom timeline and medication history is important.</li>
<li>Patients with HIV and certain autoimmune conditions such as systemic lupus erythematosus may be at greater risk for TEN.</li>
<li>SJS/TEN are conditions preceded by fever, malaise, cough, and abdominal pain. Uncomplicated SJS resolves in 1 month, and recurrence is uncommon unless there is re</li>
</ol>
<p>exposure to causative drug.</p>
<ol start="4">
<li>Poor outcome predictors for TEN include old age, widespread bullae, neutropenia, and impaired renal function.</li>
</ol>
<p>B. Clinical findings</p>
<ol>
<li>
<p>Skin lesions in SJS can develop abruptly, are flat patches and macules, atypical target morphology, purpuric macules with dusky center, on the trunk and extremities. The palms and soles may be early sites. SJS lesions are more centrally distributed on the face and trunk.</p>
</li>
<li>
<p>SJS will begin with upper respiratory symptoms, fever, chills, cough, rhinitis, and sore throat. Within 2 weeks, the mucosal erosions and rash develop.</p>
</li>
<li>
<p>Initially, patients with TEN will have diffuse, warm erythema with dusky gray macules and epidermal necrosis. This spreads over wide areas starting on the trunk and progressing to the neck, face, mucosa, and extremities. The skin becomes painful, and with mild pressure of the thumb, the skin wrinkles and slides laterally, and the skin splits at the dermal-epidermal junction. This is Nikolsky sign and is considered to be a life-threatening sign (Figure 18-18). Mucous membranes develop very painful erosions.</p>
</li>
<li>
<p>In TEN, bullae and erosions may appear on the conjunctiva and mucous membranes of the nose, mouth, anus, vulvovaginal region, and urethral meatus; lesions spread symmetrically from the face and trunk to the extremities. SJS will also have oral, genital, and perianal mucosa bullae and erosions. Figure 18-19 shows diffuse trunk involvement.</p>
</li>
<li>
<p>Corneal ulcerations occur with SJS; severe eye involvement in TEN is a frequent feature.</p>
</li>
<li>
<p>Life-threatening pulmonary involvement may occur secondary to involvement of bronchial epithelium in TEN. Septicemia and gram-negative pneumonia are the most common causes of death.</p>
</li>
<li>
<p>SJS/TEN can affect pulmonary, GI, central nervous, and renal systems.</p>
</li>
</ol>
<p>C. Differential diagnosis</p>
<ol>
<li>
<p>For SJS: anticonvulsant hypersensitivity syndrome, paraneoplastic pemphigus, pemphigus vulgaris, and SSSS</p>
</li>
<li>
<p>For TEN: SSSS, graft versus host disease (GVHD), staphylococcal toxic shock syndrome, drug-induced linear immunoglobulin A dermatosis (linear IgA), AGEP, drug reaction with eosinophilia and systemic symptoms (DRESS), and generalized morbilliform drug eruption</p>
</li>
</ol>
<p>D. Diagnostic tests</p>
<ol>
<li>
<p>Laboratory testing is not necessary; viral culture can confirm or rule out herpes. There may be elevated ESR, leukocytosis, eosinophilia, and elevated AST and ALT.</p>
</li>
<li>
<p>Skin biopsy can be helpful when diagnosis is uncertain.</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-429982a3.jpeg" alt="img-66.jpeg">
FIGURE 18-18. Bullae on patient with TEN; arrow indicates Nikolsky sign. (From Mulholland, M. W., Lillemoe, K. D., Doherty, G. M., Maier, R. V., Simeone, D. M., &amp; Upchurch, G. R. (2006). Greenfield's surgery: Scientific principles and practice (4th ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-6802d4bc.jpeg" alt="img-67.jpeg">
FIGURE 18-19. Toxic epidermal necrolysis has resulted from treatment with nevirapine. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-common-therapeutic-modalities">II. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="1-systemic-therapy">1. Systemic therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-systemic-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>a. Identify and treat source of infection, withdraw suspected drug, and maintain fluid, electrolyte, and nutritional balance. Minimize time between onset of cutaneous symptoms and arrival at appropriate specialty unit for care is crucial for improving potential for survival.
b. The role of systemic corticosteroids is controversial for SJS/TEN, and there is no consensus.
c. Intravenous immunoglobulin G (IVIG) used to improve survival if administered early in the course of TEN has been proposed; however, evidence for decreasing mortality has been inconclusive.
d. Other immunosuppressives such as cyclosporine or cyclophosphamide may be considered for TEN.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="2-topical-therapy-supportive-skin-care">2. Topical therapy/supportive skin care<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-topical-therapy-supportive-skin-care" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>a. Extensive epidermal damage requires timely supportive care focused on maintenance and reconstruction of the barrier function of the skin, fluid balance, prevention of</p>
<p>ocular damage, monitoring, and treatment of infection. This will be best in a burn unit or comparable intensive care setting.</p>
<p>b. Products used for coverage of denuded skin include paraffin gauze, porcine xenografts, and human allografts.
c. Newer products include Biobrane, a skin substitute made of synthetic bilaminar membrane, and Aquacel Ag, a moisture-retentive hydrofiber dressing that releases silver within the dressing.
d. Ocular damage can be prevented or minimized by continual lubrication of the eye and topical antibiotic use. Corticosteroid eyedrops can minimize inflammation.
e. Oral care is outlined under EM.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-home-care-and-follow-up">III. Home Care and Follow-Up<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-home-care-and-follow-up" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. If there has been oral mucosal involvement, assess nutritional status related to difficulty swallowing, review signs of dehydration, and educate patients and families about nutrition and fluid/electrolyte balance.
B. An ophthalmologist should be consulted if there is any eye involvement.
C. Immediate hospitalization and fluid resuscitation will be required for TEN.
D. Long-term sequelae of SJS and mostly TEN include effects from scarring such as contracture of joints; corneal scarring can lead to blindness.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pyoderma-gangrenosum">Pyoderma Gangrenosum<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pyoderma-gangrenosum" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The primary role of inflammation is to deliver neutrophils and other leukocytes to a site of injury and activate the cells to perform their protective function against infection; neutrophils are the first to arrive at sites of inflammation. PG is one of several neutrophilic dermatoses that often occurs in patients with underlying inflammatory or malignant disease, including Crohn disease, ulcerative colitis, rheumatoid arthritis, myelodysplasia, or multiple myeloma. Neutrophilic dermatoses are considered possible manifestations of a potentially multisystemic neutrophilic disease. Sweet syndrome and erythema elevatum diutinum are also within the spectrum, and PG will be discussed here.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-definition">A. Definition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-definition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>PG is uncommon, chronic and recurrent, noninfectious, inflammatory, neutrophilic skin disease characterized by ulcerative lesions that enlarge rapidly, usually on the legs, and are painful; lesions may begin spontaneously or secondary to trauma.</li>
<li>PG is not infectious or gangrenous.</li>
<li>Enlargement of the lesion (pathergy) with trauma is characteristic of PG.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="b-etiology">B. Etiology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-etiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>
<p>Commonly associated with inflammatory bowel disease, ulcerative colitis, Crohn disease, and rheumatoid arthritis.</p>
</li>
<li>
<p>There is less common association with chronic active hepatitis, a monoclonal gammopathy, myelodysplasia, myeloid leukemia, multiple myeloma, and solid organ tumors.</p>
</li>
<li>
<p>Approximately 50% of PG cases occur in association with ulcerative colitis; in 40% to 50% of patients, no associated disease is found; there is recent favor given to the presence of an underlying immunologic abnormality in patients with PG.</p>
</li>
</ol>
<p>C. Pathologic process</p>
<ol>
<li>
<p>Generally, the pathology is nonspecific especially if the lesions are partially treated or minimally inflamed.</p>
</li>
<li>
<p>Early lesions have a neutrophilic vascular reaction; active, untreated expanding lesions have neutrophilic infiltrate and often features of LCV.</p>
</li>
<li>
<p>Fully developed ulcers have marked tissue necrosis.</p>
</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>
<p>PG is a global disease and affects individuals between 20 and 50 years of age, most commonly women.</p>
</li>
<li>
<p>Approximately 4% of cases occur in children and infants.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History and physical examination</p>
<ol>
<li>
<p>Thorough history and physical examination, any symptoms of an associated disease (inflammatory bowel or arthritis), and review of medications</p>
</li>
<li>
<p>Description and measurement of lesions noted: painful ulcer, rapid progression of ulceration, type of lesion preceding ulcer (papule, pustule, vesicle), and pathergy</p>
</li>
<li>
<p>Character of lesions: tenderness, necrosis, irregular violaceous border, undermined, and rolled edges</p>
</li>
</ol>
<p>B. Skin findings</p>
<ol>
<li>
<p>Initial lesions are tender papulopustule with surrounding erythematous or violaceous induration, an erythematous nodule, and/or a bulla on erythematous base (Figure 18-20).</p>
</li>
<li>
<p>Generally painful, occur most often on lower legs especially pretibial region, but can occur anywhere including mucous membranes and peristomal.</p>
</li>
<li>
<p>Lesions then ulcerate with necrosis that is shallow or deep with purulent base; loss of tissue may expose tendons and muscles. Edges are rolled, elevated and inflamed, gunmetal-colored border that extends centrifugally (Figures 18-21 and 18-22).</p>
</li>
<li>
<p>Number of lesions varies from one to many, size 3 to 10 cm, and they may coalesce.</p>
</li>
</ol>
<p>C. Differential diagnosis</p>
<ol>
<li>
<p>Sweet syndrome</p>
</li>
<li>
<p>Systemic vasculitis</p>
</li>
<li>
<p>Behçet disease</p>
</li>
<li>
<p>Cellulitis</p>
</li>
<li>
<p>Insect bite reaction</p>
</li>
<li>
<p>Infections</p>
</li>
<li>
<p>Cutaneous T- and B-cell lymphomas</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="d-diagnostic-tests">D. Diagnostic tests<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d-diagnostic-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Histology analysis of PG is not always diagnostic; however, sterile biopsy of active skin lesion with depth to include subcutaneous fat evaluation is recommended.</li>
<li>Tissue may be needed for cultures (bacterial, mycobacterial, fungal, and viral).</li>
<li>Diagnosis relies on clinical, historical, and pathologic correlation and exclusion of other conditions that produce ulcerations.</li>
<li>Studies to evaluate for underlying causative conditions: GI tract studies, hematologic evaluation, chest x-ray, and urinalysis.</li>
</ol>
<p><img src="assets/images/image-20251225-20730035.jpeg" alt="img-68.jpeg">
FIGURE 18-20. Pyoderma gangrenosum, early pustules, and ulcerations on the shin. (From Goroll, A. H., &amp; Mulley, A. G. (2009). Primary care medicine. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-ef9001b9.jpeg" alt="img-69.jpeg">
FIGURE 18-21. Early pyoderma gangrenosum: shallow ulcerations on an erythematous, indurated base with a tendency to coalesce. The border extends centrifugally and is irregular; it becomes undermined and overhanging in fully developed lesions. (From Berg, D., &amp; Worzala, K. (2006). Atlas of adult physical diagnosis. Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-8748a9a1.jpeg" alt="img-70.jpeg">
FIGURE 18-22. Large ulceration of pyoderma gangrenosum healing with crater-like scar. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-systemic-therapy">A. Systemic therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-systemic-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Initial and primary goal of treatment is to reduce the inflammatory process of the wound in order to promote healing and control pain. Control of the underlying disease is done simultaneously.</li>
<li>No specific therapy is uniformly effective for patients with PG.</li>
<li>Systemic oral or intravenous steroids are given at high doses to quickly suppress the immune response in rapidly advancing disease. Often, combined local and systemic corticosteroid therapy is utilized.</li>
<li>Adjunctive systemic therapy is needed for extensive disease using other immunosuppressants, which may also reduce recurrences, that is, cyclosporine, mycophenolate mofetil, and azathioprine. Infliximab may be indicated in patient with concomitant Crohn disease.</li>
<li>The nature and intensity of treatment approach depend on the extent of lesions and if they are expanding, underlying disorder, medical status of the patient, and risk of treatment;</li>
</ol>
<p>hospitalization may be required for severe cases.</p>
<ol start="6">
<li>Oral antibiotics including sulfonamides, minocycline, and dapsone have been used with some success in limited disease.</li>
<li>Other therapies include hyperbaric oxygen.</li>
</ol>
<p>B. Topical therapy</p>
<ol>
<li>Superpotent topical corticosteroids may be used for limited disease.</li>
<li>Intralesional corticosteroids can be used for small lesions being careful not to injure the skin.</li>
<li>Topical tacrolimus ointment 0.1% or pimecrolimus cream 1% may be effective for mild or early skin lesions.</li>
<li>Care must be taken not to traumatize or injure the skin, and local wet dressings with Burrow solution may be used for local care.</li>
</ol>
<p>C. Surgical considerations</p>
<ol>
<li>Surgery should be avoided if possible due to pathergy phenomenon that can occur with surgical manipulation or grafting. This could result in wound enlargement or development of PG at a harvest site.</li>
</ol>
<p><img src="assets/images/image-20251225-9de130d4.jpeg" alt="img-71.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pyoderma-gangrenosum">Pyoderma Gangrenosum<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pyoderma-gangrenosum" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Instruct patients and family to understand diagnosis.</li>
<li>Discuss proper hygiene and daily inspections of skin necessary, reporting any skin barrier defects to health care provider immediately. Injury or trauma to skin can provoke new ulcers to form. Specifically:</li>
<li>Proper nail and foot care. Avoid walking barefoot and avoid any activity resulting in trauma to affected areas; stress importance of appropriate fitting shoes.</li>
<li>Rest and elevation are recommended; however, maintain range of motion and complete activities as tolerated.</li>
<li>Provide handouts and any other literature pertaining to diagnosis to have patient bring home. These are for future reference and to encourage patient to discuss with family for support.</li>
<li>Promote the importance of treatment compliance to promote wound healing, and lifelong therapy may be needed to prevent recurrence.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-home-care-and-follow-up">IV. Home Care and Follow-Up<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-home-care-and-follow-up" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Continuity of care.
B. Multiple methods of wound care are available, and care must be given to prevent pathergy.
C. Patients may need referrals to specialists for management of systemic illness including gastroenterology, rheumatology, oncology, or plastic surgery if indicated.
D. PG patients should receive follow-up care on a regular basis to maintain drug therapy and to access patient compliance. Wound care may be needed regularly along with regular measurements of lesion(s) to ensure proper wound healing is taking place.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="erythema-nodosum">Erythema Nodosum<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#erythema-nodosum" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>EN is a nodular erythematous eruption that usually presents on the extensor surfaces of the extremities. EN is a hypersensitivity reaction to a variety of antigenic stimuli, may be associated with certain diseases, and also is seen in drug therapies; more than half of cases are idiopathic.</p>
<p>A. Definition</p>
<ol>
<li>EN is a panniculitis (inflammation of subcutaneous adipose tissue).</li>
</ol>
<p>B. Etiology</p>
<ol>
<li>EN is a hypersensitivity reaction to a variety of antigenic stimuli and may occur in association with several systemic diseases, drug therapies, or infection; half of cases are idiopathic.</li>
<li>Most common cause in children is streptococcal infection and noninfectious inflammatory diseases.</li>
<li>In adults, the most common cause is streptococcal infection and sarcoidosis. EN may occur in up to 39% of cases of sarcoidosis.</li>
<li>Coccidioidomycosis is the most common cause of EN in the West and Southwest United States.</li>
<li>Inflammatory bowel disease may trigger EN.</li>
<li>Sulfonamides, bromides, and oral contraceptives may cause EN.</li>
</ol>
<p>C. Pathologic process</p>
<ol>
<li>Tissue samples need to be deep enough to adequately evaluate the subcutaneous fat. Tissue shows granulomatous inflammation and fibrosis in the septa of the subcutaneous fat, features of a septal panniculitis.</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>Peak incidence between ages of 18 and 34 years.</li>
<li>Female-to-male ratio is 5:1.</li>
<li>EN may occur in children and adults over 70 years. Age distribution will vary with geographic location and etiology.</li>
<li>Most cases of EN resolve without sequelae; however, rarely, EN can persist for months or years.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History and physical examination</p>
<ol>
<li>Most pertinent physical findings are limited to skin and joints.</li>
<li>There may be prodromal symptoms of fatigue and malaise or symptoms of upper respiratory tract infection; these may precede skin eruption by several weeks.</li>
<li>Pulmonary hilar adenopathy may develop in EN cases with diverse causes.</li>
<li>The possibility of an underlying primary tuberculous infection should not be overlooked.</li>
</ol>
<p>B. Skin findings</p>
<ol>
<li>Characteristic lesions are red, node-like swellings over the shins, usually both legs are involved as seen in Figures 18-23 and 18-24.</li>
<li>Lesions may occur on the extensor surface of forearms, thighs, and trunk.</li>
<li>Lesions may vary in size from 2 to 6 cm, usually oval in shape.</li>
<li>Initially, lesions are tense, hard, and painful.</li>
<li>Color changes from bright red to bluish or livid and gradually fades to yellowish hue.</li>
<li>The overlying skin will desquamate; individual lesions last approximately 2 weeks, but new lesions present for 3 to 6 weeks.</li>
<li>Ankle edema with leg pain is common.</li>
</ol>
<p>C. Nonskin findings</p>
<ol>
<li>Clinical picture usually of nonspecific illness possibly with low-grade fever, malaise, cough, headache, arthralgias, and arthritis.</li>
<li>Arthralgia occurring in more than 50% of EN cases may precede skin eruptions by 2 to 8 weeks. Joint symptoms may last for up to 2 years but resolve without destructive joint changes. Ankles, knees, and wrist are affected most commonly.</li>
<li>Bilateral hilar adenopathy may be associated with sarcoidosis; unilateral changes may occur with malignancy or infection.</li>
</ol>
<p>D. Differential diagnosis</p>
<ol>
<li>Urticaria</li>
<li>Insect bites</li>
<li>Cellulitis</li>
<li>Superficial and deep thrombophlebitis</li>
<li>Minor trauma</li>
<li>Vasculitis</li>
<li>Other forms of panniculitis</li>
</ol>
<p>E. Diagnostic tests</p>
<ol>
<li>Throat culture to exclude group A beta-hemolytic streptococcal infection.</li>
<li>Antistreptolysin (ASO) titer and ESR.</li>
<li>Chest x-ray.</li>
<li>Laboratory evaluation should be guided by history and physical examination.</li>
<li>Deep skin biopsy to evaluate subcutaneous fat will be helpful in patients with atypical lesions.</li>
<li>Stool cultures in patients with GI symptoms to exclude infection by Yersinia, Salmonella, and Campylobacter organisms.</li>
</ol>
<p><img src="assets/images/image-20251225-5c5091af.jpeg" alt="img-72.jpeg"></p>
<p><img src="assets/images/image-20251225-acf0884f.jpeg" alt="img-73.jpeg">
FIGURE 18-23. Erythema nodosum. These are acute red, tender nodules. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)
FIGURE 18-24. Erythema nodosum. Tender erythematous nodules on extensor aspects of lower legs. (Courtesy of George A. Datto, III, MD.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Systemic therapy</p>
<ol>
<li>NSAIDs are the mainstay of treatment for symptom relief.</li>
<li>Potassium iodide may be helpful for chronic recurrent EN or very painful involved lesions.</li>
<li>Colchicine has been used in some refractory cases with improvement.</li>
<li>Associated diseases and infections should be identified and treated, and precipitating drugs should be discontinued.</li>
</ol>
<p>B. Local therapy</p>
<ol>
<li>Rest and elevation of legs.</li>
<li>Cool wet compresses and gradient support stockings or bandages may help decrease edema and discomfort.</li>
</ol>
<p>PATIENT EDUCATION</p>
<p>Erythema Nodosum</p>
<ul>
<li>Instruct patients and family to understand diagnosis.</li>
<li>Restrict patient mobility during acute phase if pain and swelling are significant.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-home-care-and-follow-up">IV. Home Care and Follow-Up<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-home-care-and-follow-up" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Continuity of care concerns</p>
<ol>
<li>Bed rest and decreased activity are encouraged during the active phase.</li>
<li>The course of EN is self-limited, and the condition is benign.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bibliography">BIBLIOGRAPHY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bibliography" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Arndt, K. A., &amp; Hsu, J. T. S. (2007). Manual of dermatologic therapeutics (7th ed.). Philadelphia, PA: Wolters Kluwer/Lippincott Williams &amp; Wilkins.
Aurelian, L., Ono, F., &amp; Burnett, J. (2003). Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): A viral disease with an autoimmune component. Dermatology Online Journal, 9(1), 1.
Chung, L., Kea, B., &amp; Fiorentino, D. F. (2008). Cutaneous vasculitis. In J. L. Bolognia, J. L. Jorizzo, &amp; R. P. Rapini (Eds.), Dermatology (2nd ed., pp. 347-367). Spain: Mosby Elsevier.
Fiorentino, D. F. (2003). Cutaneous vasculitis. Journal of the American Academy of Dermatology, 48(3), 311-340.
French, L. E., &amp; Prius, C. (2008). Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. In J. L. Bolognia, J. L. Jorizzo, &amp; R. P. Rapini (Eds.), Dermatology (2nd ed., pp. 287-291). Spain: Mosby Elsevier.
Ghaffar, A. (2010). Immunology—Chapter 17. Hypersensitivity reactions. In: Microbiology and immunology on-line. University of South Carolina. <a href="http://pathmicro.med.sc.edu/ghaffar/hyper00.htm" target="_blank" rel="noopener noreferrer">http://pathmicro.med.sc.edu/ghaffar/hyper00.htm</a>
Grattan, C. E. H., &amp; Black, A. K. (2008). Urticaria and angioedema. In J. L. Bolognia, J. L. Jorizzo, &amp; R. P. Rapini (Eds.), Dermatology (2nd ed., pp. 261-276). Spain: Mosby Elsevier.
Grattan, C. E. H., Sabroe, R. A., &amp; Greaves, M. W. (2002). Chronic urticaria. Journal of the American Academy of Dermatology, 46(5), 645-647.
Habif, T. P. (2010). Clinical dermatology: A color guide to diagnosis and therapy (5th ed.). Philadelphia, PA: Mosby.
Habif, T. P., Campbell, J. L., Chapman, M. S., Dinulos, J. G., &amp; Sug, K. A. (2011). Skin disease: Diagnosis &amp; treatment (3rd ed.). Philadelphia, PA: Elsevier Saunders.
Jennette, J. C., Falk, R. J., Bacon, P. A., Basu, N., Cid, M. C., Ferrario, F., ..., Watts RA. (2013). 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis and Rheumatism, 65(1), 1-11.
Mellors, R. C. (2006). Hypersensitivity reactions: Tissue injury initiated by immune responses. In: Immunopathology. <a href="http://www.medpath.info/MainContent/Immunopathology/Immuno_02.html" target="_blank" rel="noopener noreferrer">http://www.medpath.info/MainContent/Immunopathology/Immuno_02.html</a>
Patterson, J. W. (2008). Panniculitis. In J. L. Bolognia, J. L. Jorizzo, &amp; R. P. Rapini (Eds.), Dermatology (2nd ed., pp. 1511-1535). Spain: Mosby Elsevier.
Pite, H., Wedi, B., Bornego, L. M., Kapp, A., &amp; Raap, U. (2013). Management of childhood urticaria: Current knowledge and practical recommendations. Acta Dermato-Vereneologica, 93. <a href="http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1573&amp;amp;html=1" target="_blank" rel="noopener noreferrer">http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1573&amp;amp;html=1</a>
Scharma, P., Sharma, S., Baltaro, R., &amp; Hurley, J. (2011). Systemic vasculitis. American Family Physicians, 83(5), 556-565.
Schwartz, R. A., McDonough, P. H. &amp; Lee, B. W. (2013). Toxic epidermal necrolysis. Part I. Introduction, history,</p>
<p>classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. Journal of the American Academy of Dermatology, 45(2), 173-186.
Schwartz, R. A., McDonough, P. H. &amp; Lee, B. W. (2013). Toxic epidermal necrolysis. Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. Journal of the American Academy of Dermatology, 45(2), 187-204.
Schwarzen, K., Werchniak, A. E. &amp; Ko, C. J. (Eds.). (2009). In D. M. Elston (Series Ed.), Requisites in dermatology: General dermatology. Philadelphia, PA: Saunders Elsevier.
Sokumbi, O., &amp; Wetter, D. A. (2012). Clinical features, diagnosis, and treatment of erythema multiforme: A review for the practicing dermatologist. International Journal of Dermatology, 51, 889-902.
Zuberbier, T. (2012). A summary of the New International EAACI/GA2LEN/EDF/WAO Guidelines in urticaria. World Allergy Organization Journal, 5, S1-S5.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>
<p>Characteristic of the primary lesion in urticaria is an edematous papule or plaque called:
a. Lesion
b. Mass
c. Wheal
d. Whelp</p>
</li>
<li>
<p>Which of the following drugs may produce photosensitivity diseases?
a. Doxycycline
b. Furosemide
c. HCTZ
d. All of the above</p>
</li>
<li>
<p>Morbilliform reactions are:
a. Exanthems
b. Shaking syndrome, much like Parkinson disease
c. Most commonly produced by ampicillin
d. A and C
e. All of the above</p>
</li>
<li>
<p>Chronic urticaria is defined as episodes lasting more than:
a. 6 weeks
b. 4 weeks
c. 2 weeks
d. 3 weeks</p>
</li>
<li>
<p>Which of the following statements regarding causes of angioedema is true?
a. Angioedema may have idiopathic causes.
b. Edema may cause angioedema.</p>
</li>
</ol>
<p>c. Angioedema may be medication induced.
d. A and C.</p>
<ol start="6">
<li>
<p>Common causes of anaphylactic reactions include:
a. Peanuts
b. Antibiotics
c. Trees
d. A and C</p>
</li>
<li>
<p>Cutaneous reactions may be caused by a chemical substance that is:
a. Ingested
b. Injected
c. Inhaled
d. All of the above</p>
</li>
<li>
<p>Which of the following drug may cause acute generalized exanthematous pustulosis (AGEP)?
a. Antiviral agents
b. Antibacterial agents (penicillin)
c. Topical steroids
d. Diuretic agents</p>
</li>
<li>
<p>Which of the following is the most common cause of erythema multiforme?
a. Herpes simplex virus
b. Rubella
c. Herpes zoster
d. Parvovirus</p>
</li>
<li>
<p>Primary treatment for urticaria includes:
a. Cetirizine
b. Loratadine
c. Fexofenadine
d. Doxepin
e. A, B, and C
f. All of the above</p>
</li>
<li>
<p>Management of adverse drug reactions includes:
a. Discontinuing the offending drug
b. Orally administered antihistamine</p>
</li>
</ol>
<p>c. Orally administered prednisone for severe reactions
d. Topical symptom management
e. A and B
f. All of the above</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="answers-to-study-questions">Answers to Study Questions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>1.c
2.d
3.d
4.a
5.d
6.d
7.d
8.b
9.a
10.f
11.f</p>
<p>CHAPTER 19</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="connective-tissue-disorders">Connective Tissue Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#connective-tissue-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Theresa Coyner • Karen Congelio • Katrina Nice Masterson</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>Identify and differentiate the most common connective tissue disorders.</li>
<li>Discuss treatment modalities for the most common connective tissue disorders.</li>
<li>List several important patient education aspects for each disorder.</li>
<li>Provide a list of patient resources on connective tissue disorders.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Early diagnosis and treatment may significantly slow the connective tissue disease process and increase patient’s quality of life.</li>
<li>A complete physical exam and physiological assessment should be completed if a collagen vascular disease is suspected due to possible misdiagnosis and to capture any central nervous system involvement.</li>
<li>Patient education and support are vital to treatment compliance.</li>
<li>Encourage patients to join support groups and organizations.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="overview">OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Connective tissue disorders (collagen vascular disease) are defined as a group of acquired disorders that have the commonality of immunologic and inflammatory changes in small blood vessels and connective tissue. Common features may include arthritis, skin lesions, iritis and episcleritis, pericarditis, pleuritis, subcutaneous nodules, myocarditis, vasculitis, and nephritis. Lupus, scleroderma, and myositis will be discussed in this chapter.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-lupus-erythematosis">I. LUPUS ERYTHEMATOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-lupus-erythematosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Definition: Lupus is a chronic autoimmune disease resulting in inflammation and tissue damage. The name "lupus," Latin for wolf, was coined in the 10th century possibly because the lesions resembled wolf bites.</p>
<p>B. Etiology</p>
<ol>
<li>The exact cause of lupus is unknown; however, current research points to interrelated immunologic, environmental, hormonal, and genetic factors.</li>
<li>Of the babies born with neonatal lupus erythematosus (NLE), 98% were reported to have anti-Ro antibodies and approximately one third with La antibodies. These IgG antibodies pass from the placenta to the fetus.</li>
<li>Recent studies are looking at chromosome 1 for a genetic link; however, only 10% of lupus patients will have a close relative with lupus. About 5% of children born to individuals with lupus will develop the disease.</li>
<li>Often called a "woman's disease," lupus strikes women 10 to 15 times more frequently than men and occurs most often during childbearing years.</li>
<li>Although the disease occurs worldwide, it is most prevalent in persons with African, American Indian, and Asian origins.</li>
</ol>
<p>C. Symptoms</p>
<ol>
<li>Arthralgia</li>
<li>Fever greater than 100°F</li>
<li>Arthritis</li>
<li>Prolonged or extreme fatigue</li>
<li>Skin rashes</li>
<li>Anemia</li>
<li>Kidney involvement</li>
<li>Pleurisy</li>
<li>Butterfly-shaped (malar) rash across the cheeks and nose</li>
<li>Less frequent occurring symptoms include photosensitivity, hair loss, mouth or nose ulcers, abnormal blood clotting problems, Raynaud phenomenon, and seizures.</li>
</ol>
<p>D. Types of lupus</p>
<ol>
<li>Cutaneous lupus erythematosus has many different types including:</li>
</ol>
<p>a. Chronic cutaneous lupus erythematosus (CCLE)</p>
<p>(1) The most common form of CCLE is discoid lupus erythematosus (DLE).</p>
<p>(a) DLE lesions are often erythematous, scaly, and thickened and may produce scarring or discoloration of the skin; usually painless and nonpruritic.</p>
<p>(b) Localized DLE: lesions limited to the head (possible alopecia), ears, and neck (Figures 19-1 and 19-2).</p>
<p>(c) Generalized DLE: lesions present anywhere on skin.</p>
<p>(d) Long-standing lesions are at risk for skin cancer.</p>
<p>(2) Hypertrophic (thickened) or verrucous (wart-like) lupus erythematosus (LE)</p>
<p>(3) Lupus profundus: DLE lesions occurring in conjunction with firm lumps in the fatty tissue (panniculitis) (Figure 19-3)</p>
<p>(4) Mucosal DLE: lesions that occur in mucous membranes of the mouth, nose, and eyes</p>
<p>(5) Chilblain lupus: lesions consisting of red to purplish papules that usually occur on the toes and fingers</p>
<p>b. Subacute cutaneous lupus erythematosus (SCLE)</p>
<p>(1) Papulosquamous: erythematous plaques</p>
<p>(a) May resemble psoriasis
(b) Most common on sun-exposed areas of the arms, shoulders, neck, and trunk; face less frequently involved</p>
<p>(2) Erythemic annular lesions with no scale (LE tumidus)
(3) Both forms are photosensitive to natural and artificial light.
(4) Lesions usually do not scar but may cause discoloration of skin.</p>
<p>c. Acute cutaneous lupus erythematosus (ACLE)</p>
<p>(1) Produces flat erythemic areas resembling sunburn, which can be transient, lasting several days to weeks (Figure 19-4).
(2) Localized ACLE involves both cheeks and nose presenting as a butterfly-shaped malar rash.
(3) Generalized ACLE presents with a maculopapular eruption representing a photosensitive dermatitis.</p>
<ol start="2">
<li>Systemic lupus erythematosus (SLE) attacks multiple systems in the body, which may include the skin (classic butterfly-shaped malar rash most common), liver, joints, lungs, blood vessels, heart, kidneys, liver, brain, and nervous system. SLE can have significant morbidity and potential mortality when associated with acute lupus erythematosus as a manifestation (Box 19-1).</li>
<li>Drug-induced lupus may develop after taking certain medications. Symptoms usually resolve weeks to months after discontinuation of the drug (Figure 19-5).</li>
<li>Neonatal lupus erythematosus</li>
</ol>
<p>a. NLE is rare.
b. Occurs in neonates with transplacentally acquired maternal anti-Ro (SS-A) and/or anti-La (SS-B) antibodies.
c. Manifestations may include:</p>
<p>(1) Congenital heart block
(2) Cutaneous lesions
(3) Liver disease
(4) Thrombocytopenia</p>
<p>E. Lupus as a disease continuum</p>
<ol>
<li>CCLE is seen as the mild end of the spectrum with only localized lesions.</li>
<li>SCLE presents with mild SLE.</li>
<li>Active SLE with internal organ involvement (possible death), with or without skin lesions, is at the far end of the disease spectrum.</li>
</ol>
<p>F. Diagnosis</p>
<ol>
<li>
<p>A complete history and physical should be performed, including a full-skin assessment.</p>
</li>
<li>
<p>Currently, there is no single definitive laboratory test for lupus.</p>
</li>
<li>
<p>Lupus symptoms can mimic other illnesses and are often vague and transient, resulting in misdiagnosing and underdiagnosing of lupus.</p>
</li>
<li>
<p>The American College of Rheumatology and the Systemic Lupus International Collaborating Clinics issued a list of criteria to assist the practitioner in diagnosing SLE and to establish consistency for epidemiologic surveys (Box 19-1).</p>
</li>
</ol>
<p>G. Pregnancy and lupus</p>
<ol>
<li>There is no reason why a woman with lupus should not become pregnant, unless she has organ involvement.</li>
<li>There is risk of disease activity during and 3 to 4 weeks after pregnancy; therefore, she should be monitored closely.</li>
<li>Many persons with lupus have antiphospholipid antibodies, which affect coagulation factors and are associated with miscarriage.</li>
</ol>
<p>H. Diagnostic testing may include:</p>
<ol>
<li>CBC with differential.</li>
<li>Platelet count.</li>
<li>Erythrocyte sedimentation rate.</li>
<li>Serum electrophoresis.</li>
<li>Antinuclear antibodies (ANA) and LE cell tests</li>
<li>Anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibody: this is the most specific test for lupus and correlates with disease activity.</li>
<li>Urine studies.</li>
<li>C3 and C4 serum studies</li>
<li>Chest x-rays.</li>
<li>Skin biopsy for H&amp;E. If not definitive, skin biopsy for direct immunofluorescence.</li>
<li>Lupus anticoagulant and anticardiolipin tests.</li>
</ol>
<p>I. Treatment</p>
<ol>
<li>Prevention is key to minimizing symptoms, reducing inflammation, and maintaining normal bodily functions.</li>
</ol>
<p>a. Avoid sun exposure/wear sunscreen to prevent rashes.
b. Exercise regularly to prevent muscle weakness and fatigue.
c. Participate in support groups and/or counseling to reduce stress.
d. Eliminate negative habits, such as smoking, drinking, etc.
e. Avoid artificial light sources, such as tanning beds.</p>
<ol start="2">
<li>
<p>Treatment is individualized and based upon presenting symptoms.</p>
</li>
<li>
<p>Treatments may include:</p>
</li>
</ol>
<p>a. Nonsteroidal anti-inflammatory drugs (NSAIDs).
b. Acetaminophen.
c. Corticosteroids (topical, systemic, or intralesional). Ultrapotent topical corticosteroids may be indicated even on the face.
d. Topical immunomodulators such as pimecrolimus and tacrolimus.
e. Antimalarials.</p>
<p>(1) Hydroxychloroquine sulfate. Usual dose 200 mg one to two times daily. Dosage generally should not exceed 6.5 mg/kg/daily.
(2) Chloroquine phosphate. Usual dose is 250 mg one to two times daily.
(3) Quinacrine hydrochloride. Usual dose is 100 mg one to two times daily.</p>
<p>(4) All antimalarials may cause eye toxicities. Patients should have eye examinations by optometrist/ophthalmologist every 6 months.</p>
<ol start="4">
<li>Extensive or persistent cutaneous disease</li>
</ol>
<p>a. Oral prednisone, oral retinoids, methotrexate, thalidomide, and azathioprine have all been utilized.</p>
<ol start="5">
<li>Systemic disease will be treated by rheumatology.</li>
</ol>
<p>a. Prednisone, azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine, interferon, leflunomide, TNF alpha inhibitors, CD4 monoclonal antibodies, and bone marrow transplant have all been utilized.</p>
<ol start="6">
<li>Specific treatment for systemic disease involving organ may include antihypertensive medications, dietary changes to reduce hypertension, anticoagulants, and dialysis and or kidney transplant for renal failure.</li>
</ol>
<p><img src="assets/images/image-20251225-1b131ce3.jpeg" alt="img-74.jpeg">
FIGURE 19-1. Chronic cutaneous lupus erythematosus (CCLE) causing scarring alopecia. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-5529a114.jpeg" alt="img-75.jpeg">
FIGURE 19-2. Discoid lupus erythematosus (DLE). (From Edward, S., &amp; Yung, A. (2011). Essential dermatopathology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-263321da.jpeg" alt="img-76.jpeg"></p>
<p><img src="assets/images/image-20251225-991d30ae.jpeg" alt="img-77.jpeg">
FIGURE 19-3. Lupus profundus (lupus panniculitis). (From Elder, D. E. (2012). Atlas and synopsis of Lever's histopathology of the skin. Philadelphia, PA: Wolters Kluwer.)
FIGURE 19-4. Acute cutaneous lupus erythematosus (ACLE) maculopapular eruption in a photosensitive pattern. (From Knight, L. (2013). Medical terminology: An illustrated guide. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-1cf609fc.jpeg" alt="img-78.jpeg">
FIGURE 19-5. Drug-induced cutaneous lupus. (From Elder, D. E. (2014). Lever's histopathology of the skin. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-e5966e60.jpeg" alt="img-79.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="lupus-erythematosus">Lupus Erythematosus<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lupus-erythematosus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Provide a comprehensive explanation of the disease process.</li>
<li>Discuss medication side effects and report these to the provider.</li>
<li>Acknowledge emotional stress and provide support.</li>
<li>Provide patient and families with resources for education and support (Box 19-2).</li>
<li>Encourage good nutrition to promote healing and well-being.</li>
<li>Reinforce the need for routine skin evaluations and follow for disease process.</li>
</ul>
<p>BOX 19-1. Criteria for the Diagnosis of Systemic Lupus Erythematosus</p>
<p>Patient must meet four of the following criteria, including at least one immunologic criterion and at least one clinical criterion; or the patient has biopsy-proven nephritis compatible with systemic lupus in the presence of either antinuclear antibody or anti-double-stranded deoxyribonucleic acid.</p>
<p>Clinical criteria</p>
<ul>
<li>Oral lesions</li>
<li>Nonscarring alopecia</li>
<li>Synovitis of the joints</li>
<li>Serositis of the lining around organs</li>
<li>Renal involvement</li>
<li>Neurological involvement</li>
<li>Hemolytic anemia</li>
<li>Leukopenia</li>
<li>Thrombocytopenia</li>
</ul>
<p>Immunologic criteria</p>
<ul>
<li>Elevated antinuclear antibodies</li>
<li>Elevated anti-double-stranded deoxyribonucleic acid</li>
<li>Anti-Smith antibodies</li>
<li>Antiphospholipid antibodies</li>
<li>Low complement</li>
<li>Direct Coombs (antiglobulin) test in the absence of hemolytic anemia</li>
</ul>
<p>Adapted from Petri, M., Orbai, A. M., Alarcon, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., ..., Magder, L. S. (2012). Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatology, 64(8), 2677–2686.</p>
<p>II. SCLERODERMA (SYSTEMIC SCLEROSIS)</p>
<p>A. Definition: Scleroderma (which literally means “hard skin”) is a chronic, often progressive autoimmune disease, which can cause thickening and tightening of the skin by excessive collagen production. Scleroderma widely varies in severity; in some cases, internal organs such as the lungs, heart, kidneys, esophagus, and GI tract are seriously damaged.</p>
<p>B. Etiology and incidence</p>
<ol>
<li>
<p>The exact cause(s) of scleroderma is/are unknown, but multiple genetic and environmental factors likely do play a part in determining the risk of developing systemic scleroderma.</p>
</li>
<li>
<p>Most patients do not have a family member with the disease.</p>
</li>
<li>
<p>Females are affected 4:1 over males.</p>
</li>
<li>
<p>Localized scleroderma is more common in children, whereas systemic scleroderma occurs more in adults.</p>
</li>
</ol>
<p>C. Classifications of scleroderma</p>
<ol>
<li>Localized scleroderma</li>
</ol>
<p>a. Affects the collagen-producing cells in limited skin areas and usually spares the internal organs and blood vessels
b. Occurs as patches of thickened skin: morphea (see special note below) or as linear scleroderma, a line of thickened skin that may extend down an arm or leg. If the line occurs on the forehead, it is called en coup de sabre ("cut of the saber") (Figure 19-6).
c. Affects children more often than adults
d. Topical treatment may consist of topical corticosteroids, topical immunomodulators, phototherapy, and pulse dye lasers.
e. Systemic treatment for persistent and extensive lesions may include methotrexate either alone or with a combination of systemic steroids and phototherapy.
f. Special note: Morphea is a mild, mostly benign, and self-limiting disease of the skin with less than a 1% chance of progressing to scleroderma. It is important to use proper terminology and not frighten patients/parents with the term scleroderma unless appropriately diagnosed by the practitioner.</p>
<ol start="2">
<li>Systemic scleroderma (also called progressive systemic sclerosis)</li>
</ol>
<p>a. The immune system causes damage to small blood vessels and the collagen-producing cells throughout the body.
b. The small blood vessels in the hands/fingers narrow or completely close, often causing slow healing and/or spontaneous ulcerations.
c. Patients are often cold sensitive.
d. 95% of patients with systemic scleroderma suffer from Raynaud phenomenon (intermittent attacks of ischemia of the extremities of the body, especially the fingers, toes, ears, and nose, characterized by severe blanching, cyanosis, redness, numbness, tingling, burning, and often pain).
e. Scar tissue (scleroses) may occur in one or more organs including the heart, lung, skin, kidneys, or GI tract.
f. Systemic scleroderma is divided into two forms:</p>
<p>(1) Limited scleroderma (often referred to as the CREST form): calcinosis (calcium deposits in the skin), Raynaud phenomenon (see above), esophageal dysfunction (acid in the esophagus—heartburn), sclerodactyly (tight, thick skin of the fingers), and telangiectasias (multiple, small, punctate macules that are particularly prominent on the face and hands).
(2) Diffuse scleroderma has significantly greater organ involvement.</p>
<ol start="3">
<li>Scleroderma-related disorders</li>
</ol>
<p>a. Scleroderma occurs in patients with other autoimmune disorders and may be referred to as an "overlap syndrome."</p>
<p>b. Some studies suggest that exposure to various drugs (e.g., bleomycin) and chemicals can cause lesions similar to those seen in scleroderma. Often, these skin changes are indistinguishable from those of systemic sclerosis, and the exposure may be unknown to the patient.</p>
<p>D. Diagnosis of scleroderma</p>
<ol>
<li>
<p>Medical history
a. A detailed history of signs/symptoms during general systems review that prompted medical services may indicate progression and severity of disease process.
b. Question patient as to possible exposure to drugs or chemicals.</p>
</li>
<li>
<p>Physical exam
a. Full-skin exam: see above for detailed cutaneous manifestations of each category of scleroderma
(1) Approximately 98% of patients will present with hardening or thickening of the skin of the fingers.
(2) Raynaud phenomenon is present in 95% of patients.
b. Systemic manifestations identified by a complete physical exam may include:
(1) Gastrointestinal
(a) Decreased motility/absorption
(b) Esophageal dysphagia, reflux, and/or strictures
(2) Pulmonary fibrosis
(a) Decreased pulmonary function, vital capacity
(b) Pulmonary hypertension
(c) Dyspnea and decreased breath sounds
(3) Renal vascular involvement: hypertension, insufficiency, or failure
(4) Cardiovascular
(a) Cardiac fibrosis with possible arrhythmias/myocardial infarction
(b) Pericarditis
(5) Musculoskeletal
(a) Arthralgias
(b) Myalgias</p>
</li>
<li>
<p>Skin biopsy
a. Confirms diagnosis of morphea</p>
</li>
<li>
<p>Laboratory and radiologic tests for systemic scleroderma
a. Complete blood count
b. Urinalysis
c. Renal function tests
d. Chest radiograph
e. Pulmonary function tests
f. Barium swallow
g. Antinuclear antibody test
(1) Nucleolar staining is associated with mixed connective tissue disease.
(2) Anticentromere staining is associated with CREST syndrome.
(3) A positive Scl-70 antibody indicates diffuse scleroderma.</p>
</li>
</ol>
<p>E. Treatment</p>
<ol>
<li>
<p>There is no cure for scleroderma; treatment plans are individualized to each patient's type and severity of symptoms.</p>
</li>
<li>
<p>Medications are prescribed according to treatment goals:</p>
</li>
</ol>
<p>a. Control high blood pressure
(1) ACE inhibitors
(2) Angiotensin II inhibitors
(3) Others: clonidine, prazosin</p>
<p>b. Relieve pericarditis
(1) NSAIDs
(2) Corticosteroids</p>
<p>c. Reduce joint and tendon pain
(1) NSAIDs
(2) Analgesics
(3) Corticosteroids</p>
<p>d. Prevent Raynaud phenomenon
(1) Calcium channel blockers
(2) Others: nitroglycerine ointment, prazosin, doxazosin, terazosin, and pentoxifylline</p>
<p>e. Treat small bowel dysfunction
(1) Broad-spectrum antibiotics</p>
<p>f. Relieve constipation
(1) Bulking agents
(2) Softening agent
(3) Others: lactulose, bisacodyl</p>
<p>g. Prevent heartburn
(1) Antacids
(2) H₂ blockers
(3) Proton pump inhibitors
(4) Others: sucralfate, cisapride</p>
<p>h. Improve swallowing difficulties
(1) H₂ blockers
(2) Proton pump inhibitor
(3) GI stimulants</p>
<p>i. Treat digital ulcerations
(1) Oral/topical antibiotics
(2) Recommendations from wound care specialist</p>
<p>j. Reduce skin itching
(1) Skin lotions/emollients
(2) Note: diphenhydramine not recommended as it may increase symptoms of dry eyes and dry mouth</p>
<p>k. Relieve dry mouth: saliva substitute</p>
<p>l. Relieve dry eyes: artificial tears/lubricants</p>
<p>m. Treat reactive depression</p>
<p>(1) SSRIs
(2) Tricyclic antidepressants
(3) Others: bupropion, venlafaxine, and trazodone</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-disease-modifiers">3. Disease modifiers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-disease-modifiers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>a. At present, there are no FDA-approved drugs to modify the course of scleroderma; however, there are several drugs currently under study.
b. Currently, methotrexate, cyclosporin, as well as chemotherapy and immunosuppressants are being used to impair the immune and inflammatory response.
c. Interferons (alpha and gamma) have been used to suppress collagen production, but there is no conclusive study to prove effectiveness.
d. D-penicillamine is used to weaken collagen; however, studies done have been unable to prove effectiveness.</p>
<p><img src="assets/images/image-20251225-dd00e7a7.jpeg" alt="img-80.jpeg"></p>
<p><img src="assets/images/image-20251225-8c9e01f0.jpeg" alt="img-81.jpeg">
B
FIGURE 19-6. A: Morphea: well-demarcated white plaque. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.) B: Linear morphea: "coup de sabre" lesion. (From Lugo-Somolinos, A., Lee, I., McKinley-Grant, L., Goldsmith, L. A., Papier, A., Adigun, C. G., ..., Fredeking, A. (2011). VisualDx: Essential dermatology in pigmented skin. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-d3a2b998.jpeg" alt="img-82.jpeg">
Patient Education</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="scleroderma">Scleroderma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#scleroderma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Provide education to both family and patient regarding medication protocols and possible side effects.</li>
<li>Provide resources for education and support (Box 19-2).</li>
<li>Continue to assess the patient for disease progression and emphasize the need for skin exams and follow-up.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-19-2-resources-for-patients-with-connective-tissue-disorders">BOX 19-2. Resources for Patients with Connective Tissue Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-19-2-resources-for-patients-with-connective-tissue-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>American Autoimmune and Related Diseases
22100 Gratiot Avenue
Eastpointe, MI 48021
Phone: 586-776-3900
Toll Free: 800-598-4618
Email: <a href="mailto:aarda@aarda.org" target="_blank" rel="noopener noreferrer">aarda@aarda.org</a>
<a href="http://www.aarda.org" target="_blank" rel="noopener noreferrer">www.aarda.org</a></p>
<p>American Skin Association, Inc.
6 East 43th Street, 28th Floor
New York, NY 10117
(800)499-SKIN fax (212)889-4959
Email: <a href="mailto:info@americanskin.org" target="_blank" rel="noopener noreferrer">info@americanskin.org</a>
<a href="http://www.americanskin.org" target="_blank" rel="noopener noreferrer">www.americanskin.org</a></p>
<p>Inflammatory Skin Disease Institute
Inflammatory Skin Disorders
PO Box 1074, Newport News, VA 23601
(800)484-6800 ext.6321 fax (757)595-1842</p>
<p>Lupus Foundation of America, Inc.
9302 N. Meridian Street, Suite 203, Indianapolis
IN 46260
(317)-225-4000
<a href="http://www.lupus.org" target="_blank" rel="noopener noreferrer">www.lupus.org</a></p>
<p>National Institute of Arthritis, Musculoskeletal and Skin Diseases
Information Clearinghouse
National Institutes of Health
1 AMS Circle, Bethesda, MD 20892-3675
Phone: 301-495-4484
Toll free: 877-226-4267
Fax: 301-718-6366
Email: <a href="mailto:NIAMSinfo@mail.nih.gov" target="_blank" rel="noopener noreferrer">NIAMSinfo@mail.nih.gov</a>
<a href="http://www.niams.nih.gov" target="_blank" rel="noopener noreferrer">www.niams.nih.gov</a></p>
<p>National Organization for Rare Disorders
National Organization for Rare Disorders National Headquarters
55 Kenosia Avenue
Danbury, CT 06810
Phone: 203-744-0100
<a href="http://rarediseases.org" target="_blank" rel="noopener noreferrer">http://rarediseases.org</a></p>
<p>Scleroderma Foundation
300 Rosewood Drive, Suite 105, Danvers, MA 01923
(800)-722-HOPE (4673)
Email: <a href="mailto:sfinfo@scleroderma.org" target="_blank" rel="noopener noreferrer">sfinfo@scleroderma.org</a>
<a href="http://www.scleroderma.org" target="_blank" rel="noopener noreferrer">www.scleroderma.org</a></p>
<p>Scleroderma Research Foundation
220 Montgomery Street, Suite 1411, San Francisco, CA 94104
(800)-441-CURE (2873)
<a href="http://www.srfcure.org" target="_blank" rel="noopener noreferrer">www.srfcure.org</a></p>
<p>Myositis Association of America
1737 King Street, Suite 600
Alexandria, VA 22314
<a href="http://www.myositis.org" target="_blank" rel="noopener noreferrer">www.myositis.org</a></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-inflammatory-myopathies">III. INFLAMMATORY MYOPATHIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-inflammatory-myopathies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: Inflammatory myopathies are a group of muscle diseases characterized by inflammation of connective tissue and muscle fibers that can cause extensive necrosis and destruction of the muscle fibers. They are believed to be autoimmune disorders. The inflammatory myopathies are dermatomyositis (DM), juvenile dermatomyositis (JDMS), polymyositis (PM), and inclusion body myositis (IBM).</p>
<p>B. Etiology and incidence</p>
<ol>
<li>Inflammatory myopathies have been designated as autoimmune diseases because of the presence of autoantibodies in the serum of those affected.</li>
<li>Prevalence rates are approximately 6 per 1,000,000 persons.</li>
<li>Occurs in all ethnic groups</li>
<li>PM and DM affect females 2:1 over males.</li>
<li>PM rarely affects people under the age of 20.</li>
<li>IBM symptoms usually begin after age 50 and occur in males more frequently than females.</li>
</ol>
<p>C. Classifications and descriptions of inflammatory myopathies</p>
<ol>
<li>Dermatomyositis</li>
</ol>
<p>a. Easily recognized by distinctive rash: a patchy, dusky, reddish, or lilac rash on the eyelids with periorbital edema (heliotrope), cheeks, and bridge of nose. Gottron papules, small (&lt;1 cm), flat, smooth, reddish/purplish papules found over joints such as knuckles, fingers, elbows, knees, and medial malleoli. Presence of Gottron papules is of diagnostic significance between DM and LE. Erythema of the hands in LE spares the joints (Figure 19-7).</p>
<p>b. May also include several of the following signs/symptoms:</p>
<p>(1) Proximal muscle weakness/pain usually follows rash and typically develops over a period of weeks.
(2) Nail fold changes demonstrating ragged edges with telangiectasias
(3) Poikiloderma of the scalp with pruritus
(4) Elevated serum CK-MM and oral aldolase levels
(5) Polyarthralgia/polyarthritis
(6) Positive histidyl tRNA synthetase antibody
(7) Raynaud phenomenon
(8) Signs of systemic inflammation (fever: &gt;37°C axillary, elevated CRP)
(9) Myogenic EMG changes
(10) Muscle biopsy reveals necrosis, inflammation, and degradation.
(11) Skin biopsy reveals interface dermatitis with mucin.
(12) Calcinosis cutis may occur in juvenile individuals.
(13) Possible malignancy: malignant neoplasms in older individuals.</p>
<ol start="2">
<li>Polymyositis (PM)</li>
</ol>
<p>a. Similar presentation as DM, but without characteristic rash
b. Symmetrical muscle weakness, joint pain, difficulty in swallowing, fever, fatigue, and weight loss. Muscle weakness can begin slowly or suddenly and may worsen for weeks or months.
c. Difficulty swallowing is common.</p>
<ol start="3">
<li>
<p>Inclusion body myositis (IBM)
a. Very similar in presentation to PM
b. Only definitive test is muscle biopsy.
c. Duration of illness greater than 6 months
d. Age of onset greater than 30 years old
e. Affects proximal and distal muscles of arms and legs
f. Patient will exhibit one or more of the following:
(1) Finger flex or weakness
(2) Wrist flex or greater than wrist extension or weakness
(3) Quadriceps muscle weakness
g. Serum CK-MM less than 12 times normal</p>
</li>
<li>
<p>Juvenile dermatomyositis
a. Juvenile idiopathic inflammatory myopathy (JIIM) or JDMS usually presents as dermatomyositis (JDMS) with the distinctive heliotrope rash (see DM above).
b. Proximal muscle weakness usually follows rash.
c. Dysphagia and dysphonia (hoarseness) are common.
d. Muscle pain occurs in approximately 50% of children.
e. Abdominal pain and arthralgia can occur.
f. Calcinosis cutis</p>
</li>
<li>
<p>DM sine myositis (amyopathic dermatomyositis)
a. Variant of DM
b. No muscle involvement
c. Classic heliotrope rash is present.
d. Increased incidence of malignancy is possible.</p>
</li>
</ol>
<p>D. Treatment</p>
<ol>
<li>There is no known cure for inflammatory myopathies.</li>
<li>High doses of immunosuppressants and/or steroids have been effective for many patients. Prednisone is most commonly used at 1 mg/kg/d with a slow taper over many months.</li>
<li>Intravenous immunoglobulins (IVIg) have proven effective for those patients not responding to immunosuppressants.</li>
<li>Numerous new drugs are currently being studied.</li>
<li>Physical therapy is strongly recommended to maintain mobility.</li>
<li>Referral to nutritional therapist is recommended for dysphagia and nutritional assessment.</li>
<li>Topical steroids for lesions</li>
<li>Analgesics PRN for pain</li>
<li>Protection from ultraviolet light</li>
<li>Referral to internal medicine for age appropriate malignancy screenings and treatment if malignancies are identified.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="11-evaluate-and-treat-for-possible-depression">11. Evaluate and treat for possible depression<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#11-evaluate-and-treat-for-possible-depression" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><img src="assets/images/image-20251225-617de2bc.jpeg" alt="img-83.jpeg"></p>
<p><img src="assets/images/image-20251225-a158ce2a.jpeg" alt="img-84.jpeg">
B
FIGURE 19-7. A: Heliotrope rash in dermatomyositis. B: Gottron papules erupting over the joints of extensor surfaces on the hands and fingers. (From Berg, D., &amp; Worzala, K. (2006). Atlas of adult physical diagnosis. Philadelphia, PA: Lippincott Williams &amp; Wilkins, with permission.)</p>
<p><img src="assets/images/image-20251225-b8021175.jpeg" alt="img-85.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="inflammatory-myopathies">Inflammatory Myopathies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inflammatory-myopathies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Evaluate and treat any pain on a routine basis.</li>
<li>Provide a supportive environment.</li>
<li>Assess for dysphagia at each patient encounter.</li>
<li>Educate patient and family regarding medication side effects and reporting to provider any changes in condition.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bibliography">BIBLIOGRAPHY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bibliography" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Callen, J. P., &amp; Camisa, C. (2013). Antimalarial agents. In S. E. Wolverston (Ed.), Comprehensive dermatologic drug therapy (3rd ed., pp. 241–251). Philadelphia, PA: Saunders Elsevier.</p>
<p>Connolly, M. K. (2012). Systemic sclerosis (scleroderma) and related disorders. In J. L. Bolognia, J. L. Jorizzo, &amp; J. V. Schaffer (Eds.), Dermatology (3rd ed., pp. 643–656). St. Louis, MO: Mosby Elsevier.</p>
<p>Fett, N. (2013). Morphea (localized scleroderma). JAMA Dermatology, 149(9), 1124.</p>
<p>Garza, R. M., &amp; Jacobe, H. T. (2014). Morphea. In M. G. Lebwohl, W. R. Heymann, J. Berth-Jones, &amp; I. Coulson (Eds.), Treatment of skin diseases (4th ed., pp. 183–187). Philadelphia, PA: Saunders Elsevier.</p>
<p>Gatto, M., Kiss, E., Naparstek, Y., &amp; Doria, A. (2014). In/off label use of biologic therapy in systemic lupus erythematosus. BMC Medicine, 12, 30.</p>
<p>Habif, T. P. (2010). Connective tissue diseases. In T. P. Habif (Ed.), Clinical dermatology (5th ed., pp. 671–709). St. Louis, MO: Mosby Elsevier.</p>
<p>Hachulla, E., &amp; Launay, D. (2011). Diagnosis and classification of systemic sclerosis. Clinical Reviews in Allergy and Immunology, 40(2), 78–83.</p>
<p>Jacobe, H. T., Sontheimer, R. D., &amp; Saxton-Daniels, S. (2012). Autoantibodies encountered in patients with autoimmune connective tissue diseases. In J. L. Bolognia, J. L. Jorizzo, &amp; J. V. Schaffer (Eds.), Dermatology (3rd ed., pp. 603–614). St. Louis, MO: Mosby Elsevier.</p>
<p>Jorrizzo, J. L., &amp; Vleugels, R. A. (2012). Dermatomyositis. In J. L. Bolognia, J. L. Jorizzo, &amp; J. V. Schaffer (Eds.), Dermatology (3rd ed., pp. 631–642). St. Louis, MO: Mosby Elsevier.</p>
<p>Lahouti, A. H., &amp; Christopher-Stine, L. (2015). Polymyositis and dermatomyositis: Novel insights into the pathogenesis and potential therapeutic targets. Discovery Medicine, 107, 463–470.</p>
<p>Lee, L. A., &amp; Werth, V. P. (2012). Lupus erythematosus. In J. L. Bolognia, J. L. Jorizzo, &amp; J. V. Schaffer (Eds.), Dermatology (3rd ed., pp. 615–630). St. Louis, MO: Mosby Elsevier.</p>
<p>Li, S. C., Torok, K. S., Pope, E., Dedeoglu, F., Hong, S., Jacobe, H. T., ..., Fuhlbrigge, R. C. (2012). Development of consensus treatment plans for juvenile localized scleroderma: A roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care and Research, 64(8), 1175–1185.</p>
<p>Lin, J. H., &amp; Dutz, J. P. (2007). Pathophysiology of cutaneous lupus erythematosus. Clinical Reviews in Allergy and Immunology, 33(1–2), 85–106.</p>
<p>Maverakis, E., Patel, F., Kronenberg, D. G., Chung, L., Hummers, L. K., Duong, C., ..., Gershwin, M. E. (2014). International consensus criteria for the diagnosis of Raynaud’s phenomenon. Journal of Autoimmunity, 48–49, 60–65.</p>
<p>Olsen, N. J., Yousif, M., Mutwally, A., Cory, M., Elmagboul, N., &amp; Karp, D. R. (2013). Organ damage in high-risk patients with systemic and incomplete lupus syndromes. Rheumatology International, 10, 2585–2590.</p>
<p>Petri, M., Orbai, A. M., Alarcon, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., ..., Magder, L. S. (2012). Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 64(8), 2677–2686.</p>
<p>Pope, J. E., &amp; Jonson, S. R. (2015). New classification for systemic scleroderma. Rheumatology Diseases Clinics of North America, 3, 383–398.</p>
<p>Röcken, M., &amp; Kaman G. (2012). Morphea and lichen sclerosis. In J. L. Bolognia, J. L. Jorizzo, &amp; J. V. Schaffer (Eds.), Dermatology (3rd ed., pp. 657–670). St. Louis, MO: Mosby Elsevier.</p>
<p>Sartori-Valinotti, J. C., Tollefson, M. M., &amp; Reed, A. M. (2013). Updates on morphea: Role of vascular injury and advances in treatment. Autoimmune Diseases, article ID: 467808. doi: 10.1155/2013/467808</p>
<p>Thiers, B. H. (2014). Discoid lupus erythematosus. In M. G. Lebwohl, W. R. Heymann, J. Berth-Jones, &amp; I. Coulson (Eds.), Treatment of skin diseases (4th ed., pp. 193–194). Philadelphia, PA: Saunders Elsevier.</p>
<p>Vleugels, R. A., &amp; Callen, J. P. (2014). Dermatomyositis. In M. G. Lebwohl, W. R. Heymann, J. Berth-Jones, &amp; I. Coulson (Eds.), Treatment of skin diseases (4th ed., pp. 183–187). Philadelphia, PA: Saunders Elsevier.</p>
<p>Zaglout, S. S., Marraki, N. A. Y., &amp; Goodfield, M. J. D. (2014). Scleroderma. In M. G. Lebwohl, W. R. Heymann, J. Berth-Jones, &amp; I. Coulson (Eds.), Treatment of skin diseases (4th ed., pp. 703-706). Philadelphia, PA: Saunders Elsevier.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>All of the following statements about lupus are true except:</li>
</ol>
<p>a. The exact cause of lupus is unknown.
b. Lupus is often called a "woman's disease."
c. Rash is a common symptom.
d. Currently, there is no single test that can diagnose lupus.
e. Sun exposure/ultraviolet light will help to eliminate skin lesions.</p>
<ol start="2">
<li>The ratio of lupus in women to men is:</li>
</ol>
<p>a. 3:1
b. 5:1
c. 9:1
d. 15:1</p>
<ol start="3">
<li>Morphea is:</li>
</ol>
<p>a. Just another name for scleroderma
b. A term to refer to discoid lesions associated with cutaneous lupus
c. A skin disease with a less than 1% chance of progressing to systemic scleroderma
d. A form of inflammatory myopathy, which typically occurs in adult men
e. A severe form of Raynaud phenomenon</p>
<ol start="4">
<li>Which of the following terms is not part of the CREST acronym?</li>
</ol>
<p>a. Calcinosis
b. Raynaud phenomenon
c. Esophageal dysfunction
d. Sclerodactyly
e. Trigeminal</p>
<ol start="5">
<li>Which of the following diseases is associated with a heliotrope rash?</li>
</ol>
<p>a. Inclusion body myositis (IBM)
b. Systemic lupus erythematosus (SLE)
c. Systemic scleroderma
d. Dermatomyositis (DM)
e. Acne vulgaris</p>
<ol start="6">
<li>
<p>Malignancies associated with dermatomyositis are more common in which of the following populations?
a. Older adult patients.
b. Juvenile patients.
c. It does not occur in any type of patient with dermatomyositis.
d. Its occurrence is equal between older adults and juvenile patients.</p>
</li>
<li>
<p>Which of the following medications are used in the treatment of SLE?
a. Anti-inflammatory drugs.
b. Corticosteroids.
c. Antimalarials.
d. Cytotoxic or immunosuppressive drugs.
e. All of the above are used to treat SLE.</p>
</li>
<li>
<p>Raynaud phenomenon can best be described as which of the following?
a. A syndrome in which mothers with SLE pass along the genetic trait for lupus
b. Intermittent attacks of ischemia of the extremities of the body, especially the fingers, toes, ears, and nose
c. An inflammation involving a spinal nerve root, resulting in pain and hyperesthesia
d. Discoid-shaped plaques that occur on the trunk in patients suffering from inflammatory diseases
e. A condition of abnormally increased muscle tone or strength</p>
</li>
<li>
<p>A patient is suspected of having an autoimmune connective tissue disorder. A clinical sign of erythema on the dorsal hands and fingers that spares the joints is associated with which of the following?
a. Dermatomyositis
b. Scleroderma
c. Morphea
d. Lupus erythematosus</p>
</li>
<li>
<p>The inflammatory myopathies include all of the following except:
a. Coccidioidomycosis
b. Inclusion body myositis
c. Dermatomyositis
d. Polymyositis
e. Juvenile dermatomyositis</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="answers-to-study-questions">Answers to Study Questions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1.c
2.c
3.c
4.g
5.d
6.a
7.e
8.b
9.d
10.a</p></div></div></div></div></div></div></div><div data-testid="stAppIframeResizerAnchor" data-iframe-height="true" class="st-emotion-cache-1dumvfu eht7o1d9"></div></section></div></div></div><div data-testid="portal" id="portal" class="st-emotion-cache-1q6lfs0 e19n7mk11"></div></div><div class=""></div></div>
  

</body></html>